Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y301/00—Hydrolases acting on ester bonds (3.1)
  • C12Y301/02—Thioester hydrolases (3.1.2)
  • C12Y301/02015—Ubiquitin thiolesterase (3.1.2.15)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
  • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Definitions

• the present invention relates to methods of aiding in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), by detecting changes in levels of the early biomarker ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in one or more samples (such as, for example, one or more biological samples) taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
• TBI traumatic brain injury
• TBI mild traumatic brain injuries
• head CT is unrevealing for the vast majority of the time for mild TBL is expensive, and exposes the patient to unnecessary radiation. Additionally, a negative head CT does not mean the patient has been cleared from having a concussion; rather, it may indicate that certain interventions, such as surgery, are not warranted. Clinicians and patients need objective, reliable information to accurately evaluate this condition to promote appropriate triage and recovery. To date, limited data have been available for the use of UCH-L1 in the acute care setting to aid in patient evaluation and management
• Mild TBI (or concussion) is much harder to objectively detect and presents an everyday challenge in emergency care units globally. Mild TBI usually causes no gross
• the present disclosure is directed to a method of aiding in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head (or head injury).
• the method comprises: a) performing an assay on a biological sample taken from the subject within 24 hours after a suspected injury to the head to measure or detect a level of ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in the biological sample; and b) determining whether the subject has sustained mild or moderate to severe traumatic brain injury (TBI) , wherein the subject is determined as having moderate or severe traumatic brain injury when (i) the level of UCH-L1 in the biological sample is higher than a reference level of UCH-L1 and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the biological sample is lower than a reference level of UCH-L1; (ii) there is a statistically significant increase or decrease from the level of UCH-L1 in a biological sample taken at a first time point to the level
• TBI mild
• the present disclosure is directed to a method of aiding in determining the extent of traumatic brain injury in a human subject who has sustained or may have sustained a suspected injury to the head (or head injury).
• the method comprises: a) performing an assay on at least two biological samples obtained from the subject, the first biological sample taken from the subject within 24 hours of the suspected injury and the second biological sample taken from the subject from about 3 to about 6 hours after the first biological sample is taken; b) detecting in the at least two biological samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy- terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; c) determining the level of UCH- Ll in each of the first biological sample and second biological sample and determining if the level of UCH-L1 decreases or increases from the first biological sample to the second biological sample; and d) determining the extent of the traumatic
• the present disclosure is directed to a method of aiding in the determination of whether to perform a head computerized tomography (CT) scan on a human subject that has sustained or may have sustained a suspected injury to the head (or head injury).
• CT computerized tomography
• the method comprises: a) performing an assay on at least two biological samples obtained from the subject, the first biological sample taken from the subject within 24 hours of the suspected injury and the second biological sample taken from the subject from about 3 to about 6 hours after the first biological sample is taken; b) detecting in the at least two biological samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; c) determining the level of UCH-L1 in each of the first biological sample and second biological sample and determining if the level of UCH-L1 decreases or increases from the first biological sample to the second biological sample; and d) determining whether to perform a CT scan on the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first biological sample to the second biological sample.
• the present disclosure relates to a
• TBI traumatic brain injury
• the level of UCH-L1 in the sample is higher than a reference level of UCH-L1 and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1;
• the level of UCH-L1 decreases or increases by at least a first absolute amount from the first sample to the second sample or is determined as having mild traumatic brain injury when the level of UCH-L1 decreases or increases by at least a second absolute amount from the first sample to the second sample;
• the level of UCH-L1 in the sample is higher than a reference level of UCH-L1 or when there is a significant increase or decrease of an amount X from the level of UCH-L1 in a sample taken at a first time point to the level of UCH-L1 in a sample taken at a second time point and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1 or when there is no significant increase or decrease greater than amount X from the level of UCH-L1 in a sample taken at a first time point to the level of UCH-L1 in a sample taken at a second time point.
• the present disclosure relates to a method of evaluating a human subject for a head injury (such as a traumatic brain injury).
• a head injury such as a traumatic brain injury.
• the method can comprise:
• TBI traumatic brain injury
• the subject has sustained a moderate to severe TBI when the level of UCH-L1 in the sample is higher than a reference level of UCH-L1, and wherein the subject has sustained a mild TBI when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1;
• the subject has sustained a moderate to severe TBI when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the subject has sustained a mild TBI when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample;
• the subject has sustained a moderate to severe TBI when the level of UCH-L1 decreases or increases by at least a first absolute amount from the first sample to the second sample, and wherein the subject has sustained a mild TBI when the level of UCH-L1 decreases or increases by at least a second absolute amount from the first sample to the second sample.
• the first time point can be about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease can be selected from the group consisting of: (a) more than about 1-fold from the second time point to the first time point; (b) more than about 0.73-fold from the second time point to the first time point; or (c) more than about 0.73-fold from the second time point to the first time point and the reference level of UCH- Ll is between about 350 pg/mL and about 550 pg/mL.
• the significant increase or decrease is more than about 1-fold from the second time point to the first time point.
• the significant increase or decrease is more than about 0.73- fold from the second time point to the first time point. In some embodiments, the significant increase or decrease is more than about 0.73-fold from the second time point to the first time point and the reference level of UCH-L1 is between about 350 pg/mL and about 550 pg/mL.
• the subject may have received a Glasgow Coma Scale score before or after the assay is performed.
• the subject may be suspected as having moderate to severe TBI based on the Glasgow Coma Scale score.
• the subject may be suspected as having mild TBI based on the Glasgow Coma Scale score.
• the subject may not have received a Glasgow Coma Scale score before the assay is performed.
• the subject may have received a head CT before the assay is performed.
• the subject may not have received a head CT before the assay is performed.
• the subject may not have received a Glasgow Coma Scale or a head CT before the assay is performed.
• the subject may have received a Glasgow Coma Scale but not a head CT before the assay is performed. Yet further, the subject may have received a head CT but not a Glasgow Coma Scale before the assay is performed. Still further, the subject may have received a head CT and a Glasgow Coma Scale before the assay is performed. [0012] In any of the above described methods for evaluating a human subject for a head injury, the reference level may be correlated with subjects having moderate to severe TBI (when compared to subjects having a mild TBI). Alternatively, the reference level may be correlated with subjects having mild TBI (when compared to subjects having no TBI).
• the reference level can indicate that the subject has a moderate to severe TBI (when compared to subjects having a mild TBI). Yet further, the reference level can indicate that the subject has a mild TBI (when compared to subject having no TBI). Still further, the reference level may be correlated with a Glasgow Coma Scale score of 13-15. It will be evident to a skilled person which reference level to select for use in the methods of the invention.
• the reference level can be (a) determined by an assay having a sensitivity of between at least about 85% to about 100% and a specificity of between at least about 30% to about 100%; (b) determined by an assay having a sensitivity of at least about 99% and a specificity of at least about 75%; (c) between at least about 50 pg/mL to about 12000 pg/mL; or (d) between at least about 65 pg/mL to about 9019 pg/mL.
• the reference level can be determined by an assay having a sensitivity of between at least about 85% to about 100% and a specificity of between at least about 30% to about 100%. In some embodiments, the reference level can be determined by an assay having a sensitivity of at least about 99% and a specificity of at least about 75%. In some embodiments, the reference level can be between at least about 50 pg/mL to about 12000 pg/mL; or (d) between at least about 65 pg/mL to about 9019 pg/mL.
• the sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 33%; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of about 100%; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 30%; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 63%; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 90% and a specificity
• the sample can be taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 33%. In some embodiments, the sample can be taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of about 100%. In some embodiments, the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 30%.
• the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 63%. In some embodiments, the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 96%.
• the sample can be (a) taken within 0 to about 6 hours after the suspected head injury and the reference level is about 311 pg/mL; (b) taken within 0 to 6 hours after the suspected head injury and the reference level is about 9019 pg/mL; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 98 pg/mL; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 209 pg/mL; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 569 pg/mL.
• the sample can be taken within 0 to about 6 hours after the suspected head injury and the reference level is about 311 pg/mL. In some embodiments, the sample can be taken within 0 to 6 hours after the suspected head injury and the reference level is about 9019 pg/mL. In some embodiments, the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 98 pg/mL. In some embodiments, the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 209 pg/m. In some embodiments, the sample can be taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 569 pg/mL.
• the reference level may be correlated with subjects having moderate to severe TBI (when compared to subjects having a mild TBI).
• the reference level may be correlated with subjects having mild TBI (when compared to subjects having no TBI).
• the reference level can indicate that the subject has a moderate to severe TBI (when compared to subjects having a mild TBI).
• the reference level can indicate that the subject has a mild TBI (when compared to subject having no TBI).
• the reference level may be correlated with a Glasgow Coma Scale score of 13-15. It will be evident to a skilled person which reference level to select for use in the methods of the invention.
• the absolute amount can be determined by an assay having a sensitivity of between at least about 70% to about 100% and a specificity of between at least about 30% to about 100%.
• the sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of about 100%; (b) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 70% and a specificity of at least about 92%; (c) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 36%; (d) taken within about 0 to about 11 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 32%; or (e) taken within about 0 to about 12 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 75% and
• the sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the absolute amount is about 2528 pg/mL; (b) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is about 129 pg/mL; (c) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is about 25 pg/mL; (d) taken within 0 to 11 hours after the suspected head injury and the absolute amount is about 25 pg/mL; or (e) taken within about 0 to about 12 hours after the suspected head injury and the absolute amount is about 129 pg/mL.
• the sample (or biological sample) be a whole blood sample, a serum sample or a plasma sample.
• the sample (or biological sample) can be a whole blood sample.
• the sample (or biological sample) can be a serum sample.
• the sample (or biological sample) can be a plasma sample.
• the UCH-L1 be measured or detected using an immunoassay.
• the sample (or biological sample) can be a whole blood sample and that the UCH-L1 be measured or detected using an immunoassay.
• the sample (or biological sample) can be a serum sample and that the UCH-L1 be measured or detected using an immunoassay.
• the sample (or biological sample) can be a plasma sample and that the UCH-L1 be measured or detected using an immunoassay.
• the above-described methods for evaluating a human subject for a head injury can further comprise treating a human subject assessed as having mild or moderate to severe TBI with a treatment for TBI.
• a treatment for TBI can also, optionally, be monitored during and after any course of treatment.
• said methods can further comprise monitoring a subject assessed as having mild or moderate TBI (such as those, who as of yet, may not be receiving any treatment).
• the present disclosure relates to a method of aiding in determining the extent of traumatic brain injury in a human subject who has sustained or may have sustained a head injury.
• the method can comprise:
• said early biomarker consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1);
• determining the extent of the traumatic brain injury in the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first sample to the second sample, wherein determining the extent of the traumatic brain injury comprises determining whether the subject has sustained a mild or a moderate to severe traumatic brain injury.
• the present disclosure relates to a method of evaluating the extent of traumatic brain injury (TBI) in a human subject.
• TBI traumatic brain injury
• the method can comprise:
• determining the extent of the TBI in the subject comprises determining whether the subject has sustained a mild or a moderate to severe traumatic brain injury.
• the first sample can be taken within about 0 to about 6 hours after the suspected head injury.
• the subject can be determined to have moderate to severe TBI when the level of UCH- Ll increases or decreases between at least about 20 pg/mL to at least about 6100 pg/mL from the first sample to the second sample.
• the first sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 2528 pg/mL; (b) taken within about 6 to about 12 hours after the suspected head injury and the level of UCH- Ll increases or decreases by at least about 129 pg/mL; (c) taken within about 0 to about 10 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 25 pg/mL; (d) taken within about 0 to about 11 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 25 pg/mL; or (e) taken within about 0 to about 12 hours after the suspected head injury and the level of UCH- Ll increases or decreases at least about 129 pg/mL.
• the sample (or biological sample) can be a whole blood sample, a serum sample or a plasma sample.
• the sample (or biological sample) can be a whole blood sample.
• the sample (or biological sample) can be a serum sample.
• the sample (or biological sample) can be a plasma sample.
• the sample (or biological sample) can be a whole blood sample and that the UCH-L1 be measured or detected using an immunoassay.
• the sample (or biological sample) can be a serum sample and that the UCH-L1 be measured or detected using an immunoassay.
• the sample (or biological sample) can be a plasma sample and that the UCH-L1 be measured or detected using an immunoassay.
• the above-described methods for determining or evaluating the extent of the TBI can further comprise treating a human subject assessed as having mild or moderate to severe TBI with a treatment for TBI.
• a treatment for TBI can also, optionally, be monitored as described herein during and after any course of treatment.
• said methods can further comprise monitoring a subject assessed as having mild or moderate TBI (such as those, who as of yet, may not be receiving any treatment).
• the present disclosure relates to a method of aiding in the determination of whether to perform a head computerized tomography (CT) scan on a human subject that has sustained or may have sustained a head injury.
• CT computerized tomography
• the method can comprise: performing an assay to detect or measure ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in at least two samples which have been obtained from the subject, the first sample taken from the subject within 24 hours of the suspected head injury and the second sample taken from the subject from about 3 to about 6 hours after the first sample is taken;
• UCH-L1 ubiquitin carboxy-terminal hydrolase LI
• the CT scan is performed when there is a statistically significant increase or decrease in the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample, and wherein the CT scan is not performed when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample;
• the CT scan is performed when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the CT scan is not performed when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample.
• the present disclosure relates to a method of evaluating whether to perform a head computerized tomography (CT) scan on a human subject.
• CT head computerized tomography
• the method can comprise:
• the CT scan is performed when the level of UCH-L1 in the first sample is higher than a reference level of UCH-L1, and wherein the CT scan is not performed when the level of UCH-L1 in the first sample is lower than a reference level of UCH-L1;
• the CT scan is performed when there is a statistically significant increase or decrease in the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample, and wherein the CT scan is not performed when there is no statistically significant increase or decrease from the level of UCH- Ll in the first sample to the level of UCH-L1 in the second sample; or
• the CT scan is performed when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the CT scan is not performed when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample.
• the first time point can be about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease is less than about 2-fold from the first time point to the second time point; the first time point can be about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease is less than about 1.81 -fold from the first time point to the second time point; the first time point can be about 0 to about 12 hours after the suspected head injury and the statistically significant increase is more than about 0.50-fold from the second time point to the first time point; the first time point can be about 0 to about 12 hours after the suspected head injury and the statistically significant increase is more than about 0.55-fold from the second time point to the first time point; or the first time point can be about 0 to about 12 hours after the suspected head injury, the reference level of UCH-L1 is about 550 pg/mL, and the statistically significant increase is more than about 0.55-fold from the
• the subject may be suspected of having a traumatic brain injury based on a CT scan that already was performed. For example, depending upon a subject's medical condition (such as, if the patient is unconscious), a CT scan may be conducted shortly after the subject arrives at an emergency room, trauma center, or other site in order to assess and/or evaluate whether the subject has a TBI. Such a CT scan may be performed prior to the assay being performed to confirm and determine whether or not the subject has a mild or moderate or severe TBI.
• one or more subsequent CT scans can be performed based on the results of the assay as part of the physician's (or other medical personnel's) management of the TBI (such as, for example, to determine whether surgical and/or pharmacological intervention may be required).
• the reference level can be correlated with positive head CT scan.
• the reference level can be (a) determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%; (b) between at least about SO pg/mL to about 1000 pg/mL; or (c) between at least about 86 pg/mL to about 700 pg/mL.
• the sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 37.5%; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 75%; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 96% and a specificity of at least about 30%; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 86% and a specificity of at least about 35%; or (e) taken between about 0 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 37.5%; (b) taken within about
• the sample can be (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is about 370 pg/mL; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is about 509 pg/mL; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 96 pg/mL; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 86 pg/mL; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 550 pg/mL.
• the absolute amount is correlated with positive head CT scan.
• the absolute amount can be determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%.
• the sample can be: (a) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 85% and a specificity of at least about 41%; or (b) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 35%.
• the sample can be (a) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is about 25 pg/mL; or (b) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is about 23 pg/mL.
• the above-described methods for determining or evaluating whether to perform a head CT can further comprise treating a human subject assessed as having mild or moderate to severe TBI with a treatment for TBI.
• a treatment for TBI can also, optionally, be monitored during and after any course of treatment.
• said methods can further comprise monitoring a subject assessed as having mild or moderate TBI (such as those, who as of yet, may not be receiving any treatment).
• the sample (or biological sample) be a whole blood sample, a serum sample or a plasma sample.
• the sample (or biological sample) can be a whole blood sample.
• the sample (or biological sample) can be a serum sample.
• the sample (or biological sample) can be a plasma sample.
• UCH-L1 can be measured or detected using an immunoassay.
• the sample (or biological sample) can be a whole blood sample and UCH-L1 can be measured or detected using an immunoassay.
• the sample (or biological sample) can be a serum sample and UCH-L1 can be measured or detected using an immunoassay.
• the sample (or biological sample) can be a plasma sample and UCH-L1 can be measured or detected using an immunoassay.
• the second sample be taken from the subject between about 5 hours to about 16 hours or about 3 hours to about 6 hours after the suspected head injury. More specifically, the second sample can be taken from the subject at about 3 hours, at about 4 hours, at about 5 hours, at about 6 hours, at about 7 hours, at about 8 hours, at about 9 hours, at about 10 hours, at about 11 hours, or at about 12 hours after the suspected head injury.
• Any of the above-described methods can further comprise performing an assay on the samples to measure or detect a level of one or more other biomarkers that are not UCH- Ll.
• the assay can comprise:
• the one or more other biomarkers is selected from the group consisting of S100p, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), Apo lipoprotein 1, Tau, C-reactive protein (CRP), free brain-derived neurotrophic factor (BDNF), p-Tau, total BDNF, troponin I (Tnl), and a combination thereof. More specifically, the one or more other biomarkers is S100p, BDNF, or CRP.
• the level of UCH-L1 can be measured by performing an immunoassay.
• the level of UCH-L1 can be measured by
• a capture antibody which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a capture antibody-UCH-Ll antigen complex
• a detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the capture antibody, to form a UCH- Ll antigen-detection antibody complex
• the sample can be a whole blood sample, a serum sample, a cerebrospinal fluid sample or a plasma sample.
• the sample is a whole blood sample.
• the sample is a serum sample.
• the sample is a plasma sample.
• Such a sample can be obtained in a variety of ways.
• the sample can be obtained after the subject sustained a head injury caused by physical shaking, blunt impact by an external mechanical or other force that results in a closed or open head trauma, one or more falls, explosions or blasts or other types of blunt force trauma.
• the sample can be obtained after the subject has ingested or been exposed to a chemical, toxin or combination of a chemical and toxin.
• the sample can be obtained from a subject that suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, a virus, meningitis, hydrocephalus or
• any of the above-described methods can be carried out on any human subject without regard to factors selected from the group consisting of the human subject's clinical condition, the human subject's laboratory values, the human subject's classification as suffering from mild or moderate to severe TBI, the human subject's exhibition of low or high levels of UCH-L1, and the timing of any event wherein the human subject may have sustained head injury.
• FIG. 1 shows biomarker UCH-L1 result vs. time from injury.
• FIG. 2 shows a receiver operating characteristic (ROC) analysis of UCH-L1 levels correlated with CT by time point.
• ROC receiver operating characteristic
• FIG. 3 shows receiver operating characteristic (ROC) analysis of change in UCH- Ll levels at time point 2 compared to time point 1 ("delta" (i.e., time point 2 - time point 1)) correlated with CT.
• ROC receiver operating characteristic
• FIG. 4 shows receiver operating characteristic (ROC) analysis of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between UCH-L1 levels at Time Point 2 and UCH-L1 levels at Time Point 1) correlated with CT.
• ROC receiver operating characteristic
• FIG. 5 shows a box plot of UCH-L1 assay results by time point.
• FIG. 6 shows assay kinetics median Z-score of testing results by time point.
• FIG. 7 A shows box plot of UCH-L1 assay results at Time Point 1 (taken within 0 to 6 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1) correlated with positive vs. negative CT scan results.
• FIG. 7B shows ROC curve of UCH-L1 assay results at Time Point 1 and Time Point 2 correlated with positive vs. negative CT scan results.
• FIG. 8 A shows box plot of UCH-L1 assay results at Time Point 1 (taken within 6 to 12 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1) correlated with positive vs. negative CT scan results.
• FIG. 8B shows ROC curve of UCH-L1 assay results at Time Point 1 and Time Point 2 correlated with positive vs. negative CT scan results.
• FIGS. 9 A and 9B show box plots of the difference or change between Time Point 2 and Time Point 1 ("delta") UCH-L1 assay results correlated with positive vs. negative CT scan results by time range of when the first sample was taken.
• FIG. 9A shows the box plots for the 0-6 hour group and
• FIG. 9B shows the box plots for the 6-12 hour group.
• FIGS. 10A and 10B show box plots of absolute amount ("absolute delta") of UCH- Ll results ⁇ i.e., the absolute difference between Time Point 2 and Time Point 1) correlated with positive vs. negative CT scan results by time range of when the first sample was taken.
• FIG. 10A shows the box plots for the 0-6 hour group and
• FIG. 10B shows the box plots for the 6-12 hour group.
• FIG. 11 A shows box plot of UCH-L1 assay results at Time Point 1 (taken within 0 to 6 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 1 IB shows ROC curve of UCH-L1 assay results at Time Point 1 and Time Point 2 correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 12A shows box plot of UCH-L1 assay results at Time Point 1 (taken within 6 to 12 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 12B shows ROC curve of UCH-L1 assay results at Time Point 1 and Time Point 2 correlated with mild vs. moderate/severe TBI GCS scores.
• FIGS. 13 A and 13B show box plots of the difference or change between Time Point 2 and Time Point 1 ("delta") UCH-L1 assay results correlated with mild vs.
• FIG. 13 A shows the box plots for the 0-6 hour group and FIG. 13B shows the box plots for the 6- 12 hour group.
• FIG. 14A shows box plot of absolute amount (“absolute delta”) UCH-L1 assay results ⁇ i.e., the absolute difference between Time Point 1 (taken within 0 to 6 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 14B shows ROC curve of absolute amount (“absolute delta”) UCH-L1 assay results correlated with mild vs.
• FIG. 15A shows box plot of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken within 6 to 12 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 15B shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 16 shows ROC curve of fold change in the UCH-L1 levels between Time Point 1 (taken within 0 to 6 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 17 shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken within 0 to 10 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with CT scan.
• FIG. 18 shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken more than 10 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with CT scan.
• FIG. 19 shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken within 0 to 11 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 20 shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken more than 11 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 21 shows ROC curve of absolute amount ("absolute delta") of UCH-L1 results (i.e., the absolute difference between Time Point 1 (taken within 0 to 10 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• FIG. 22 shows ROC curve of absolute amount ("absolute delta") of UCH-L 1 results (i.e., the absolute difference between Time Point 1 (taken more than 12 hours after head injury) and Time Point 2 (taken 3 to 6 hours after the sample of Time Point 1)) correlated with mild vs. moderate/severe TBI GCS scores.
• the present invention relates to methods that aid in the diagnosis and evaluation of a subject (such as, for example, a human subject) that has sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase LI (UCH-L1).
• TBI traumatic brain injury
• UCH-L1 ubiquitin carboxy-terminal hydrolase LI
• the detection of an increase in or elevated levels of UCH-L1 that may be followed by a subsequent decrease in UCH-L1 levels within the first 24 hours after injury or suspected injury to the head provides an aid in accurately evaluating or diagnosing the subject, thus allowing for the subsequent early treatment and monitoring of patients with mild or moderate to severe traumatic brain injury.
• subjects having a statistical significant change in UCH-L1 levels in a first sample taken within the first 6 hours, such as within 2 to 6 hours, after the injury or suspected injury compared to a second sample taken about 0.5 to 10 hours, such as 3 to 6 hours, after the first sample is taken may be identified as having moderate to severe traumatic brain injury.
• subjects having a UCH-L1 level higher than a reference level may also be identified as having moderate to severe traumatic brain injury.
• subjects having at least an increase or decrease by an absolute amount may also be identified as having moderate to severe traumatic brain injury.
• the present invention also relates to methods that aid in determining whether a subject that has sustained an injury to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1.
• CT head computerized tomography
• These methods involve detecting UCH-L1 levels in one or more samples taken from the subject at different time points within 24 hours of the injury to the head or suspected injury to the head.
• the detection of an increase in or elevated levels of UCH-L1 that may be followed by a subsequent decrease in UCH-L1 levels within the first 24 hours after injury or suspected injury to the head provides an aid in determining whether a subject should receive a head CT scan.
• subjects having a statistical significant change in UCH-L1 levels in a first sample taken within the first 6 hours, such as within 2 to 6 hours, after the injury or suspected injury compared to a second sample taken about 0.S to 10 hours, such as 3 to 6 hours, after the first sample is taken may be identified as likely to have a positive head CT scan and thus benefit from having a CT scan.
• subjects having a UCH-L1 level higher than a reference level may also be identified as likely to have a positive head CT scan and thus benefit from having a CT scan.
• subjects having at least an increase or decrease by an absolute amount may also be identified as likely to have a positive head CT scan (e.g., thus indicating a potential TBI) and thus benefit from having a CT scan.
• each intervening number there between with the same degree of precision is explicitly contemplated.
• the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
• affinity matured antibody is used herein to refer to an antibody with one or more alterations in one or more CDRs, which result in an improvement in the affinity (i.e., K D , 13 ⁇ 4 or k a ) of the antibody for a target antigen compared to a parent antibody, which does not possess the alteration(s).
• Exemplary affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen.
• a variety of procedures for producing affinity matured antibodies is known in the art, including the screening of a combinatory antibody library that has been prepared using bio-display. For example, Marks et al., BioTechnology, 10: 779-783 (1992) describes affinity maturation by VH and VL domain shuffling.
• Random mutagenesis of CDR and/or framework residues is described by Barbas et al., Proc. Nat. Acad. Sci. USA, 91: 3809-3813 (1994); Schier etal, Gene, 169: 147-155 (1995); Yelton ei al., J. Immunol., 155: 1994-2004 (1995); Jackson et al., J. Immunol., 154(7): 3310-3319 (1995); and Hawkins et al, J. Mol. Biol., 226: 889-896 (1992).
• Selective mutation at selective mutagenesis positions and at contact or hypermutation positions with an activity- enhancing amino acid residue is described in U.S. Patent No. 6,914,128 Bl.
• Antibody and “antibodies” as used herein refers to monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies (fully or partially humanized), animal antibodies such as, but not limited to, a bird (for example, a duck or a goose), a shark, a whale, and a mammal, including a non-primate (for example, a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, etc.) or a non-human primate (for example, a monkey, a chimpanzee, etc.), recombinant antibodies, chimeric antibodies, single-chain Fvs (“scFv”), single chain antibodies, single domain antibodies, Fab fragments, F(ab') fragments, F(ab')2 fragments, disulfide
• immunoglobulin molecules namely, molecules that contain an analyte-binding site.
• Immunoglobulin molecules can be of any type (for example, IgG, IgE, IgM, IgD, IgA, and IgY), class (for example, IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2), or subclass.
• an antibody against an analyte is frequently referred to herein as being either an "anti-analyte antibody” or merely an “analyte antibody” (e.g., an anti-UCH-Ll antibody or a UCH-Ll antibody).
• Antibody fragment refers to a portion of an intact antibody comprising the antigen-binding site or variable region. The portion does not include the constant heavy chain domains (i.e., CH2, CH3, or CH4, depending on the antibody isotype) of the Fc region of the intact antibody.
• antibody fragments include, but are not limited to, Fab fragments, Fab 1 fragments, Fab'-SH fragments, F(ab')2 fragments, Fd fragments, Fv fragments, diabodies, single-chain Fv (scFv) molecules, single-chain polypeptides containing only one light chain variable domain, single-chain polypeptides containing the three CDRs of the light-chain variable domain, single-chain polypeptides containing only one heavy chain variable region, and single-chain polypeptides containing the three CDRs of the heavy chain variable region.
• AUC area under curve
• AUC under a ROC curve is a measure of accuracy.
• An AUC of 1 represents a perfect test, whereas an AUC of 0.5 represents an insignificant test.
• a preferred AUC may be at least approximately 0.700, at least approximately 0.750, at least approximately 0.800, at least approximately 0.850, at least approximately 0.900, at least approximately 0.910, at least approximately 0.920, at least approximately 0.930, at least approximately 0.940, at least approximately 0.950, at least approximately 0.960, at least approximately 0.970, at least approximately 0.980, at least approximately 0.990, or at least approximately 0.995.
• Bead and “particle” are used herein interchangeably and refer to a substantially spherical solid support.
• a bead or particle is a microparticle.
• Microparticles that can be used herein can be any type known in the art.
• the bead or particle can be a magnetic bead or magnetic particle.
• Magnetic beads/particles may be ferromagnetic, ferrimagnetic, paramagnetic, superparamagnetic or ferrofluidic.
• Exemplary ferromagnetic materials include Fe, Co, Ni, Gd, Dy, C1O2, MnAs, MnBi, EuO, and NiO/Fe.
• ferrimagnetic materials include NiFe 2 0 4 , CoFe 2 0 4 , Fe 3 0 4 (or FeO"Fe 2 0 3 ).
• Beads can have a solid core portion that is magnetic and is surrounded by one or more non-magnetic layers. Alternately, the magnetic portion can be a layer around a non-magnetic core.
• microparticles can be of any size that would work in the methods described herein, e.g., from about 0.75 to about 5 nm, or from about 1 to about 5 nm, or from about 1 to about 3 nm.
• Binding protein is used herein to refer to a monomelic or multimeric protein that binds to and forms a complex with a binding partner, such as, for example, a polypeptide, an antigen, a chemical compound or other molecule, or a substrate of any kind.
• a binding protein specifically binds a binding partner.
• Binding proteins include antibodies, as well as antigen-binding fragments thereof and other various forms and derivatives thereof as are known in the art and described herein below, and other molecules comprising one or more antigen-binding domains that bind to an antigen molecule or a particular site (epitope) on the antigen molecule.
• a binding protein includes, but is not limited to, an antibody a tetrameric immunoglobulin, an IgG molecule, an IgGl molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, an affinity matured antibody, and fragments of any such antibodies that retain the ability to bind to an antigen.
• Bispecific antibody is used herein to refer to a full-length antibody that is generated by quadroma technology (see Milstein etal., Nature, 305(5934): 537-540 (1983)), by chemical conjugation of two different monoclonal antibodies (see, Staerz etal., Nature, 314(6012): 628-631 (1985)), or by knob-into-hole or similar approaches, which introduce mutations in the Fc region (see Holliger etal., Proc. Natl. Acad. Sci. USA, 90(14): 6444-6448 (1993)), resulting in multiple different immunoglobulin species of which only one is the functional bispecific antibody.
• a bispecific antibody binds one antigen (or epitope) on one of its two binding arms (one pair of HC/LC), and binds a different antigen (or epitope) on its second arm (a different pair of HC/LC).
• a bispecific antibody has two distinct antigen-binding arms (in both specificity and CDR sequences), and is monovalent for each antigen to which it binds to.
• CDR is used herein to refer to the "complementarity determining region" within an antibody variable sequence. There are three CDRs in each of the variable regions of the heavy chain and the light chain. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted “CDR1", “CDR2", and “CDR3”, for each of the variable regions.
• CDR set refers to a group of three CDRs that occur in a single variable region that binds the antigen. An antigen-binding site, therefore, may include six CDRs, comprising the CDR set from each of a heavy and a light chain variable region.
• a polypeptide comprising a single CDR may be referred to as a "molecular recognition unit.” Crystallographic analyses of antigen-antibody complexes have demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units may be primarily responsible for the specificity of an antigen- binding site. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
• Component refer generally to a capture antibody, a detection or conjugate a calibrator, a control, a sensitivity panel, a container, a buffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, a detection reagent, a pretreatment reagent/solution, a substrate ⁇ e.g., as a solution), a stop solution, and the like that can be included in a kit for assay of a test sample, such as a patient urine, whole blood, serum or plasma sample, in accordance with the methods described herein and other methods known in the art. Some components can be in solution or lyophilized for reconstitution for use in an assay.
• CT scan refers to a computerized tomography (CT) scan.
• a CT scan combines a series of X-ray images taken from different angles and uses computer processing to create cross-sectional images, or slices, of the bones, blood vessels and soft tissues inside your body.
• the CT scan may use X-ray CT, positron emission tomography (PET), single-photon emission computed tomography (SPECT), computed axial tomography (CAT scan), or computer aided tomography.
• PET positron emission tomography
• SPECT single-photon emission computed tomography
• CAT scan computed axial tomography
• the CT scan may be a conventional CT scan or a spiral/helical CT scan.
• a conventional CT scan the scan is taken slice by slice and after each slice the scan stops and moves down to the next slice, e.g., from the top of the abdomen down to the pelvis.
• the conventional CT scan requires patients to hold their breath to avoid movement artefact.
• the spiral/helical CT scan is a continuous scan which is taken in a spiral fashion and is a much quicker process where the scanned images are contiguous.
• Derivative of an antibody as used herein may refer to an antibody having one or more modifications to its amino acid sequence when compared to a genuine or parent antibody and exhibit a modified domain structure.
• the derivative may still be able to adopt the typical domain configuration found in native antibodies, as well as an amino acid sequence, which is able to bind to targets (antigens) with specificity.
• Typical examples of antibody derivatives are antibodies coupled to other polypeptides, rearranged antibody domains, or fragments of antibodies.
• the derivative may also comprise at least one further compound, e.g., a protein domain, said protein domain being linked by covalent or non- covalent bonds. The linkage can be based on genetic fusion according to the methods known in the art.
• the additional domain present in the fusion protein comprising the antibody may preferably be linked by a flexible linker, advantageously a peptide linker, wherein said peptide linker comprises plural, hydrophilic, peptide-bonded amino acids of a length sufficient to span the distance between the C-terminal end of the further protein domain and the N-terminal end of the antibody or vice versa.
• the antibody may be linked to an effector molecule having a conformation suitable for biological activity or selective binding to a solid support, a biologically active substance (e.g., a cytokine or growth hormone), a chemical agent, a peptide, a protein, or a drug, for example.
• Determined by an assay is used herein to refer to the determination of a reference level or an absolute amount by any appropriate assay.
• the determination of a reference level or an absolute amount may, in some embodiments, be achieved by an assay of the same type as the assay that is to be applied to the sample from the subject (for example, by an immunoassay, protein immunoprecipitation, immunoelectrophoresis, chemical analysis, SDS- PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC/MS)).
• HPLC high-performance liquid chromatography
• LC/MS liquid chromatography-mass spectrometry
• a reference level or an absolute amount may, in some embodiments, be achieved by an assay of the same type and under the same assay conditions as the assay that is to be applied to the sample from the subject.
• this disclosure provides exemplary reference levels and absolute amounts (e.g., calculated by comparing reference levels at different time points). It is well within the ordinary skill of one in the art to adapt the disclosure herein for other assays to obtain assay-specific reference levels and absolute amounts for those other assays based on the description provided by this disclosure.
• a set of training samples comprising samples obtained from human subjects known to have sustained an injury to the head (and more particularly, samples obtained from human subjects known to have sustained (i) mild TBI; or (ii) moderate to severe TBI and samples obtained from human subjects known not to have sustained an injury to the head (and more particularly, samples obtained from human subjects known not to have sustained any TBI) may be used to obtain assay- specific reference levels and absolute amounts.
• a reference level or absolute amount “determined by an assay” and having a recited level of "sensitivity” and/or “specificity” is used herein to refer to a reference level or absolute amount which has been determined to provide a method of the recited sensitivity and/or specificity when said reference level or absolute amount is adopted in the methods of the invention. It is well within the ordinary skill of one in the art to determine the sensitivity and specificity associated with a given reference level or absolute amount in the methods of the invention, for example by repeated statistical analysis of assay data using a plurality of different possible reference levels and absolute amounts.
• Drugs of abuse is used herein to refer to one or more additive substances (such as a drug) taken for non-medical reasons (such as for, example, recreational and/or mind- altering effects). Excessive overindulgence, use or dependence of such drugs of abuse is often referred to as “substance abuse”.
• drugs of abuse examples include alcohol, barbiturates, benzodiazepines, cannabis, cocaine, hallucinogens (such as ketamine, mescaline (peyote), PCP, psilocybin, DMT and/or LSD), methaqualone, opioids, amphetamines (including methamphetamines), anabolic steroids, inhalants (namely, substances which contain volatile substances that contain psychoactive properties such as, for example, nitrites, spray paints, cleaning fluids, markers, glues, etc.) and combinations thereof.
• hallucinogens such as ketamine, mescaline (peyote), PCP, psilocybin, DMT and/or LSD
• methaqualone opioids
• amphetamines including methamphetamines
• anabolic steroids inhalants
• Dual-specific antibody is used herein to refer to a full-length antibody that can bind two different antigens (or epitopes) in each of its two binding arms (a pair of HC/LC) (see PCT publication WO 02/02773). Accordingly, a dual-specific binding protein has two identical antigen binding arms, with identical specificity and identical CDR sequences, and is bivalent for each antigen to which it binds.
• DVDs may be monospecific, i.e., capable of binding one antigen (or one specific epitope), or multispecific, i.e., capable of binding two or more antigens (i.e., two or more epitopes of the same target antigen molecule or two or more epitopes of different target antigens).
• a preferred DVD binding protein comprises two heavy chain DVD polypeptides and two light chain DVD polypeptides and is referred to as a "DVD immunoglobulin" or "DVD-Ig.”
• DVD-Ig binding protein is thus tetrameric and reminiscent of an IgG molecule, but provides more antigen binding sites than an IgG molecule.
• each half of a tetrameric DVD-Ig molecule is reminiscent of one half of an IgG molecule and comprises a heavy chain DVD polypeptide and a light chain DVD polypeptide, but unlike a pair of heavy and light chains of an IgG molecule that provides a single antigen binding domain, a pair of heavy and light chains of a DVD-Ig provide two or more antigen binding sites.
• Each antigen binding site of a DVD-Ig binding protein may be derived from a donor ("parental") monoclonal antibody and thus comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) with a total of six CDRs involved in antigen binding per antigen binding site.
• a DVD-Ig binding protein that binds two different epitopes comprises an antigen binding site derived from a first parental monoclonal antibody and an antigen binding site of a second parental monoclonal antibody.
• a preferred example of such DVD-Ig molecules comprises a heavy chain that comprises the structural formula VDl-(Xl)n-VD2-C- (X2)n, wherein VDl is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant domain, XI is a linker with the proviso that it is not CHI, X2 is an Fc region, and n is 0 or 1, but preferably 1; and a light chain that comprises the structural formula VDl-(Xl)n-VD2-C-(X2)n, wherein VDl is a first light chain variable domain, VD2 is a second light chain variable domain, C is a light chain constant domain, XI is a linker with the proviso that it is not CHI, and X2 does not comprise an Fc region; and n is 0 or 1, but preferably 1.
• Such a DVD-Ig may comprise two such heavy chains and two such light chains, wherein each chain comprises variable domains linked in tandem without an intervening constant region between variable regions, wherein a heavy chain and a light chain associate to form tandem functional antigen binding sites, and a pair of heavy and light chains may associate with another pair of heavy and light chains to form a tetrameric binding protein with four functional antigen binding sites.
• a DVD-Ig molecule may comprise heavy and light chains that each comprise three variable domains (VDl, VD2, VD3) linked in tandem without an intervening constant region between variable domains, wherein a pair of heavy and light chains may associate to form three antigen binding sites, and wherein a pair of heavy and light chains may associate with another pair of heavy and light chains to form a tetrameric binding protein with six antigen binding sites.
• VDl variable domains
• VD2 variable domains
• an additional property is an antibody parameter of one or more of the parental monoclonal antibodies.
• Antibody parameters that may be contributed to a DVD-Ig binding protein from one or more of its parental monoclonal antibodies include, but are not limited to, antigen specificity, antigen affinity, potency, biological function, epitope recognition, protein stability, protein solubility, production efficiency, immunogenicity, pharmacokinetics, bioavailability, tissue cross reactivity, and orthologous antigen binding.
• a DVD-Ig binding protein binds at least one epitope of UCH-L1.
• Non-limiting examples of a DVD-Ig binding protein include a DVD-Ig binding protein that binds one or more epitopes of UCH-L1, a DVD-Ig binding protein that binds an epitope of a human UCH- Ll and an epitope of UCH-L1 of another species (for example, mouse), and a DVD-Ig binding protein that binds an epitope of a human UCH-L1 and an epitope of another target molecule.
• “Dynamic range” as used herein refers to range over which an assay readout is proportional to the amount of target molecule or analyte in the sample being analyzed.
• "Evaluating” and “evaluate” as used herein refers to assessing a subject with a head inury or a suspected head injury in order to obtain information pertinent to the head injury, such as the presense, absence, and/or degree of tramautic brain injury.
• “Evaluating” can include detecting, measuring, and/or quantifying levels of a TBI biomarker, such as UCH-L1, in a sample from a subject.
• “Evaluating” can also include performing various clinical assessments of a subject with a head injury or a suspected head injury, such as, but not limited to, performing a GCS assessment, a GOSE assessment, and/or imaging analysis (e.g., CT scan or MRI imaging).
• Epitope refers to a site(s) on any molecule that is recognized and can bind to a complementary site(s) on its specific binding partner.
• the molecule and specific binding partner are part of a specific binding pair.
• an epitope can be on a polypeptide, a protein, a hapten, a carbohydrate antigen (such as, but not limited to, glycolipids, glycoproteins or lipopolysaccharides), or a polysaccharide.
• Its specific binding partner can be, but is not limited to, an antibody.
• fragment antigen-binding fragment or "Fab fragment” as used herein refers to a fragment of an antibody that binds to antigens and that contains one antigen-binding site, one complete light chain, and part of one heavy chain.
• Fab is a monovalent fragment consisting of the VL, VH, CL and CHI domains.
• Fab is composed of one constant and one variable domain of each of the heavy and the light chain.
• the variable domain contains the paratope (the antigen-binding site), comprising a set of complementarity determining regions, at the amino terminal end of the monomer. Each arm of the Y thus binds an epitope on the antigen.
• Fab fragments can be generated such as has been described in the art, e.g., using the enzyme papain, which can be used to cleave an immunoglobulin monomer into two Fab fragments and an Fc fragment, or can be produced by recombinant means.
• F(ab')2 fragment refers to antibodies generated by pepsin digestion of whole IgG antibodies to remove most of the Fc region while leaving intact some of the hinge region. F(ab')2 fragments have two antigen-binding F(ab) portions linked together by disulfide bonds, and therefore are divalent with a molecular weight of about 110 kDa.
• F(ab')2 fragments Divalent antibody fragments
• F(ab')2 fragments are smaller than whole IgG molecules and enable a better penetration into tissue thus facilitating better antigen recognition in immunohistochemistry.
• the use of F(ab')2 fragments also avoids unspecific binding to Fc receptor on live cells or to Protein A/G.
• F(ab')2 fragments can both bind and precipitate antigens.
• Framework (FR) or “Framework sequence” as used herein may mean the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems (for example, see above), the meaning of a framework sequence is subject to correspondingly different interpretations.
• the six CDRs also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3, and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4.
• a framework region represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain.
• a FR represents one of the four sub- regions, and FRs represents two or more of the four sub-regions constituting a framework region.
• Human heavy chain and light chain FR sequences are known in the art that can be used as heavy chain and light chain "acceptor” framework sequences (or simply, "acceptor” sequences) to humanize a non-human antibody using techniques known in the art.
• human heavy chain and light chain acceptor sequences are selected from the framework sequences listed in publicly available databases such as V-base (hypertext transfer protocol://vbase.mrc-cpe.cam.ac.uk/) or in the international ImMunoGeneTics® (IMGT®) information system (hypertext transfer
• “Functional antigen binding site” as used herein may mean a site on a binding protein (e.g., an antibody) that is capable of binding a target antigen.
• the antigen binding affinity of the antigen binding site may not be as strong as the parent binding protein, e.g., parent antibody, from which the antigen binding site is derived, but the ability to bind antigen must be measurable using any one of a variety of methods known for evaluating protein, e.g., antibody, binding to an antigen.
• the antigen binding affinity of each of the antigen binding sites of a multivalent protein, e.g., multivalent antibody, herein need not be quantitatively the same.
• Glasgow Coma Scale or “GCS” as used herein refers to a 15 point scale for estimating and categorizing the outcomes of brain injury on the basis of overall social capability or dependence on others.
• the test measures the motor response, verbal response and eye opening response with these values: I. Motor Response (6 - Obeys commands fully; 5 - Localizes to noxious stimuli; 4 - Withdraws from noxious stimuli; 3 - Abnormal flexion, i.e., decorticate posturing; 2 - Extensor response, i.e., decerebrate posturing; and 1 - No response); ⁇ .
• Motor Response (6 - Obeys commands fully; 5 - Localizes to noxious stimuli; 4 - Withdraws from noxious stimuli; 3 - Abnormal flexion, i.e., decorticate posturing; 2 - Extensor response, i.e., decerebrate posturing; and 1 - No response);
• Verbal Response (5 - Alert and Oriented; 4 - Confused, yet coherent, speech; 3 - Inappropriate words and jumbled phrases consisting of words; 2 - Incomprehensible sounds; and 1 - No sounds); and III. Eye Opening (4 - Spontaneous eye opening; 3 - Eyes open to speech; 2 - Eyes open to pain; and 1 - No eye opening).
• the final score is determined by adding the values of ⁇ + ⁇ + ⁇ .
• the final score can be categorized into four possible levels for survival, with a lower number indicating a more severe injury and a poorer prognosis: Mild (13-15); Moderate Disability (9-12) (Loss of consciousness greater than 30 minutes; Physical or cognitive impairments which may or may resolve: and Benefit from Rehabilitation); Severe Disability (3-8) (Coma: unconscious state. No meaningful response, no voluntary activities); and Vegetative State (Less Than 3) (Sleep wake cycles; Arousal, but no interaction with environment; No localized response to pain).
• Moderate brain injury is defined as a brain injury resulting in a loss of consciousness from 20 minutes to 6 hours and a Glasgow Coma Scale of 9 to 12.
• Severe brain injury is defined as a brain injury resulting in a loss of consciousness of greater than 6 hours and a Glasgow Coma Scale of 3 to 8.
• Glasgow Outcome Scale refers to a global scale for functional outcome that rates patient status into one of five categories: Dead, Vegetative State, Severe Disability, Moderate Disability or Good Recovery.
• "Extended Glasgow Outcome Scale” or “GOSE” as used interchangeably herein provides more detailed categorization into eight categories by subdividing the categories of severe disability, moderate disability and good recovery into a lower and upper category as shown in Table 1.
• Humanized antibody is used herein to describe an antibody that comprises heavy and light chain variable region sequences from a non-human species ⁇ e.g., a mouse) but in which at least a portion of the VH and/or VL sequence has been altered to be more "humanlike,” i.e., more similar to human germline variable sequences.
• a “humanized antibody” is an antibody or a variant, derivative, analog, or fragment thereof, which immunospecifically binds to an antigen of interest and which comprises a framework (FR) region having substantially the amino acid sequence of a human antibody and a complementary determining region (CDR) having substantially the amino acid sequence of a non-human antibody.
• FR framework
• CDR complementary determining region
• the term "substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the amino acid sequence of a non-human antibody CDR.
• a humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab')2, FabC, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin ⁇ i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence.
• a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• a humanized antibody contains the light chain as well as at least the variable domain of a heavy chain.
• the antibody also may include the CHI, hinge, CH2, CH3, and CH4 regions of the heavy chain.
• a humanized antibody only contains a humanized light chain.
• a humanized antibody only contains a humanized heavy chain.
• a humanized antibody only contains a humanized variable domain of a light chain and/or humanized heavy chain.
• a humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including without limitation IgGl, IgG2, IgG3, and IgG4.
• a humanized antibody may comprise sequences from more than one class or isotype, and particular constant domains may be selected to optimize desired effector functions using techniques well-known in the art.
• the framework regions and CDRs of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor antibody CDR or the consensus framework may be mutagenized by substitution, insertion, and/or deletion of at least one amino acid residue so that the CDR or framework residue at that site does not correspond to either the donor antibody or the consensus framework. In a preferred embodiment, such mutations, however, will not be extensive. Usually, at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% of the humanized antibody residues will correspond to those of the parental FR and CDR sequences.
• the term "consensus framework" refers to the framework region in the consensus
• immunoglobulin sequence refers to the sequence formed from the most frequently occurring amino acids (or
• a "consensus immunoglobulin sequence” may thus comprise a "consensus framework region(s)" and/or a "consensus CDR(s)".
• each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
• Identity as used herein in the context of two or more polypeptide or polynucleotide sequences, can mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of the single sequence are included in the denominator but not the numerator of the calculation.
• Trauma to the head or “head injury” as used interchangeably herein, refers to any trauma to the scalp, skull, or brain. Such injuries may include only a minor bump on the skull or may be a serious brain injury. Such injuries include primary injuries to the brain and/or secondary injuries to the brain. Primary brain injuries occur during the initial insult and result from displacement of the physical structures of the brain. More specifically, a primary brain injury is the physical damage to parenchyma (tissue, vessels) that occurs during the traumatic event, resulting in shearing and compression of the surrounding brain tissue.
• parenchyma tissue, vessels
• Secondary brain injuries occur subsequent to the primary injury and may involve an array of cellular processes. More specifically, a secondary brain injury refers to the changes that evolve over a period of time (from hours to days) after the primary brain injury. It includes an entire cascade of cellular, chemical, tissue, or blood vessel changes in the brain that contribute to further destruction of brain tissue.
• An injury to the head can be either closed or open (penetrating).
• a closed head injury refers to a trauma to the scalp, skull or brain where there is no penetration of the skull by a striking object.
• An open head injury refers a trauma to the scalp, skull or brain where there is penetration of the skull by a striking object.
• An injury to the head may be caused by physical shaking of a person, by blunt impact by an external mechanical or other force that results in a closed or open head trauma (e.g., vehicle accident such as with an automobile, plane, train, etc.; blow to the head such as with a baseball bat, or from a firearm), a cerebral vascular accident (e.g., stroke), one or more falls (e.g., as in sports or other activities), explosions or blasts (collectively, "blast injuries”) and by other types of blunt force trauma.
• a closed or open head trauma e.g., vehicle accident such as with an automobile, plane, train, etc.; blow to the head such as with a baseball bat, or from a firearm
• a cerebral vascular accident e.g., stroke
• one or more falls e.g., as in sports or other activities
• explosions or blasts collectively, "blast injuries”
• an injury to the head may be caused by the ingestion and/or exposure to a chemical, toxin or a combination of
• Examples of such chemicals and/or toxins include fires, molds, asbestos, pesticides and insecticides, organic solvents, paints, glues, gases (such as carbon monoxide, hydrogen sulfide, and cyanide), organic metals (such as methyl mercury, tetraethyl lead and organic tin) and/or one or more drugs of abuse.
• gases such as carbon monoxide, hydrogen sulfide, and cyanide
• organic metals such as methyl mercury, tetraethyl lead and organic tin
• an injury to the head may be caused as a result of a subject suffering from an autoimmune disease, a metabolic disorder, a brain tumor, one or more viruses, meningitis, hydrocephalus, hypoxia or any combinations thereof. In some cases, it is not possible to be certain whether any such event or injury has occurred or taken place.
• the closed head injury does not include and specifically excludes a cerebral vascular accident, such as stroke.
• isolated polynucleotide as used herein may mean a polynucleotide (e.g., of genomic, cDNA, or synthetic origin, or a combination thereof) that, by virtue of its origin, the isolated polynucleotide is not associated with all or a portion of a polynucleotide with which the "isolated polynucleotide” is found in nature; is operably linked to a polynucleotide that it is not linked to in nature; or does not occur in nature as part of a larger sequence.
• a polynucleotide e.g., of genomic, cDNA, or synthetic origin, or a combination thereof
• Label and “detectable label” as used herein refer to a moiety attached to an antibody or an analyte to render the reaction between the antibody and the analyte detectable, and the antibody or analyte so labeled is referred to as “detectably labeled.”
• a label can produce a signal that is detectable by visual or instrumental means.
• Various labels include signal-producing substances, such as chromagens, fluorescent compounds, chemiluminescent compounds, radioactive compounds, and the like.
• Representative examples of labels include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. Other labels are described herein.
• the moiety itself, may not be detectable but may become detectable upon reaction with yet another moiety. Use of the term “detectably labeled” is intended to encompass such labeling.
• the detectable label can be a radioactive label (such as 3H, 14C, 32P, 33P, 35S, 90Y, 99Tc, lllln, 1251, 1311, 177Lu, 166Ho, and 153Sm), an enzymatic label (such as horseradish peroxidase, alkaline peroxidase, glucose 6-phosphate dehydrogenase, and the like), a chemiluminescent label (such as acridinium esters, thioesters, or sulfonamides; luminol, isoluminol, phenanthridinium esters, and the like), a fluorescent label (such as fluorescein (e.g., 5-fluorescein, 6-carboxyfluorescein, 3'6-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachloro-fluorescein, 6-
• a radioactive label such as 3H, 14C, 32P, 33P,
• An acridinium compound can be used as a detectable label in a homogeneous chemiluminescent assay (see, e.g., Adamczyk etal., Bioorg. Med Ghent. Lett. 16: 1324-1328 (2006); Adamczyk et al., Bioorg. Med Chem. Lett. 4: 2313-2317 (2004); Adamczyk et al, Biorg. Med Chem. Lett. 14: 3917-3921 (2004); and Adamczyk etal., Org. Lett. 5: 3779-3782 (2003)).
• the acridinium compound is an acridinium-9-carboxamide.
• Methods for preparing acridinium 9-carboxamides are described in Mattingly, J. Biolumin.
• an acridinium compound is an acridinium-9-carboxylate aryl ester.
• An example of an acridinium-9-carboxylate aryl ester of formula ⁇ is 10-methyl-9- (phenoxycarbonyl)acridinium fluorosulfonate (available from Cayman Chemical, Ann Arbor, MI).
• Methods for preparing acridinium 9-carboxylate aryl esters are described in McCapra et al., Photochem. Photobiol. 4: 1111-21 (1965); Razavi etal., Luminescence 15: 245-249 (2000); Razavi etal., Luminescence 15: 239-244 (2000); and U.S. Patent No.
• chemiluminescent emission for the acridinium-9-carboxylate aryl ester is completed rapidly, i.e., in under 1 second, while the acridinium-9-carboxamide chemiluminescent emission extends over 2 seconds.
• Acridinium-9-carboxylate aryl ester loses its
• the amount of protein removed or separated from the test sample can be about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%.
• Acridinium-9-carboxylate aryl ester can be dissolved in any suitable solvent, such as degassed anhydrous N,N-dimethylformamide (DMF) or aqueous sodium cholate.
• DMF degassed anhydrous N,N-dimethylformamide
• aqueous sodium cholate aqueous sodium cholate
• Linking sequence refers to a natural or artificial polypeptide sequence that is connected to one or more polypeptide sequences of interest (e.g., full-length, fragments, etc.).
• the term "connected” refers to the joining of the linking sequence to the polypeptide sequence of interest.
• Such polypeptide sequences are preferably joined by one or more peptide bonds.
• Linking sequences can have a length of from about 4 to about 50 amino acids. Preferably, the length of the linking sequence is from about 6 to about 30 amino acids. Natural linking sequences can be modified by amino acid
• Linking sequences can be used for many purposes, including in recombinant Fabs.
• Exemplary linking sequences include, but are not limited to: (i) Histidine (His) tags, such as a 6X His tag, which has an amino acid sequence of HHHHHH (SEQ ID NO:2), are useful as linking sequences to facilitate the isolation and purification of polypeptides and antibodies of interest; (ii) Histidine (His) tags, such as a 6X His tag, which has an amino acid sequence of HHHHHH (SEQ ID NO:2), are useful as linking sequences to facilitate the isolation and purification of polypeptides and antibodies of interest; (ii)
• Enterokinase cleavage sites like His tags, are used in the isolation and purification of proteins and antibodies of interest. Often, enterokinase cleavage sites are used together with His tags in the isolation and purification of proteins and antibodies of interest.
• enterokinase cleavage sites are known in the art. Examples of enterokinase cleavage sites include, but are not limited to, the amino acid sequence of DDDDK (SEQ ID NO:3) and derivatives thereof (e.g., ADDDDK (SEQ ID NO:4), etc.); (iii) Miscellaneous sequences can be used to link or connect the light and/or heavy chain variable regions of single chain variable region fragments. Examples of other linking sequences can be found in Bird et al., Science 242: 423-426 (1988); Huston etal., PNAS USA 85: 5879-5883 (1988); and
• Linking sequences also can be modified for additional functions, such as attachment of drugs or attachment to solid supports.
• the monoclonal antibody for example, can contain a linking sequence, such as a His tag, an enterokinase cleavage site, or both.
• Monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
• the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
• MRI magnetic resonance imaging
• NMR nuclear magnetic resonance
• Multivalent binding protein is used herein to refer to a binding protein comprising two or more antigen binding sites (also referred to herein as “antigen binding domains").
• a multivalent binding protein is preferably engineered to have three or more antigen binding sites, and is generally not a naturally occurring antibody.
• multi specific binding protein refers to a binding protein that can bind two or more related or unrelated targets, including a binding protein capable of binding two or more different epitopes of the same target molecule.
• NDV Negative predictive value
• Reference level refers to an assay cutoff value that is used to assess diagnostic, prognostic, or therapeutic efficacy and that has been linked or is associated herein with various clinical parameters (e.g., presence of disease, stage of disease, severity of disease, progression, non-progression, or improvement of disease, etc.).
• An “absolute amount” as used herein refers to the absolute value of a change or difference between at least two assay results taken or sampled at different time points and, which similar to a reference level, has been linked or is associated herein with various clinical parameters (e.g., presence of disease, stage of disease, severity of disease, progression, non-progression, or
• Absolute value refers to the magnitude of a real number (such as, for example, the difference between two compared levels (such as levels taken at a first time point and levels taken at a second time point)) without regard to its sign, i.e., regardless of whether it is positive or negative.
• reference levels and absolute amounts e.g., calculated by comparing reference levels at different time points.
• reference levels and absolute amounts may vary depending on the nature of the immunoassay (e.g., antibodies employed, reaction conditions, sample purity, etc.) and that assays can be compared and standardized. It further is well within the ordinary skill of one in the art to adapt the disclosure herein for other immunoassays to obtain immunoassay-specific reference levels and absolute amounts for those other immunoassays based on the description provided by this disclosure. Whereas the precise value of the reference level and absolute amount may vary between assays, the findings as described herein should be generally applicable and capable of being extrapolated to other assays.
• the data provided herein provide greater temporal resolution of UCH-L1 levels in the context of TBI, and are not limited to single time-point assessments. Data from the present disclosure demonstrate that UCH-L1 levels vary dynamically post-injury, which can be evaluated using a variety of different assays.
• Point-of-care device refers to a device used to provide medical diagnostic testing at or near the point-of-care (namely, outside of a laboratory), at the time and place of patient care (such as in a hospital, physician's office, urgent or other medical care facility, a patient's home, a nursing home and/or a long term care and/or hospice facility).
• point-of- care devices include those produced by Abbott Laboratories (Abbott Park, IL) (e.g., i-STAT and i-STAT Alinity, Universal Biosensors (Rowville, Australia) (see US 2006/0134713), Axis-Shield PoC AS (Oslo, Norway) and Clinical Lab Products (Los Angeles, USA).
• PSV Positive predictive value
• Quantality control reagents in the context of immunoassays and kits described herein, include, but are not limited to, calibrators, controls, and sensitivity panels.
• calibrator typically is used (e.g., one or more, such as a plurality) in order to establish calibration (standard) curves for interpolation of the concentration of an analyte, such as an antibody or an analyte.
• a single calibrator which is near a reference level or control level (e.g., “low,” “medium,” or “high” levels), can be used.
• Multiple calibrators i.e., more than one calibrator or a varying amount of calibrators) can be used in conjunction to comprise a "sensitivity panel.”
• a "receiver operating characteristic” curve or "ROC” curve refers to a graphical plot that illustrates the performance of a binary classifier system as its discrimination threshold is varied.
• the ROC curve demonstrates the tradeoff between sensitivity and specificity (any increase in sensitivity will be accompanied by a decrease in specificity); the closer the curve follows the left-hand border and then the top border of the ROC space, the more accurate the test; the closer the curve comes to the 45-degree diagonal of the ROC space, the less accurate the test; the slope of the tangent line at a cutoff point gives the likelihood ratio (LR) for that value of the test; and the area under the curve is a measure of text accuracy.
• Recombinant antibody and “recombinant antibodies” refer to antibodies prepared by one or more steps, including cloning nucleic acid sequences encoding all or a part of one or more monoclonal antibodies into an appropriate expression vector by recombinant techniques and subsequently expressing the antibody in an appropriate host cell.
• the terms include, but are not limited to, recombinantly produced monoclonal antibodies, chimeric antibodies, humanized antibodies (fully or partially humanized), multi-specific or multivalent structures formed from antibody fragments, bifunctional antibodies, heteroconjugate Abs, DVD-Ig®s, and other antibodies as described in (i) herein.
• bifunctional antibody refers to an antibody that comprises a first arm having a specificity for one antigenic site and a second arm having a specificity for a different antigenic site, i.e., the bifunctional antibodies have a dual specificity.
• stratification of subjects refers to the evaluation of factors including biomarkers, to predict the risk of occurrence of future events including disease onset or disease progression, so that treatment decisions regarding the subject may be made on a more informed basis.
• sample may be used interchangeably and may be a sample of blood such as whole blood, tissue, urine, serum, plasma, amniotic fluid, cerebrospinal fluid, placental cells or tissue, endothelial cells, leukocytes, or monocytes.
• the sample can be used directly as obtained from a patient or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art.
• the sample is a whole blood sample, plasma or a serum sample. In another embodiment, the sample is whole blood. In another embodiment, the sample is serum. In yet another embodiment, the sample is plasma. In yet other embodiments, the sample is a whole blood sample obtained from a human. In still another embodiment, the sample is a plasma sample obtained from a human. In still yet another embodiment, the sample is a serum sample obtained from a human.
• a variety of cell types, tissue, or bodily fluid may be utilized to obtain a sample.
• Such cell types, tissues, and fluid may include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood (such as whole blood), plasma, serum, red blood cells, platelets, interstitial fluid, cerebral spinal fluid, etc.
• Cell types and tissues may also include lymph fluid, cerebrospinal fluid, a fluid collected by
• a tissue or cell type may be provided by removing a sample of cells from a human and a non-human animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose).
• Archival tissues such as those having treatment or outcome history, may also be used. Protein or nucleotide isolation and/or purification may not be necessary.
• Sensitivity refers to the proportion of subjects for whom the outcome is positive that are correctly identified as positive (e.g., correctly identifing those subjects with a disease or medical condition for which they are being tested). For example, this might include correctly identifying subjects as having a moderate to severe TBI from those having a mild TBI, correctly identifying subjects as having a mild TBI from those having a moderate to severe TBI, correctly identifying subjects as having a moderate to severe TBI from those having no TBI or correctly identifying subjects as having a mild TBI from those having no TBI).
• Specificity of an assay as used herein refers to the proportion of subjects for whom the outcome is negative that are correctly identified as negative (e.g., correctly identifying those subjects who do not have a disease or medical condition for which they are being tested). For example, this might include correctly identifying subjects as not having a moderate to severe TBI from those having a mild TBI, correctly identifying subjects as not having a mild TBI from those having a moderate to severe TBI or correctly identifying subjects as not having any TBI).
• Series of calibrating compositions refers to a plurality of compositions comprising a known concentration of UCH-L1, wherein each of the compositions differs from the other compositions in the series by the concentration of UCH-L1.
• Single molecule detection refers to the detection and/or measurement of a single molecule of an analyte in a test sample at very low levels of concentration (such as pg/mL or femtogram/mL levels).
• a number of different single molecule analyzers or devices are known in the art and include nanopore and nanowell devices. Examples of nanopore devices are described in International Patent Publication No. WO 2016/161402, which is hereby incorporated by reference in its entirety. Examples of nanowell device are described in International Patent Publication No. WO 2016/161400, which is hereby incorporated by reference in its entirety.
• Solid phase or “solid support” as used interchangeably herein, refers to any material that can be used to attach and/or attract and immobilize (1) one or more capture agents or capture specific binding partners, or (2) one or more detection agents or detection specific binding partners.
• the solid phase can be chosen for its intrinsic ability to attract and immobilize a capture agent.
• the solid phase can have affixed thereto a linking agent that has the ability to attract and immobilize the (1) capture agent or capture specific binding partner, or (2) detection agent or detection specific binding partner.
• the linking agent can include a charged substance that is oppositely charged with respect to the capture agent (e.g., capture specific binding partner) or detection agent (e.g., detection specific binding partner) itself or to a charged substance conjugated to the (1) capture agent or capture specific binding partner or (2) detection agent or detection specific binding partner.
• the linking agent can be any binding partner (preferably specific) that is immobilized on (attached to) the solid phase and that has the ability to immobilize the (1) capture agent or capture specific binding partner, or (2) detection agent or detection specific binding partner through a binding reaction.
• the linking agent enables the indirect binding of the capture agent to a solid phase material before the performance of the assay or during the performance of the assay.
• the solid phase can be plastic, derivatized plastic, magnetic, or non-magnetic metal, glass or silicon, including, for example, a test tube, microtiter well, sheet, bead, microparticle, chip, and other configurations known to those of ordinary skill in the art.
• Specific binding or “specifically binding” as used herein may refer to the interaction of an antibody, a protein, or a peptide with a second chemical species, wherein the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope "A”, the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled "A” and the antibody, will reduce the amount of labeled A bound to the antibody.
• a particular structure e.g., an antigenic determinant or epitope
• Specific binding partner is a member of a specific binding pair.
• a specific binding pair comprises two different molecules, which specifically bind to each other through chemical or physical means. Therefore, in addition to antigen and antibody specific binding pairs of common immunoassays, other specific binding pairs can include biotin and avidin (or streptavidin), carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzymes and enzyme inhibitors, and the like.
• specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog.
• Immunoreactive specific binding members include antigens, antigen fragments, and antibodies, including monoclonal and polyclonal antibodies as well as complexes and fragments thereof, whether isolated or recombinantly produced.
• Statistically significant refers to the likelihood that a relationship between two or more variables is caused by something other than random chance.
• Statistical hypothesis testing is used to determine whether the result of a data set is statistically significant. In statistical hypothesis testing, a statistical significant result is attained whenever the observed /rvalue of a test statistic is less than the significance level defined of the study. The /7-value is the probability of obtaining results at least as extreme as those observed, given that the null hypothesis is true. Examples of statistical hypothesis analysis include Wilcoxon signed-rank test, t-test, Chi-Square or Fisher's exact test.
• “Significant” as used herein refers to a change that has not been determined to be statistically significant (e.g., it may not have been subject to statistical hypothesis testing).
• “Subject” and “patient” as used herein interchangeably refers to any vertebrate, including, but not limited to, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (for example, a monkey, such as a cynomolgous or rhesus monkey, chimpanzee, etc.) and a human).
• the subject may be a human or a non-human.
• the subject is a human.
• the subject or patient may be undergoing other forms of treatment.
• Treatment are each used interchangeably herein to describe reversing, alleviating, or inhibiting the progress of a disease and/or injury, or one or more symptoms of such disease, to which such term applies.
• the term also refers to preventing a disease, and includes preventing the onset of a disease, or preventing the symptoms associated with a disease.
• a treatment may be either performed in an acute or chronic way.
• the term also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease.
• Such prevention or reduction of the severity of a disease prior to affliction refers to administration of a pharmaceutical composition to a subject that is not at the time of administration afflicted with the disease. "Preventing” also refers to preventing the recurrence of a disease or of one or more symptoms associated with such disease. "Treatment” and “therapeutically,” refer to the act of treating, as “treating” is defined above.
• TBI Traumatic Brain Injury
• TBI tissue-like vascular accidents
• causes of TBI include the ingestion and/or exposure to one or more chemicals or toxins (such as fires, molds, asbestos, pesticides and insecticides, organic solvents, paints, glues, gases (such as carbon monoxide, hydrogen sulfide, and cyanide), organic metals (such as methyl mercury, tetraethyl lead and organic tin), one or more drugs of abuse or combinations thereof).
• chemicals or toxins such as fires, molds, asbestos, pesticides and insecticides, organic solvents, paints, glues, gases (such as carbon monoxide, hydrogen sulfide, and cyanide), organic metals (such as methyl mercury, tetraethyl lead and organic tin), one or more drugs of abuse or combinations thereof).
• TBI can occur in subjects suffering from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, one or more viruses, meningitis, hydrocephalus or combinations thereof. Young adults and the elderly are the age groups at highest risk for TBI.
• traumatic brain injury or TBI does not include and specifically excludes cerebral vascular accidents such as strokes.
• Mild ⁇ ' refers to a brain injury where loss of consciousness is brief and usually a few seconds or minutes and/or confusion and disorientation is shorter than 1 hour. Mild TBI is also referred to as a concussion, minor head trauma, minor TBI, minor brain injury, and minor head injury. While MRI and CT scans are often normal, the individual with mild TBI may have cognitive problems such as headache, difficulty thinking, memory problems, attention deficits, mood swings and frustration.
• Mild TBI is the most prevalent TBI and is often missed at time of initial injury. Typically, a subject has a Glasgow Coma scale number of between 13-15 (such as 13-15 or 14-15). Fifteen percent (15%) of people with mild TBI have symptoms that last 3 months or more. Mild TBI is defined as the result of the forceful motion of the head or impact causing a brief change in mental status (confusion, disorientation or loss of memory) or loss of consciousness for less than 30 minutes. Common symptoms of mild TBI include fatigue, headaches, visual disturbances, memory loss, poor attention/concentration, sleep
• TBI Trizziness/loss of balance
• irritability-emotional disturbances feelings of depression
• Other symptoms associated with mild TBI include nausea, loss of smell, sensitivity to light and sounds, mood changes, getting lost or confused, and/or slowness in thinking.
• Modemize ⁇ ' refers to a brain injury where loss of consciousness and/or confusion and disorientation is between 1 and 24 hours and the subject has a Glasgow Coma scale number of between 9-13 (such as 9-12 or 9-13). The individual with moderate TBI have abnormal brain imaging results.
• severe TBI refers to a brain injury where loss of consciousness is more than 24 hours and memory loss after the injury or penetrating skull injury longer than 24 hours and the subject has a Glasgow Coma scale number between 3-8. The deficits range from impairment of higher level cognitive functions to comatose states. Survivors may have limited function of arms or legs, abnormal speech or language, loss of thinking ability or emotional problems. Individuals with severe injuries can be left in long-term unresponsive states. For many people with severe TBI, long-term rehabilitation is often necessary to maximize function and independence.
• Common symptoms of moderate to severe TBI include cognitive deficits including difficulties with attention, concentration, distractibility, memory, speed of processing, confusion, perseveration, impulsiveness, language processing, and/or "executive functions", not understanding the spoken word (receptive aphasia), difficulty speaking and being understood (expressive aphasia), slurred speech, speaking very fast or very slow, problems reading, problems writing, difficulties with interpretation of touch, temperature, movement, limb position and fine discrimination, the integration or patterning of sensory impressions into psychologically meaningful data, partial or total loss of vision, weakness of eye muscles and double vision (diplopia), blurred vision, problems judging distance, involuntary eye movements (nystagmus), intolerance of light (photophobia), hearing, such as decrease or loss of hearing, ringing in the ears (tinnitus), increased sensitivity to sounds, loss or diminished sense of smell (anosmia), loss or diminished sense of taste, the convulsions associated with epilepsy that can be several types and can involve
• Ubiquitin carboxy-terminal hydrolase LI or "UCH-L1” as used interchangeably herein refers to a deubiquitinating enzyme encoded by the UCH-L1 gene in humans.
• UCH- Ll also known as ubiquitin carboxyl-terminal esterase LI and ubiquitin thiolesterase, is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer.
• UCH-L1 status can mean either the level or amount of UCH-L1 at a point in time (such as with a single measure of UCH-L1), the level or amount of UCH-L1 associated with monitoring (such as with a repeat test on a subject to identify an increase or decrease in UCH-L1 amount), the level or amount of UCH-L1 associated with treatment for traumatic brain injury (whether a primary brain injury and/or a secondary brain injury) or combinations thereof.
• Variant is used herein to describe a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity.
• biological activity include the ability to be bound by a specific antibody or to promote an immune response.
• Variant is also used herein to describe a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity.
• a conservative substitution of an amino acid i.e., replacing an amino acid with a different amino acid of similar properties ⁇ e.g., hydrophilicity, degree, and distribution of charged regions) is recognized in the art as typically involving a minor change.
• hydropathic index of amino acids As understood in the art. Kyte etal , J. Mol. Biol. 157:105-132 (1982).
• the hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ⁇ 2 are substituted.
• the hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function.
• Variant also can be used to refer to an antigenically reactive fragment of an anti-UCH-Ll antibody that differs from the corresponding fragment of anti-UCH-Ll antibody in amino acid sequence but is still antigenically reactive and can compete with the corresponding fragment of anti-UCH-Ll antibody for binding with UCH-L1.
• Variant also can be used to describe a polypeptide or a fragment thereof that has been differentially processed, such as by proteolysis,
• Vector is used herein to describe a nucleic acid molecule that can transport another nucleic acid to which it has been linked.
• plasmid refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated.
• viral vector Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
• Certain vectors can replicate autonomously in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
• vectors e.g., non-episomal mammalian vectors
• vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
• certain vectors are capable of directing the expression of genes to which they are operatively linked.
• Such vectors are referred to herein as "recombinant expression vectors” (or simply, “expression vectors”).
• expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
• “Plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector.
• RNA versions of vectors may also find use in the context of the present disclosure.
• the present disclosure relates, among other methods, to a method of aiding in the diagnosis and evaluation of whether a human subject has sustained or may have sustained an injury to the head.
• the method can aid in diagnosing and evaluating the extent of traumatic brain injury in a subject with a suspected injury to the head (e.g., determining whether the subject has mild TBI or moderate to severe TBI).
• determining whether the subject has mild traumatic brain injury or moderate to severe traumatic brain injury refers to use of the method (e.g., with other information such as clinical assessment data) to determine that the subject is more likely than not to have mild TBI or moderate to severe TBI.
• the method can include obtaining a sample within 24 hours of a suspected injury to the subject, contacting the sample with an antibody for an early biomarker of traumatic brain injury, the early biomarker of traumatic brain injury consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), to allow formation of a complex of the antibody and UCH-L1.
• an antibody for an early biomarker of traumatic brain injury consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), to allow formation of a complex of the antibody and UCH-L1.
• the method can include obtaining a first sample taken at a first time point and a second sample taken at a second time point from the human subject, the first sample taken from the human subject within 24 hours of injury and the second sample taken from the human subject at a second time point after the first time point, such as about 3 hours to about 6 hours after the first sample is taken, contacting the first sample and the second sample separately with an antibody for an early biomarker of traumatic brain injury, the early biomarker of traumatic brain injury consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), to allow formation of a complex of the antibody and UCH-L1.
• the method also includes detecting the resulting antibody-UCH-Ll complex.
• the early biomarker increases within about 0 to about 6 hours after the suspected injury and then decreases or increases thereafter in subjects with traumatic brain injury.
• the onset of the presence of UCH-L1 appears within about 0, about 0.5 hours, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, or about 6 hours after injury to the head.
• the sample can be a biological sample from a subject (e.g., serum or blood sample).
• the method includes: performing an assay on a first sample and optionally a second sample to measure or detect a level of ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in the first sample and/or second sample, wherein the first sample is taken from the subject at a first time point within 24 hours after a suspected injury to the head and the second sample is taken from the subject at a second time point after the first time point, such as about 3 hours to about 6 hours after the first time point; and determining whether the subject has sustained an injury to the head by determining the extent of the traumatic brain injury.
• UCH-L1 ubiquitin carboxy-terminal hydrolase LI
• the subject is determined as having moderate to severe traumatic brain injury when (i) the level of UCH-L1 in the first and/or second sample is higher than a reference level of UCH-L1 and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the first and/or second sample is lower than a reference level of UCH-L1; (ii) there is a statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample and the subject is determined as having mild traumatic brain injury when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample; (iii) the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample or is determined as having mild traumatic brain injury when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample; (iv)
• the first absolute amount and the second absolute amount can be the same. In some embodiments, the first absolute amount and the second absolute amount can be different.
• X refers to an integer that has a value other than 0.
• determining whether the subject has mild traumatic brain injury or moderate to severe traumatic brain injury refers to use of the method, with or without other methods, to determine that the subject is more likely than not to have mild TBI or moderate to severe TBI.
• the subject has received a Glasgow Coma Scale score before or after the assay is performed. In some embodiments, the subject is suspected as having moderate to severe traumatic brain injury based on the Glasgow Coma Scale score. In some embodiments, the reference level is correlated with subjects having moderate to severe traumatic brain injury. In some embodiments, the reference level is correlated with subjects having moderate to severe traumatic brain injury by analysis of corresponding samples using a corresponding assay type to identify the reference level.
• the subject may not have received a Glasgow Coma Scale score before the assay is performed. Alternatively, in some embodiments, the subject may not have received a Glasgow Coma Scale score after the assay is performed. Additionally, in other embodiments, the subject may receive a head CT before the assay is performed. Also, alternatively, in other embodiments, the subject may not have received a head CT before the assay is performed. Still further, the subject may not have received a Glasgow Coma Scale or a head CT before the assay is performed. Still in further,
• the subject may have received a Glasgow Coma Scale but not a head CT before the assay is performed. Yet in further embodiments, the subject may have received a head CT but not a Glasgow Coma Scale before the assay is performed. In still further embodiments, the subject may have received a head CT and a Glasgow Coma Scale before the assay is performed.
• the reference level is correlated with a Glasgow Coma Scale score of 3-12. In some embodiments, the subject is suspected as having mild traumatic brain injury based on the Glasgow Coma Scale score. In some embodiments, the reference level is correlated with subjects having mild traumatic brain injury. In some embodiments, the reference level is correlated with a Glasgow Coma Scale score of 13-15. In some
• the reference level is correlated with subjects having mild traumatic brain injury by analysis of corresponding samples using a corresponding assay type to identify the reference level.
• a reference level can also be employed as a benchmark against which to assess results obtained upon assaying a test sample for UCH-L1.
• the reference level is obtained by running a particular assay a sufficient number of times and under appropriate conditions such that a linkage or association of analyte presence, amount or concentration with a particular stage or endpoint of TBI or with particular indicia can be made.
• the reference level is obtained with assays of reference subjects (or populations of subjects).
• the UCH-L1 measured can include UCH-L1 fragments thereof, degradation products thereof, and/or enzymatic cleavage products thereof.
• the reference level is determined by an assay having a sensitivity of between at least about 85% to about 100% and a specificity of between at least about 30% to about 100%.
• the sensitivity is at least about 85.0%, at least about 87.5%, at least about 90.0%, at least about 95.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or about 100.0%.
• the specificity is at least about 30.0%, at least about 31.0%, at least about 32.0%, at least about 33.0%, at least about 34.0%, at least about 35.0%, at least about 36.0%, at least about 37.0%, at least about 38.0%, at least about 39.0%, at least about 40.0%, at least about 45.0%, at least about 50.0%, at least about 55.0%, at least about 60.0%, at least about 65.0%, at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 90.0%, at least about 91.0%, at least about 92.0%, at least about 93.0%, at least about 94.0%, at least about 95.0%, at least about 96.0%, at least about 97.0%, at least about 98.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at
• the sensitivity is at least about 99% and the specificity is at least about 75%, the sensitivity is at least about 99% and the specificity is at least about 99%, or the sensitivity is about 100% and the specificity is about 100%. In some embodiments, is at least about 99% and the specificity is at least about 75%. In yet other embodiments, the sensitivity is at least about 99% and the specificity is at least about 99%. In still further embodiments, the sensitivity is about 100% and the specificity is about 100%.
• the reference level can be between at least about 50 pg/mL to about 12000 pg/mL. In some embodiments, the reference level can be between at least about 50 pg/mL to about 12000 pg/mL, between at least about 50 pg/mL to about 11000 pg/mL, between at least about 50 pg/mL to about 10000 pg/mL, between at least about 50 pg/mL to about 9500 pg/mL, between at least about 50 pg/mL to about 9000 pg/mL, between at least about 50 pg/mL to about 8500 pg/mL, between at least about 50 pg/mL to about 8000 pg/mL, between at least about 50 pg/mL to about 7500 pg/mL, between at least about 50 pg/mL to about 7000 pg/mL, between at least about 50 pg/mL
• the reference level can be between at least about 65 pg/mL to about 9019 pg/mL.
• the reference level can be at least about 50 pg/mL, at least about 55 pg/mL, at least about 60 pg/mL, at least about 65 pg/mL, at least about 70 pg/mL, at least about 75 pg/mL, at least about 80 pg/mL, at least about 85 pg/mL, at least about 90 pg/mL, at least about 95 pg/mL, at least about 96 pg/mL, at least about 97 pg/mL, at least about 98 pg/mL, at least about 99 pg/mL, at least about 100 pg/mL, at least about 150 pg/mL, at least about 200 pg/mL, at least about 205 pg/mL, at least about 206 pg/mL, at
• the first sample is taken within 24 hours after the suspected injury and the second sample is taken within about 3 hours to about 6 hours after the first sample and the reference level is determined by an assay having a particular sensitivity and specificity, as described above.
• the first sample can be taken within about 0 hours, within about thirty minutes, within about 1 hour, within about 2 hours, within about 3 hours, within about 4 hours, within about 5 hours, within about 6 hours, within about 7 hours, within about 8 hours, within about 9 hours, within about 10 hours, within about 11 hours, within about 12 hours, within about 13 hours, within about 14 hours, within about 15 hours, within about 16 hours, within about 17 hours, within about 18 hours, within about 19 hours, within about 20 hours, within about 21 hours, within about 22 hours, within about 23 hours, within about 24 hours, or more than about 24 hours after the suspected injury.
• the first sample is taken within about 0 to about 1 hours, within about 0 to about 2 hours, within about 0 to about 3 hours, within about 0 to about 4 hours, within about 0 to about 5 hours, within about 0 to about 6 hours, within about 0 to about 7 hours, within about 0 to about 8 hours, within about 0 to about 9 hours, within about 0 to about 10 hours, within about 0 to about 11 hours, within about 0 to about 12 hours, within about 0 to about 18 hours, within about 6 to about 12 hours, within about 12 to about 18 hours, within about 18 to about 24 hours, or greater than 24 hours after the suspected injury and the reference level is determined by an assay having a particular sensitivity and specificity, such as a sensitivity between at least about 85% and 100% and a specificity of between at least about 30% and 100%, such as a sensitivity of about 100% and a specificity of at least about 75%, a sensitivity of at least about 99% and a specificity of at least about 75%,
• the first sample can be obtained within about 0 to about 6 hours, the reference level can be about 311 pg/mL and the assay has a sensitivity of about 100% and a specificity of at least about 33%. In some embodiments, the first sample can be obtained within about 0 to about 6 hours, the reference level can be about 509 pg/mL and the assay has a sensitivity of about 100% and a specificity of at least about 66%. In some embodiments, the first sample can be obtained within about 0 to about 6 hours, the reference level can be about 710 pg/mL and the assay has a sensitivity of about 100% and a specificity of at least about 92%. In some embodiments, the first sample can be obtained within about 0 to about 6 hours, the reference level can be about 9019 pg/mL and the assay has a sensitivity of about 100% and a specificity of about 100%.
• the first sample can be obtained between about 6 hours to 12 hours after the suspected injury and the reference level is between about 65 pg/mL and about 9019 pg/mL and determined by an assay having a sensitivity between at least about 85% to about 100% and a specificity between at least about 30% and about 100%. In some embodiments, the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 98 pg/mL and determined by an assay having a sensitivity of about 100% and a specificity of at least about 30%.
• the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 209 pg/mL and determined by an assay having a sensitivity of about 100% and a specificity of at least about 63%. In some embodiments, the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 238 pg/mL and determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 70%. In some embodiments, the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 569 pg/mL and determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 96%.
• the first sample is obtained at a first time point and the second sample is obtained at second time point to determine whether the subject has a mild or moderate to severe TBI.
• the first time point is about 0 to about 24 hours after the injury or suspected injury to the head.
• the first time point can be between about 0 to about 24 hours, about 0 to about 20 hours, about 0 to about 18 hours, about 0 to about 16 hours, about 0 to about 14 hours, about 0 to about 12 hours, about 0 to about 10 hours, about 0 to about 8 hours, about 0 to about 6 hours, about 0 to about 4 hours, about 0 to about 2 hours, about 0 to about 1 hours, about 0 to about 1.5 hours, about 0.5 hours to about 24 hours, about 0.5 hours to about 20 hours, about 0.5 hours to about 18 hours, about 0.5 hours to about 16 hours, about 0.5 hours to about 14 hours, about 0.5 hours to about 12 hours, about 0.5 hours to about 10 hours, about 0.5 hours to about 8 hours, about 0.5 hours to about 6 hours, about 0.5 hours to about 4 hours, about 0.5 hours to about 2 hours, about 0.5 hours to about 1 hours, about 0.5 hours to about 1.5 hours, about 1 hour to about 24 hours, about 1 hour to about 20 hours, about 1 hour to about 18 hours, about
• the first time point can be between about 0 hour to 6 hours, between about 6 hours to 12 hours, between about 12 hours to 18 hours, or between about 18 hours to 24 hours. In some embodiments, the first time point is between about 0 hour to 6 hours. In some embodiments, the first time point is between about 6 hours to about 12 hours. In some embodiments, the first time point is between about 12 hour to about 18 hours. In other embodiments, the first time point is between about 18 hours to about 24 hours.
• the second time point is about 1 hour to about 10 hours after the first time point, such as about 3 hours to about 6 hours after the first time point. In some embodiments, the second time point is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours after the first time point.
• the statistically significant increase or decrease is at least about 0.1-fold, at least about 0.2-fold, at least about 0.3-fold, at least about 0.4-fold, at least about 0.5-fold, at least about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, at least about 1-fold, at least 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16- fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20-fold from the level of UCH-L1 in the first sample taken at a first time point to the level of
• the statistically significant increase or decrease is less than about 0.1-fold, less than about 0.2-fold, less than about 0.3-fold, less than about 0.4-fold, less than about 0.5-fold, at least about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, less than about 1-fold, less than 1.5-fold, less than about 2-fold, less than about 3-fold, less than about 4-fold, less than about 5-fold, less than about 6-fold, less than about 7-fold, less than 8-fold, less than 9- fold, less than 10-fold, less than 11-fold, less than 12-fold, less than 13-fold, less than 14- fold, less than 15-fold, less than 16-fold, less than 17-fold, less than 18-fold, less than 19- fold, or less than 20-fold from the level of UCH-L1 in the first sample taken at a first time point to the level of
• the statistically significant increase or decrease is more than about 0.1-fold, more than about 0.2-fold, more than about 0.3-fold, more than about 0.4-fold, more than about 0.5-fold, more than about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, more than about 1-fold, more than 1.5-fold, more than about 2-fold, more than about 3-fold, more than about 4-fold, more than about 5-fold, more than about 6-fold, more than about 7-fold, more than 8-fold, more than 9-fold, more than 10-fold, more than 11-fold, more than 12-fold, more than 13-fold, more than 14-fold, more than 15-fold, more than 16-fold, more than 17-fold, more than 18-fold, more than 19-fold, or more than 20-fold from the level of UCH-L1 in the second sample taken at a second time point to the level of
• the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 1-fold from the second time point to the first time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 0.73-fold from the second time point to the first time point. In some
• the first time point is about 0 to about 12 hours after the suspected injury
• the reference level of UCH-L1 is between about 350 pg/mL and about 550 pg/mL
• the statistically significant increase is more than about 0.73-fold from the second time point to the first time point.
• the absolute amount can be determined by an assay having a sensitivity of between at least about 70% to about 100% and a specificity of between at least about 30% to about 100%.
• the sensitivity is at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 87.5%, at least about 90.0%, at least about 95.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or at least about 100.0%.
• the specificity is at least about 30.0%, at least about 31.0%, at least about 32.0%, at least about 33.0%, at least about 34.0%, at least about 35.0%, at least about 36.0%, at least about 37.0%, at least about 38.0%, at least about 39.0%, at least about 40.0%, at least about 45.0%, at least about 50.0%, at least about 55.0%, at least about 60.0%, at least about 65.0%, at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 90.0%, at least about 91.0%, at least about 92.0%, at least about 93.0%, at least about 94.0%, at least about 95.0%, at least about 96.0%, at least about 97.0%, at least about 98.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at
• the absolute amount can be between at least about 20 pg/mL to about 6100 pg/mL. In some embodiments, the absolute amount can be between at least about 20 pg/mL to about 6100 pg/mL, between at least about 20 pg/mL to about 6000 pg/mL, between at least about 20 pg/mL to about 5500 pg/mL, between at least about 20 pg/mL to about 5000 pg/mL, between at least about 20 pg/mL to about 4500 pg/mL, between at least about 20 pg/mL to about 4000 pg/mL, between at least about 20 pg/mL to about 3500 pg/mL, between at least about 20 pg/mL to about 3000 pg/mL, between at least about 20 pg/mL to about 2500 pg/mL, between at least about 20 pg/mL, between at least about 20 p
• the absolute amount can be at least about 20 pg/mL, at least about 21 pg/mL, at least about 22 pg/mL, at least about 23 pg/mL, at least about 24 pg/mL, at least about 25 pg/mL, at least about 26 pg/mL, at least about 27 pg/mL, at least about 28 pg/mL, at least about 29 pg/mL, at least about 30 pg/mL, at least about 35 pg/mL, at least about 40 pg/mL, at least about 45 pg/mL, at least about 50 pg/mL, at least about 55 pg/mL, at least about 60 pg/mL, at least about 65 pg/mL, at least about 70 pg/mL, at least about 75 pg/mL, at least about 80 pg/mL, at least about 85 pg/mL, at least about
• the first sample can be obtained within about 0 to about 6 hours and the reference level can be about 2528 pg/mL determined by an assay having a sensitivity of about 100% and a specificity of about 100%. In some embodiments, the first sample can be obtained within about 0 to about 6 hours and the reference level can be about 129 pg/mL determined by an assay having a sensitivity of at least about 70% and a specificity of at least about 92%. In some embodiments, the first sample can be obtained within about 0 to about 10 hours and the reference level can be about 25 pg/mL determined by an assay having a sensitivity of about 100% and a specificity of at least about 36%.
• the first sample can be obtained within about 0 to about 11 hours and the reference level can be about 25 pg/mL determined by an assay having a sensitivity of about 100% and a specificity of at least about 32%. In some embodiments, the first sample can be obtained within about 0 to about 12 hours and the reference level can be about 129 pg/mL determined by an assay having a sensitivity of at least about 75% and a specificity of at least about 76%.
• the method further includes treating a human subject assessed as having moderate to severe traumatic brain injury with a traumatic brain injury treatment, as described below. In some embodiments, the method further includes monitoring a human subject assessed as having mild traumatic brain injury, as described below.
• test can be any assay known in the art such as, for example, immunoassays, clinical chemistry assays, single molecule detection assays, protein immunoprecipitation,
• Immunoelectrophoresis chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high- performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC/MS).
• HPLC high- performance liquid chromatography
• LC/MS liquid chromatography-mass spectrometry
• the assay can be employed in a clinical chemistry format such as would be known by one of ordinary skill in the art. Such assays are described in further detail herein in Sections 9-11.
• the values used in an assay that employs specific sample type (e.g., such as an immunoassay that utilizes serum or a point-of-care device that employs whole blood) can be extrapolated to other assay formats using known techniques in the art, such as assay standardization.
• specific sample type e.g., such as an immunoassay that utilizes serum or a point-of-care device that employs whole blood
• assay standardization one way in which assay standardization can be performed is by applying a factor to the calibrator employed in the assay to make the sample concentration read higher or lower to get a slope that aligns with the comparator method.
• the present disclosure relates to a method of aiding in determining the extent of traumatic brain injury in a human subject with a suspected injury to the head (e.g., determining whether the subject has mild traumatic brain injury or moderate to severe traumatic brain injury).
• determining the extent of traumatic brain injury in a human subject refers to use of the method, with or without other methods, to determine that the subject is more likely than not to have mild TBI or moderate to severe TBI.
• the method includes performing an assay on at least two samples obtained from the subject and detecting in the at least two samples an early biomarker of traumatic brain injury.
• the first sample is taken from the human subject within 24 hours of injury and the second sample is taken from the human subject about 3 to about 6 hours after the first sample is taken.
• the early biomarker is ubiquitin carboxy-terminal hydrolase LI (UCH-L1).
• the UCH-L1 appears within about 2 to about 24 hours after the onset of injury to the head.
• the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the onset of the suspected injury.
• Levels of UCH-L1 are determined for each of the first sample and second sample.
• the level of UCH-L1 is determined to decrease or increase.
• the extent of the traumatic brain injury is determined in the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first sample to the second sample.
• the early biomarker increases within about 0 to about 6 hours after the suspected injury and then decreases or increases thereafter in subjects with traumatic brain injury. In some
• the onset of the presence of UCH-L1 appears within about 0, about 0.5 hours, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about S hours, or about 6 hours after injury to the head.
• the samples can be biological samples.
• the method includes performing an assay on at least two samples obtained from the subject.
• the first sample is taken from the subject within 24 hours of the suspected injury and the second sample is taken from the subject from about 3 to about 6 hours after the first sample is taken.
• the method includes detecting in the at least two samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy- terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; determining the level of UCH-L1 in each of the first sample and second sample and determining if the level of UCH-L1 decreases or increases from the first sample to the second sample; and determining the extent of the traumatic brain injury in the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first sample to the second sample.
• UCH-L1 ubiquitin carboxy- terminal hydrolase LI
• the first sample is taken from the subject at a first time point within 24 hours of the suspected injury and the second sample is taken from the subject at a second time point after the first time point and the subject is determined to have mild or mild to severe traumatic brain injury when the level of UCH-L1 decreases from the first sample to the second sample.
• the UCH-L1 decreases at least about 5% from the increased levels.
• the UCH-L1 levels may decrease about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900%, or about 1000% from the increased levels.
• the UCH-L1 decreases at least about 0.1-fold, at least about 0.2-fold, at least about 0.3-fold, at least about 0.4-fold, at least about 0.5-fold, at least about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, at least about 1-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20-fold from the increased levels.
• the UCH-L1 decreases less than about 0.1 -fold, less than about 0.2-fold, less than about 0.3-fold, less than about 0.4-fold, less than about 0.5-fold, less than about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, less than about 1-fold, less than about 1.5-fold, less than about 2-fold, less than about 3-fold, less than about 4-fold, less than about 5-fold, less than about 6-fold, less than about 7-fold, less than 8-fold, less than 9-fold, less than 10-fold, less than 11 -fold, less than 12-fold, less than 13-fold, less than 14- fold, less than 15-fold, less than 16-fold, less than 17-fold, less than 18-fold, less than 19- fold, or less than 20-fold from the increased levels.
• the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 1-fold from the second time point to the first time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 0.73-fold from the second time point to the first time point. In some
• the first time point is about 0 to about 12 hours after the suspected injury
• the reference level of UCH-L1 is between about 350 pg/mL and about 550 pg/mL
• the statistically significant increase is more than about 0.73-fold from the second time point to the first time point.
• the subject is assessed as having mild or mild to severe traumatic brain injury when the levels of UCH-L1 in the first sample changes ⁇ i.e., increases or decreases) compared to the levels of UCH-L1 in the second sample from at least about 20 pg/mL to at least about 6100 pg/mL.
• the change (i.e., an increase or a decrease) in UCH-L1 levels can be from at least about 20 pg/mL to about 6100 pg/mL, at least about 25 pg/mL to about 6100 pg/mL, at least about 30 pg/mL to about 6100 pg/mL, at least about 40 pg/mL to about 6100 pg/mL, at least about 50 pg/mL to about 6100 pg/mL, at least about 100 pg/mL to about 6100 pg/mL, at least about 129 pg/mL to about 6100 pg/mL, at least about 200 pg/mL to about 6100 pg/mL, at least about 300 pg/mL to about 6100 pg/mL, at least about 400 pg/mL to about 6100 pg/mL, at least about 500 pg/mL to about 6100
• the change (i.e., the increase or decrease) can be at least about 20 pg/mL, at least about 25 pg/mL, at least about 30 pg/mL, at least about 40 pg/mL, at least about SO pg/mL, at least about 60 pg/mL, at least about 70 pg/mL, at least about 80 pg/mL, at least about 90 pg/mL, at least about 100 pg/mL, at least about 129 pg/mL, at least about 200 pg/mL, at least about 300 pg/mL, at least about 400 pg/mL, at least about S00 pg/mL, at least about 600 pg/mL, at least about 700 pg/mL, at least about 800 pg/mL, at least about 900 pg/mL, at least about 1000 pg/mL, at least about 1500 pg/mL
• the first sample is taken within 24 hours after the suspected injury.
• the first sample can be taken within about 0 hours, within about 1 hour, within about 2 hours, within about 3 hours, within about 4 hours, within about 5 hours, within about 6 hours, within about 7 hours, within about 8 hours, within about 9 hours, within about 10 hours, within about 11 hours, within about 12 hours, within about 13 hours, within about 14 hours, within about 15 hours, within about 16 hours, within about 17 hours, within about 18 hours, within about 19 hours, within about 20 hours, within about 21 hours, within about 22 hours, within about 23 hours, within about 24 hours, or more than about 24 hours after the suspected injury.
• the first sample is taken within about 0 to about 1 hours, within about 0 to about 2 hours, within about 0 to about 3 hours, within about 0 to about 4 hours, within about 0 to about 5 hours, within about 0 to about 6 hours, within about 0 to about 7 hours, within about 0 to about 8 hours, within about 0 to about 9 hours, within about 0 to about 10 hours, within about 0 to about 11 hours, within about 0 to about 12 hours, within about 0 to about 18 hours, within about 6 to about 12 hours, within about 12 to about 18 hours, within about 18 to about 24 hours, or greater than 24 hours after the suspected injury.
• the second sample is obtained within about 1 hour to about 10 hours after the first sample is obtained, such as about 3 hours to about 6 hours after the first sample is obtained. In some embodiments, the second sample is obtained within about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours after the first sample is obtained.
• the first sample is taken within 0 to about 6 hours after the suspected injury and the subject is determined to have moderate to severe traumatic brain injury when the level of UCH-L1 increases or decreases between at least about 20 pg/mL to at least about 6100 pg/mL from the first sample to the second sample.
• the first sample can be obtained within about 0 to about 6 hours and the increase or decrease in UCH-L1 levels is at least about 2528 pg/mL. In some embodiments, the first sample can be obtained within about 0 to about 6 hours and the increase or decrease in UCH-L1 levels is at least about 129 pg/mL. In some embodiments, the first sample can be obtained within about 0 to about 10 hours and the increase or decrease in UCH-L1 levels is at least about 25 pg/mL. In some embodiments, the first sample can be obtained within about 0 to about 11 hours and the increase or decrease in UCH-L1 levels is at least about 25 pg/mL. In some embodiments, the first sample can be obtained within about 0 to about 12 hours and the increase or decrease in UCH-L1 levels is at least about 129 pg/mL.
• a subject can be considered as suffering from moderate to severe traumatic brain injury when the amount of UCH-L1 -antibody complex detected increases to an elevated amount (e.g., about 100 pg/mL to about 1000 pg/mL) in one or more first samples taken from the subject within about 0 to about 6 hours after injury or suspected injury to the head.
• an elevated amount e.g., about 100 pg/mL to about 1000 pg/mL
• the UCH-L1 levels may increase within about 0 to about 6 hours, about 0.5 hours to about 6 hours, about 1 hour to about 6 hours, about 1.5 hours to about 6 hours, about 2 hours to about 6 hours, about 2.5 hours to about 6 hours, about 3 hours to about 6 hours, about 4 hours to about 6 hours, about 5 hours to about 6 hours, about 0 to about 5 hours, about 0.5 hours to about 5 hours, about 1 hour to about 5 hours, about 1.5 hours to about 5 hours, about 2 hours to about 5 hours, about 2.5 hours to about 5 hours, about 3 hours to about 5 hours, about 4 hours to about 5 hours, about 0 to about 4 hours, about 0.5 hours to about 4 hours, about 1 hour to about 4 hours, about 1.5 hours to about 4 hours, about 2 hours to about 4 hours, about 2.5 hours to about 4 hours, about 3 hours to about 4 hours, about 0 to about 3 hours, about 0.5 hours to about 3 hours, about 1 hour to about 3 hours, about 1.5 hours to about 3 hours, about 2 hours to about 4 hours, about 2.5 hours to about 4 hours,
• UCH-L1 levels may increase within about 0, about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, or about 6 hours after injury to the head. [0191] In some embodiments, UCH-L1 levels can increase to an elevated amount after injury or suspected injury to the head. The elevated amount of UCH-L1 can be between at least about 20 pg/mL to at least about 25000 pg/mL.
• the elevated amount of UCH-L1 can be between at least about 20 pg/mL to at least about 25000 pg/mL, at least about 50 pg/mL to at least about 25000 pg/mL, at least about 100 pg/mL to at least about 25000 pg/mL, at least about 200 pg/mL to at least about 25000 pg/mL, at least about 300 pg/mL to at least about 25000 pg/mL, at least about 400 pg/mL to at least about 25000 pg/mL, at least about 500 pg/mL to at least about 25000 pg/mL, at least about 1000 pg/mL to at least about 25000 pg/mL, at least about 2000 pg/mL to at least about 25000 pg/mL, least about 3000 pg/mL to at least about 25000 pg/mL, at least about 4000 pg/m
• the elevated amount of UCH-L1 can be at least about 100 pg/mL, at least about 200 pg/mL, at least about 300 pg/mL, at least about 400 pg/mL, at least about 500 pg/mL, at least about 600 pg/mL, at least about 700 pg/mL, at least about 800 pg/mL, at least about 900 pg/mL, at least about 1000 pg/mL, at least about 21000 pg/mL, at least about 3000 pg/mL, at least about 4000 pg/mL, at least about 5000 pg/mL, at least about 10000 pg/mL, or at least about 15000 pg/mL.
• the method further includes treating a subject assessed as having moderate to severe traumatic brain injury with a traumatic brain injury treatment, as described below. In some embodiments, the method further includes monitoring the subject assessed as having mild traumatic brain injury, as described below..
• test can be any assay known in the art such as, for example, immunoassays, protein immunoprecipitation, Immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high-performance liquid chromatography (HPLC) or liquid
• LC/MS chromatography-mass spectrometry
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art. Such assays are described in further detail herein in Sections 9-11.
• the present disclosure relates to a method, among other methods, of aiding in the determination or evaluation of whether to perform a computerized tomography (CT) scan on a human subject who has sustained or may have sustained a suspected injury to the head.
• CT computerized tomography
• determination of whether to perform a CT scan on a human subject refers to use of the method, with or without other methods, to determine that the subject is more likely than not to have a positive head CT scan.
• such a method can comprise the steps of: (a) performing an assay on at least two samples obtained from the subject, the first sample taken from the subject within 24 hours of the suspected injury and the second sample taken from the subject from about 3 to about 6 hours after the first sample is taken; (b) detecting in the at least two samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; (c) determining the level of UCH-L1 in each of the first sample and second sample and determining if the level of UCH-L1 decreases or increases from the first sample to the second sample; and (d) determining whether to perform a CT scan on the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first sample to the second sample.
• UCH-L1 ubiquitin carboxy-terminal hydrolase LI
• a CT scan is performed on the subject when the level of UCH-L1 in the first sample or the second sample is higher than a reference level of UCH- Ll. In some embodiments, a CT scan is not performed on the subject when the level of UCH-L1 in the in the first sample or the second sample is lower than a reference level of UCH-L1. In some embodiments, a CT scan is performed on the subject when there is a statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample.
• a CT scan is not performed on the subject when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample. In some embodiments, a CT scan is performed on the subject when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample. In some embodiments, a CT scan is not performed on the subject when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample.
• a CT scan is performed on the subject when the level of UCH-L1 in the first sample is higher than a reference level of UCH-L1 or when there is a statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample. In some embodiments, a CT scan is not performed on the subject when the level of UCH-L1 in the first sample is lower than a reference level of UCH-L1 or when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample.
• the samples can be biological samples.
• the subject has received a CT scan before or after the assay is performed.
• the subject is suspected as having a traumatic brain injury based on the CT scan.
• the reference level is correlated with positive head CT scan.
• a reference level can be employed as a benchmark against which to assess results obtained upon assaying a test sample for UCH-L1.
• the reference level is obtained by running a particular assay a sufficient number of times and under appropriate conditions such that a linkage or association of analyte presence, amount or concentration with a particular stage or endpoint of TBI or with particular indicia can be made.
• the reference level is obtained with assays of reference subjects (or populations of subjects).
• the UCH-L1 measured can include UCH-L1 fragments thereof, degradation products thereof, and/or enzymatic cleavage products thereof.
• the reference level is determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%.
• the sensitivity is at least about 80.0%, at least about 85.0%, at least about 87.5%, at least about 90.0%, at least about 95.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or at least about 100.0%.
• the specificity is at least about 30.0%, at least about 31.0%, at least about 32.0%, at least about 33.0%, at least about 34.0%, at least about 35.0%, at least about 36.0%, at least about 37.0%, at least about 38.0%, at least about 39.0%, at least about 40.0%, at least about 45.0%, at least about 50.0%, at least about 55.0%, at least about 60.0%, at least about 65.0%, at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 90.0%, at least about 91.0%, at least about 92.0%, at least about 93.0%, at least about 94.0%, at least about 95.0%, at least about 96.0%, at least about 97.0%, at least about 98.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at
• the reference level can be between at least about 50 pg/mL to about 1000 pg/mL. In some embodiments, the reference level can be between at least about 50 pg/mL to about 1000 pg/mL, between at least about 50 pg/mL to about 900 pg/mL, between at least about 50 pg/mL to about 800 pg/mL, between at least about 50 pg/mL to about 750 pg/mL, between at least about 50 pg/mL to about 700 pg/mL, between at least about 50 pg/mL to about 600 pg/mL, between at least about 50 pg/mL to about 500 pg/mL, between at least about 50 pg/mL to about 400 pg/mL, between at least about 50 pg/mL to about 300 pg/mL, between at least about 50 pg/mL to about 200 pg/m
• the reference level can be at least about 50 pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80 pg/mL, 85 pg/mL, 90 pg/mL, 95 pg/mL, 96 pg/mL, 97 pg/mL, 98 pg/mL, 98 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 350 pg/mL, 370 pg/mL, 400 pg/mL, 450 pg/mL, 500 pg/mL, 509 pg/mL 550 pg/mL, 600 pg/mL, 700 pg/mL, 800 pg/mL, 900 pg/m
• the first sample is taken within 24 hours after the suspected injury.
• the first sample can be taken within about 0 hours, within about 30 minutes, within about 1 hour, within about 2 hours, within about 3 hours, within about 4 hours, within about 5 hours, within about 6 hours, within about 7 hours, within about 8 hours, within about 9 hours, within about 10 hours, within about 11 hours, within about 12 hours, within about 13 hours, within about 14 hours, within about 15 hours, within about 16 hours, within about 17 hours, within about 18 hours, within about 19 hours, within about 20 hours, within about 21 hours, within about 22 hours, within about 23 hours, within about 24 hours, or more than about 24 hours after the suspected injury.
• the first sample is taken within about 0 to about 6 hours, within about 6 to about 12 hours, within about 12 to about 18 hours, within about 18 to about 24 hours, or greater than 24 hours after the suspected injury.
• the second sample is obtained within about 1 hour to about 10 hours after the first sample is obtained, such as about 3 hours to about 6 hours after the first sample is obtained. In some embodiments, the second sample is obtained within about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours after the first sample is obtained.
• the first sample is taken within 24 hours after the suspected injury and the reference level is determined by an assay having a particular sensitivity and specificity, as described above.
• the sample is taken within about 0 to about 6 hours, within about 0 to about 7 hours, within about 0 to about 8 hours, within about 0 to about 9 hours, within about 0 to about 10 hours, within about 0 to about 11 hours, within about 0 to about 12 hours, within about 6 to about 12 hours, within about 12 to about 18 hours, within about 18 to about 24 hours, or greater than 24 hours after the suspected injury and the reference level is determined by an assay having a particular sensitivity and specificity, such as a sensitivity of about 100% and a specificity of at least about 75%, a sensitivity of at least about 99% and a specificity of at least about 75%, or a sensitivity of about 100% and a specificity of about 100%.
• the first sample can be obtained between about 0 hours to 6 hours after the suspected injury and the reference level is at least about 370 pg/mL and determined by an assay having a sensitivity of about 100% and a specificity of at least about 37.5%. In some embodiments, the first sample is taken between about 0 hours to 6 hours after the suspected injury and the reference level is about 509 pg/mL and determined by an assay having a sensitivity of about 100% and a specificity of at least about 75%.
• the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 96 pg/mL and determined by an assay having a sensitivity of at least about 96% and a specificity of at least about 30%.
• the first sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 86 pg/mL and determined by an assay having a sensitivity of at least about 86% and a specificity of at least about 35%.
• the absolute amount can be determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%.
• the sensitivity is at least about 80.0%, at least about 85.0%, at least about 87.5%, at least about 90.0%, at least about 95.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or at least about 100.0%.
• the specificity is at least about 30.0%, at least about 31.0%, at least about 32.0%, at least about 33.0%, at least about 34.0%, at least about 35.0%, at least about 36.0%, at least about 37.0%, at least about 38.0%, at least about 39.0%, at least about 40.0%, at least about 45.0%, at least about 50.0%, at least about 55.0%, at least about 60.0%, at least about 65.0%, at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 90.0%, at least about 91.0%, at least about 92.0%, at least about 93.0%, at least about 94.0%, at least about 95.0%, at least about 96.0%, at least about 97.0%, at least about 98.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at
• the sensitivity can be at least about 99% and the specificity can be at least about 75%, the sensitivity can be at least about 99% and the specificity can be at least about 99%, or the sensitivity can be about 100% and the specificity can be about 100%.
• the absolute amount can be between at least about 20 pg/mL to about 6100 pg/mL. In some embodiments, the absolute amount can be between at least about 20 pg/mL to about 6100 pg/mL, between at least about 20 pg/mL to about 6000 pg/mL, between at least about 20 pg/mL to about 5500 pg/mL, between at least about 20 pg/mL to about 5000 pg/mL, between at least about 20 pg/mL to about 4500 pg/mL, between at least about 20 pg/mL to about 4000 pg/mL, between at least about 20 pg/mL to about 3500 pg/mL, between at least about 20 pg/mL to about 3000 pg/mL, between at least about 20 pg/mL to about 2500 pg/mL, between at least about 20 pg/mL, between at least about 20 p
• the absolute amount can be at least about 20 pg/mL, at least about 21 pg/mL, at least about 22 pg/mL, at least about 23 pg/mL, at least about 24 pg/mL, at least about 25 pg/mL, at least about 26 pg/mL, at least about 27 pg/mL, at least about 28 pg/mL, at least about 29 pg/mL, at least about 30 pg/mL, at least about 35 pg/mL, at least about 40 pg/mL, at least about 45 pg/mL, at least about 50 pg/mL, at least about 55 pg/mL, at least about 60 pg/mL, at least about 65 pg/mL, at least about 70 pg/mL, at least about 75 pg/mL, at least about 80 pg/mL, at least about 85 pg/mL, at least about
• the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount, such as about 25 pg/mL, is determined by an assay having a sensitivity of at least about 85% and a specificity of at least about 41%.
• the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 25 pg/mL. In some embodiments, the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount, such as about 23 pg/mL, is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 35%. In some embodiments, the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 23 pg/mL.
• a CT scan is performed on the subject when there is a statistically significant increase or decrease from the level of UCH-L1 in the first sample taken at a first time point to the level of UCH-L1 in the second sample taken at a second point. In some embodiments, a CT scan is not performed on the subject when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample taken at a second time point. In some
• the statistically significant increase or decrease is more than about 0.1-fold, more than about 0.2-fold, more than about 0.3-fold, more than about 0.4-fold, more than about 0.5-fold, more than about 0.55-fold, more than about 0.6-fold, more than about 0.7- fold, more than about 0.73-fold, more than about 0.8-fold, more than about 0.9-fold, more than about 1-fold, more than 1.5-fold, more than 1.81-fold, more than about 2-fold, more than about 3-fold, more than about 4-fold, more than about 5-fold, more than about 6-fold, more than about 7-fold, more than 8-fold, more than 9-fold, more than 10-fold, more than 11-fold, more than 12-fold, more than 13-fold, more than 14-fold, more than 15-fold, more than 16- fold, more than 17-fold, more than 18-fold, more than 19-fold, or more than 20-fold from the level of UCH-L1 in the first sample taken at a first time point to the level of
• the statistically significant increase or decrease is less than about 0.1-fold, less than about 0.2-fold, less than about 0.3-fold, less than about 0.4-fold, less than about 0.5-fold, at least about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, less than about 1-fold, less than 1.5-fold, less than 1.81-fold, less than about 2-fold, less than about 3-fold, less than about 4-fold, less than about 5-fold, less than about 6-fold, less than about 7-fold, less than 8- fold, less than 9-fold, less than 10-fold, less than 11-fold, less than 12-fold, less than 13-fold, less than 14-fold, less than 15-fold, less than 16-fold, less than 17-fold, less than 18-fold, less than 19-fold, or less than 20-fold from the level of UCH-L1 in the first sample taken at a first
• no statistically significant increase or decrease from the level of UCH-L1 in the first sample taken at a first time point to the level of UCH-L1 in the second sample taken at a second time point indicates that the subject does not need a CT scan performed.
• the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 2-fold from the first time point to the second time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 1.81-fold from the first time point to the second time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about O.SO-fold from the second time point to the first time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about O.SS-fold from the second time point to the first time point.
• the method further includes treating the subject with a traumatic brain injury treatment and/or monitoring the subject, as described below.
• test can be any assay known in the art such as, for example, immunoassays, protein immunoprecipitation, Immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high-performance liquid chromatography (HPLC) or liquid
• LC/MS chromatography-mass spectrometry
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art. Such assays are described in further detail herein in Sections 9-11.
• the present disclosure relates, among other methods, to a method of predicting or aiding in the prediction of whether a human subject suspected of having an injury to the head will have a positive or negative head CT scan.
• prediction of whether to perform a CT scan on a human subject refers to use of the method, with or without other methods, to predict that the subject is more likely than not to have a positive head CT scan.
• the method includes: (a) performing an assay on a first sample and optionally a second sample to measure or detect a level of ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in the sample, wherein the first sample is taken from the subject at a first time point within 24 hours after a suspected injury to the head and the second sample is taken from the subject at a second time point after the first time point, such as about 3 hours to about 6 hours after the first time point; (b) detecting in the first and/or second sample an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy- terminal hydrolase LI (UCH-L1); and (c) determining whether the subject will have a positive or negative head CT scan based on the UCH-L1 levels.
• UCH-L1 ubiquitin carboxy-terminal hydrolase LI
• the subject is (i) determined as likely having a positive head CT scan when the level of UCH-L1 in the first and/or second sample is higher than a reference level of UCH-L1 and the subject is determined as likely having a negative head CT scan when the level of UCH-L1 in the first and/or second sample is lower than a reference level of UCH-L1; (ii) determined as likely having a positive head CT scan when there is a statistically significant increase or decrease from the level of UCH- Ll in the first sample to the level of UCH-L1 in the second sample and the subject is determined likely having a negative head CT scan when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample; (iii) determined as likely having a positive head CT scan when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample and the subject is determined likely having a negative head CT scan when there is no decrease or increase
• the first and/or second sample is taken from the subject between about 2 hours to about 12 hours after the suspected injury.
• the first and/or second sample is take between about 2 hours to about 12 hours, about 2 hours to about 10 hours, about 2 hours to about 8 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, about 4 hours to about 12 hours, about 4 hours to about 10 hours, about 4 hours to about 8 hours, about 4 hours to about 6 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, or about 6 hours to about 8 hours after injury to the head.
• the first and/or second sample is taken at about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, or about 12 hours after injury.
• the subject is assessed as having likely having a positive head CT scan when the level of UCH-L1 in the first and/or second sample is greater than or equal to about 100 pg/mL or 300 pg/mL, and the subject is assessed as not having any traumatic brain injury when the level of UCH-L1 in the first and/or second sample is less than about 100 pg/mL or 300 pg/mL.
• the subject is determined as likely having a positive head CT scan when the level of UCH-L1 in the first and/or second sample is greater than or equal to about 50 pg/mL, about 100 pg/mL, about 150 pg/mL, about 200 pg/mL, about 250 pg/mL, about 300 pg/mL, about 350 pg/mL, about 400 pg/mL, about 450 pg/mL, or about 500 pg/mL.
• the subject is determined likely having a negative head CT scan when the level of UCH-L1 in the first and/or second sample is less than about 50 pg/mL, about 100 pg/mL, about 150 pg/mL, about 200 pg/mL, about 250 pg/mL, about 300 pg/mL, about 350 pg/mL, about 400 pg/mL, about 450 pg/mL, or about 500 pg/mL.
• the reference level can be determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%.
• the sensitivity is at least about 80.0%, at least about 85.0%, at least about 87.5%, at least about 90.0%, at least about 95.0%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or at least about 100.0%.
• the specificity is at least about 30.0%, at least about 31.0%, at least about 32.0%, at least about 33.0%, at least about 34.0%, at least about 35.0%, at least about 36.0%, at least about 37.0%, at least about 38.0%, at least about 39.0%, at least about 40.0%, at least about 45.0%, at least about 50.0%, at least about 55.0%, at least about 60.0%, at least about 65.0%, at least about 70.0%, at least about 75.0%, at least about 80.0%, at least about 85.0%, at least about 90.0%, at least about 91.0%, at least about 92.0%, at least about 93.
• the sensitivity is at least about 99% and the specificity is at least about 75%, the sensitivity is at least about 99% and the specificity is at least about 99%, or the sensitivity is about 100% and the specificity is about 100%
• the reference level can be between at least about 50 pg/mL to about 1000 pg/mL. In some embodiments, the reference level can be between at least about 50 pg/mL to about 1000 pg/mL, between at least about 50 pg/mL to about 900 pg/mL, between at least about 50 pg/mL to about 800 pg/mL, between at least about 50 pg/mL to about 750 pg/mL, between at least about 50 pg/mL to about 700 pg/mL, between at least about 50 pg/mL to about 600 pg/mL, between at least about 50 pg/mL to about 500 pg/mL, between at least about 50 pg/mL to about 400 pg/mL, between at least about 50 pg/mL to about 300 pg/mL, between at least about 50 pg/mL to about 200 pg/m
• the reference level can be at least about 50 pg/mL, 55 pg/mL, 60 pg/mL, 65 pg/mL, 70 pg/mL, 75 pg/mL, 80 pg/mL, 85 pg/mL, 90 pg/mL, 95 pg/mL, 96 pg/mL, 97 pg/mL, 98 pg/mL, 98 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 350 pg/mL, 370 pg/mL, 400 pg/mL, 450 pg/mL, 500 pg/mL, 509 pg/mL 550 pg/mL, 600 pg/mL, 700 pg/mL, 800 pg/mL, 900 pg/m
• a first sample is obtained at a first time point within 24 hours of the suspected injury and a second sample is obtained at second time point, or optionally a third time point or fourth time point, after the first time point to determine whether the subject will have a positive or negative head CT scan.
• the first time point is about 0 to about 24 hours after the injury or suspected injury to the head.
• the first time point can be between about 0 to about 24 hours, about 0 to about 20 hours, about 0 to about 18 hours, about 0 to about 16 hours, about 0 to about 14 hours, about 0 to about 12 hours, about 0 to about 10 hours, about 0 to about 8 hours, about 0 to about 6 hours, about 0 to about 4 hours, about 0 to about 2 hours, about 0 to about 1 hours, about 0 to about 1.5 hours, about 0.5 hours to about 24 hours, about 0.5 hours to about 20 hours, about 0.5 hours to about 18 hours, about 0.5 hours to about 16 hours, about 0.5 hours to about 14 hours, about 0.5 hours to about 12 hours, about 0.5 hours to about 10 hours, about 0.5 hours to about 8 hours, about 0.5 hours to about 6 hours, about 0.5 hours to about 4 hours, about 0.5 hours to about 2 hours, about 0.5 hours to about 1 hours, about 0.5 hours to about 1.5 hours, about 1 hour to about 24 hours, about 1 hour to about 20 hours, about 1 hour to about 18 hours, about
• the second time point is about 1 hour to about 10 hours after the first time point, such as about 3 hours to about 6 hours after the first time point. In some embodiments, the second time point is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about S hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours after the first time point.
• the statistically significant increase or decrease is at least about 1-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20- fold from the level of UCH-L1 in the first sample taken at a first time point to the level of UCH-L1 in the second sample taken at a second time point, or optionally a third time point or fourth time point.
• no statistically significant increase or decrease from the level of UCH-L1 in the first sample taken at a first time point to the level of UCH-L1 in the second sample taken at a second time point, or optionally a third time point or fourth time point, indicates that the subject will have a negative head CT scan.
• the statistically significant increase or decrease is more than about 0.1-fold, more than about 0.2-fold, more than about 0.3-fold, more than about 0.4-fold, more than about 0.5-fold, more than about 0.55-fold, more than about 0.6-fold, more than about 0.7-fold, more than about 0.73-fold, more than about 0.8-fold, more than about 0.9- fold, more than about 1-fold, more than 1.5-fold, more than 1.81-fold, more than about 2- fold, more than about 3-fold, more than about 4-fold, more than about 5-fold, more than about 6-fold, more than about 7-fold, more than 8-fold, more than 9-fold, more than 10-fold, more than 11-fold, more than 12-fold, more than 13-fold, more than 14-fold, more than 15- fold, more than 16-fold, more than 17-fold, more than 18-fold, more than 19-fold, or more than 20-fold from the level of UCH-L1 in the second sample taken at a second
• no statistically significant increase or decrease from the level of UCH-L1 in the second sample taken at a second time point to the level of UCH-L1 in the first sample taken at a first time point, or optionally a third time point or fourth time point, indicates that the subject will likely have a negative head CT scan.
• the statistically significant increase or decrease is less than about 0.1-fold, less than about 0.2-fold, less than about 0.3-fold, less than about 0.4-fold, less than about 0.5-fold, at least about 0.55-fold, at least about 0.6-fold, at least about 0.7-fold, at least about 0.73-fold, at least about 0.8-fold, at least about 0.9-fold, less than about 1-fold, less than 1.5-fold, less than 1.81-fold, less than about 2-fold, less than about 3-fold, less than about 4-fold, less than about 5-fold, less than about 6-fold, less than about 7-fold, less than 8- fold, less than 9-fold, less than 10-fold, less than 11-fold, less than 12-fold, less than 13-fold, less than 14-fold, less than 15-fold, less than 16-fold, less than 17-fold, less than 18-fold, less than 19-fold, or less than 20-fold from the level of UCH-L1 in the first sample taken at a first
• no statistically significant increase or decrease from the level of UCH-L1 in the first sample taken at a first time point to the level of UCH-L1 in the second sample taken at a second time point indicates that the subject will likely have a negative head CT scan.
• the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 2-fold from the first time point to the second time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 1.81 -fold from the first time point to the second time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about O.SO-fold from the second time point to the first time point. In some embodiments, the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 0.55-fold from the second time point to the first time point.
• the subject is assessed as likely having a positive head CT scan when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample.
• the absolute amount is between at least about 20 pg/mL to about 6100 pg/mL.
• the absolute amount can be between at least about 20 pg/mL to about 6100 pg/mL, between at least about 20 pg/mL to about 6000 pg/mL, between at least about 20 pg/mL to about 5500 pg/mL, between at least about 20 pg/mL to about 5000 pg/mL, between at least about 20 pg/mL to about 4500 pg/mL, between at least about 20 pg/mL to about 4000 pg/mL, between at least about 20 pg/mL to about 3500 pg/mL, between at least about 20 pg/mL to about 3000 pg/mL, between at least about 20 pg/mL to about 2500 pg/mL, between at least about 20 pg/mL to about 2000 pg/mL, between at least about 20 pg/mL to about 1500 pg/mL, between at least about 20 pg/
• the absolute amount can be at least about 20 pg/mL, at least about 21 pg/mL, at least about 22 pg/mL, at least about 23 pg/mL, at least about 24 pg/mL, at least about 25 pg/mL, at least about 26 pg/mL, at least about 27 pg/mL, at least about 28 pg/mL, at least about 29 pg/mL, at least about 30 pg/mL, at least about 35 pg/mL, at least about 40 pg/mL, at least about 45 pg/mL, at least about 50 pg/mL, at least about 55 pg/mL, at least about 60 pg/mL, at least about 65 pg/mL, at least about 70 pg/mL, at least about 75 pg/mL, at least about 80 pg/mL, at least about 85 pg/mL, at least about
• the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount, such as about 25 pg/mL, is determined by an assay having a sensitivity of at least about 85% and a specificity of at least about 41%.
• the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 25 pg/mL. In some embodiments, the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount, such as about 23 pg/mL, is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 35%. In some embodiments, the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 23 pg/mL.
• test can be any assay known in the art such as, for example, immunoassays, protein immunoprecipitation, Immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high-performance liquid chromatography (HPLC) or liquid
• LC/MS chromatography-mass spectrometry
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art. Such assays are described in further detail herein in Sections 9-11.
• the present disclosure relates to a method of aiding in the early detection of traumatic brain injury in a human subject who has sustained or may have sustained an injury to the head.
• the method can aid in early detection of traumatic brain injury in a human subject who has sustained or may have sustained an injury to the head (e.g., determining whether the subject has traumatic brain injury).
• determining whether the subject has traumatic brain injury refers to use of the method (e.g., with other information such as clinical assessment data) to determine that the subject is more likely than not to have TBI.
• the method includes performing an assay on samples from the human subject to measure or detect a level of ubiquitin carboxy-terminal hydrolase LI (UCH-L1) in a first sample and a second sample.
• UCH-L1 level of ubiquitin carboxy-terminal hydrolase LI
• the first sample is taken from the human subject within 24 hours after an injury to the head, and the second sample is taken from the human subject after about 3 hours to about 6 hours after the first sample is taken.
• a decrease or decline in the level of UCH-L1 from the first sample to the second sample is determined and the subject is assessed as having mild or moderate to severe traumatic brain injury if there is a statistically significant decrease in the level of UCH-L1 from the first sample to the level of UCH-L1 in the second sample.
• the samples can be biolocal samples.
• the statistically significant decrease comprises a decrease or decline in UCH-L1 levels of at least 5% lower than the UCH-L1 levels in the first sample. In some embodiments, the statistically significant decrease comprises a decrease or decline in UCH-L1 levels, wherein the UCH-L1 level in the second sample is about 5% to about 1000% lower than the UCH-L1 level in the first sample.
• the UCH -LI levels may be at least about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900%, or about 1000% lower than the UCH-L1 levels in the first
• the UCH-L1 levels may be at least about 1-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18- fold, at least 19-fold or at least 20-fold lower than the UCH-L1 levels in the first sample.
• the statistically significant decrease comprises a decrease or decline in UCH-L1 levels, wherein the level of UCH-L1 in the second sample is from at least about 20 pg/mL to at least about 6100 pg/mL lower than the level of UCH-L1 in the first sample.
• the method further comprises comparing the concentration or amount of UCH-L1 as determined in step (b), for example, with a reference level. Further, optionally the method comprises treating the subject with one or more pharmaceutical compositions for a period of time if the comparison shows that the concentration or amount of UCH-L1 as determined in step (b), for example, is unfavorably altered with respect to the reference level.
• the amount or concentration of UCH-L1 or UCH- Ll fragment may be "unchanged,” “favorable” (or “favorably altered”), or “unfavorable” (or “unfavorably altered”).
• “Elevated” or “increased” refers to an amount or a concentration in a test sample that is higher or greater than a typical or normal level or range (e.g., reference level), or is higher or greater than another reference level or range (e.g., earlier or baseline sample).
• lowered or reduced refers to an amount or a concentration in a test sample that is lower or less than a typical or normal level or range (e.g., reference level), or is lower or less than another reference level or range (e.g., earlier or baseline sample).
• altered refers to an amount or a concentration in a sample that is altered (increased or decreased) over a typical or normal level or range (e.g., reference level), or over another reference level or range (e.g., earlier or baseline sample).
• the typical or normal level or range for UCH-L1 is defined in accordance with standard practice. A so-called altered level or alteration can be considered to have occurred when there is any net change as compared to the typical or normal level or range, or reference level or range that cannot be explained by experimental error or sample variation. Thus, the level measured in a particular sample will be compared with the level or range of levels determined in similar samples from a so-called normal subject.
• a "normal subject” is an individual with no detectable disease or disorder
• a "normal” (sometimes termed "control") patient or population is/are one(s) that exhibit(s) no detectable disease or disorder, respectively, for example.
• An "apparently normal subject” is a normal subject (namely, an individual with no detectable disease or disorder) in which UCH-L1 has not been or is being assessed.
• the level of an analyte is said to be "elevated” when the analyte is normally undetectable (e.g., the normal level is zero, or within a range of from about 25 to about 75 percentiles of normal populations), but is detected in a test sample, as well as when the analyte is present in the test sample at a higher than normal level.
• the disclosure provides a method of screening for a subject having, or at risk of having, mild or moderate to severe traumatic brain injury.
• a reference level can also be employed as a benchmark against which to assess results obtained upon assaying a test sample for UCH-L1.
• the reference level is obtained by running a particular assay a sufficient number of times and under appropriate conditions such that a linkage or association of analyte presence, amount or concentration with a particular stage or endpoint of TBI or with particular indicia can be made.
• the reference level is obtained with assays of reference subjects (or populations of subjects).
• the UCH-L1 measured can include UCH-L1 fragments thereof, degradation products thereof, and/or enzymatic cleavage products thereof.
• the reference level in this method can be the level of UCH-L1 in a patient having mild or moderate to severe traumatic brain injury.
• levels higher than or equal to 100000 pg/mL, 500000 pg/mL, 1000000 pg/mL, 150000 pg/mL, 200000 pg/mL, or 500000 pg/mL in serum of UCH-L1 identify the subject as having mild or moderate to severe traumatic brain injury.
• the method further includes treating the human subject who was determined to have a CT scan with a traumatic brain injury treatment, as described below. In some embodiments, the method further includes monitoring, as described below, the human subject who was determined to have a CT scan.
• test can be any assay known in the art such as, for example, immunoassays, protein immunoprecipitation, Immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high-performance liquid chromatography (HPLC) or liquid
• LC/MS chromatography-mass spectrometry
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art. Such assays are described in further detail herein in Sections 9-11. 7. Combinations of UCH-L1 with other Biomarkers
• the method further includes performing an assay on the samples to measure or detect a level of one or more other biomarkers.
• the assay may be an assay to measure or the levels of the one or more other biomarkers in a sample, such as immunoassay, mass spectrometry, etc.
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art.
• the assay includes: measuring or detecting a level of one or more other biomarkers in the first sample and the second sample, determining an increase and/or decrease or rise or decline in the level of the one or more other biomarkers from the first sample to the second sample, and assessing the human subject as having mild or moderate to severe traumatic brain injury if there is a statistically significant increase or decrease in the level of the one or more other biomarkers from the first sample to the level of the one or more other biomarkers in the second sample.
• the present invention contemplates that the combination of UCH-L1 with one or more biomarkers or immunoassays specific for disease may provide a greater discrimination between healthy controls and individuals with disease compared to measuring UCH-L1 alone. For example, measuring a panel of UCH-L1 and additional traumatic brain injury biomarkers may provide a greater discrimination between healthy controls and individuals with disease compared to a panel of UCH-L1 alone. The combination of UCH-L1 with at least one or more biomarkers may provide greater discrimination between healthy controls and individuals who have mild or moderate to severe traumatic brain injury.
• the one or more biomarkers include Glial fibrillary acidic protein (GFAP), SI 00 calcium-binding protein B (S100p), neuron-specific enolase (NSE), crystallin B chain (CRYAB), brain lipid binding protein (BLBP), aldolase C (ALDOC), astrocytic phosphoprotein 15 (PEA15), glutamine synthetase (GS), Apo lipoprotein 1, Tau, C-reactive protein (CRP), free brain- derived neurotrophic factor (BDNF), p-Tau, total BDNF, troponin I (Tnl), and a combination thereof.
• the one or more other biomarkers is SIOOP, CRP, Apo lipoprotein 1, or crystallin B chain (CRYAB).
• the subject identified or assessed in the methods described above as having traumatic brain injury may be treated or monitored.
• the method further includes treating a human subject assessed as having traumatic brain injury with a traumatic brain injury treatment, such as any treatments known in the art.
• treatment of traumatic brain injury can take a variety of forms depending on the severity of the injury to the head.
• the treatment may include one or more of rest, abstaining for physical activities, such as sports, avoiding light or wearing sunglasses when out in the light, medication for relief of a headache or migraine, anti-nausea medication, etc.
• Treatment for patients suffering from severe TBI might include
• the method further includes monitoring a human subject assessed as having traumatic brain injury (e.g., mild or moderate to severe traumatic).
• a subject identified as having traumatic brain injury such as mild traumatic brain injury or severe traumatic brain injury, may be monitored with CT scan or MRI.
• UCH-L1 levels can be measured by any means, such as antibody dependent methods, such as immunoassays, protein immunoprecipitation, immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, or protein immunostaining, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, or chromatography or spectrometry methods, such as high- performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC/MS).
• the assay can be employed in clinical chemistry format such as would be known by one of ordinary skill in the art.
• measuring the level of UCH-L1 includes contacting the sample with a first specific binding member and second specific binding member.
• the first specific binding member is a capture antibody and the second specific binding member is a detection antibody.
• measuring the level of UCH- Ll includes contacting the sample, either simultaneously or sequentially, in any order: (1) a capture antibody, which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a capture antibody-UCH-Ll antigen complex, and (2) a detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the capture antibody, to form a UCH-L1 antigen-detection antibody complex, such that a capture antibody-UCH-Ll antigen-detection antibody complex is formed, and measuring the amount or concentration of UCH-L1 in the sample based on the signal generated by the detectable label in the capture antibody-UCH-Ll antigen-dete
• the first specific binding member is immobilized on a solid support.
• the second specific binding member is immobilized on a solid support.
• the first specific binding member is a UCH-L1 antibody as described below.
• the sample is diluted or undiluted.
• the sample can be from about 1 to about 25 microliters, about 1 to about 24 microliters, about 1 to about 23 microliters, about 1 to about 22 microliters, about 1 to about 21 microliters, about 1 to about 20 microliters, about 1 to about 18 microliters, about 1 to about 17 microliters, about 1 to about 16 microliters, about 15 microliters or about 1 microliter, about 2 microliters, about 3 microliters, about 4 microliters, about 5 microliters, about 6 microliters, about 7 microliters, about 8 microliters, about 9 microliters, about 10 microliters, about 11 microliters, about 12 microliters, about 13 microliters, about 14 microliters, about 15 microliters, about 16 microliters, about 17 microliters, about 18 microliters, about 19 microliters, about 20 microliters, about 21 microliters, about 22 microliters, about 23 microliters, about 24 microliters or about 25
• Some instruments such as, for example the Abbott Laboratories instrument ARCHITECT®, and other core laboratory instruments
• a point-of-care device may be capable of measuring levels of UCH-L1 in a sample higher or greater than 25,000 pg/mL.
• the methods described herein may use an isolated antibody that specifically binds to ubiquitin carboxy-terminal hydrolase LI ("UCH-Ll") (or fragments thereof), referred to as "UCH-Ll antibody.”
• UCH-Ll antibodies can be used to assess the UCH-Ll status as a measure of traumatic brain injury, detect the presence of UCH-L1 in a sample, quantify the amount of UCH-L1 present in a sample, or detect the presence of and quantify the amount of UCH-L1 in a sample.
• the terms “measuring,” “detecting,” and “quantifying,” and any derivatives thereof, can be used interchangeably to describe the methods disclosed herein for assessing levels UCH-L1 levels in a sample.
• Ubiquitin carboxy-terminal hydrolase LI which is also known as "ubiquitin C-terminal hydrolase," is a deubiquitinating enzyme.
• UCH-L1 is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer.
• Expression of UCH-L1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. It is abundantly present in all neurons (accounts for 1-2% of total brain protein), expressed specifically in neurons and testis/ovary.
• the catalytic triad of UCH-L1 contains a cysteine at position 90, an aspartate at position 176, and a histidine at position 161 that are responsible for its hydrolase activity.
• Human UCH-L1 may have the following amino acid sequence:
• the human UCH-L1 may be a fragment or variant of SEQ ID NO: 1.
• the fragment of UCH-L1 may be between 5 and 225 amino acids, between 10 and 225 amino acids, between 50 and 225 amino acids, between 60 and 225 amino acids, between 65 and 225 amino acids, between 100 and 225 amino acids, between 150 and 225 amino acids, between 100 and 175 amino acids, or between 175 and 225 amino acids in length.
• the fragment may comprise a contiguous number of amino acids from SEQ ID NO: 1.
• the antibody is an antibody that binds to UCH-L1, a fragment thereof, an epitope of UCH-L1, or a variant thereof.
• the antibody may be a fragment of the anti-UCH-Ll antibody or a variant or a derivative thereof.
• the antibody may be a polyclonal or monoclonal antibody.
• the antibody may be a chimeric antibody, a single chain antibody, an affinity matured antibody, a human antibody, a humanized antibody, a fully human antibody or an antibody fragment, such as a Fab fragment, or a mixture thereof.
• Antibody fragments or derivatives may comprise F(ab')2, Fv or scFv fragments.
• the antibody derivatives can be produced by peptidomimetics. Further, techniques described for the production of single chain antibodies can be adapted to produce single chain antibodies.
• the anti-UCH-Ll antibodies may be a chimeric anti-UCH-Ll or humanized anti- UCH-L1 antibody.
• both the humanized antibody and chimeric antibody are monovalent.
• both the humanized antibody and chimeric antibody comprise a single Fab region linked to an Fc region.
• Human antibodies may be derived from phage-display technology or from transgenic mice that express human immunoglobulin genes.
• the human antibody may be generated as a result of a human in vivo immune response and isolated. See, for example, Funaro et al., BMC Biotechnology, 2008(8): 85. Therefore, the antibody may be a product of the human and not animal repertoire. Because it is of human origin, the risks of reactivity against self-antigens may be minimized.
• standard yeast display libraries and display technologies may be used to select and isolate human anti-UCH-Ll antibodies. For example, libraries of nai ve human single chain variable fragments (scFv) may be used to select human anti-UCH-Ll antibodies.
• Transgenic animals may be used to express human antibodies.
• Humanized antibodies may be antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
• CDRs complementarity determining regions
• the antibody is distinguishable from known antibodies in that it possesses different biological function(s) than those known in the art.
• the antibody may immunospecifically bind to UCH-L1 (SEQ ID NO: 1), a fragment thereof, or a variant thereof.
• the antibody may immunospecifically recognize and bind at least three amino acids, at least four amino acids, at least five amino acids, at least six amino acids, at least seven amino acids, at least eight amino acids, at least nine amino acids, or at least ten amino acids within an epitope region.
• the antibody may immunospecifically recognize and bind to an epitope that has at least three contiguous amino acids, at least four contiguous amino acids, at least five contiguous amino acids, at least six contiguous amino acids, at least seven contiguous amino acids, at least eight contiguous amino acids, at least nine contiguous amino acids, or at least ten contiguous amino acids of an epitope region.
• Antibodies may be prepared by any of a variety of techniques, including those well known to those skilled in the art.
• antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies via conventional techniques, or via transfection of antibody genes, heavy chains, and/or light chains into suitable bacterial or mammalian cell hosts, in order to allow for the production of antibodies, wherein the antibodies may be recombinant.
• the various forms of the term "transfection" are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
• eukaryotic cells Although it is possible to express the antibodies in either prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells is preferable, and most preferable in mammalian host cells, because such eukaryotic cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.
• Exemplary mammalian host cells for expressing the recombinant antibodies include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216-4220 (1980)), used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp, J. Mol. Biol, 159: 601-621 (1982), NS0 myeloma cells, COS cells, and SP2 cells.
• Chinese Hamster Ovary CHO cells
• dhfr-CHO cells described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216-4220 (1980)
• a DHFR selectable marker e.g., as described in Kaufman and Sharp, J. Mol. Biol, 159: 601-621 (1982
• NS0 myeloma cells e.g., as described in Kaufman and Sharp,
• the antibodies When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods.
• Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be understood that variations on the above procedure may be performed. For example, it may be desirable to transfect a host cell with DNA encoding functional fragments of either the light chain and/or the heavy chain of an antibody. Recombinant DNA technology may also be used to remove some, or all, of the DNA encoding either or both of the light and heavy chains that is not necessary for binding to the antigens of interest. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies.
• Afunctional antibodies may be produced in which one heavy and one light chain are an antibody (i.e., binds human UCH-L1) and the other heavy and light chain are specific for an antigen other than human UCH-L1 by crosslinking an antibody to a second antibody by standard chemical crosslinking methods.
• a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr-CHO cells by calcium phosphate- mediated transfection.
• the antibody heavy and light chain genes are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes.
• the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
• the selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium.
• Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells, and recover the antibody from the culture medium.
• the method of synthesizing a recombinant antibody may be by culturing a host cell in a suitable culture medium until a recombinant antibody is synthesized. The method can further comprise isolating the recombinant antibody from the culture medium.
• Methods of preparing monoclonal antibodies involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity.
• Such cell lines may be produced from spleen cells obtained from an immunized animal.
• the animal may be immunized with UCH-L1 or a fragment and/or variant thereof.
• the peptide used to immunize the animal may comprise amino acids encoding human Fc, for example the fragment crystallizable region or tail region of human antibody.
• the spleen cells may then be immortalized by, for example, fusion with a myeloma cell fusion partner. A variety of fusion techniques may be employed.
• the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports that growth of hybrid cells, but not myeloma cells.
• a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports that growth of hybrid cells, but not myeloma cells.
• One such technique uses hypoxanthine, aminopterin, thymidine (HAT) selection.
• Another technique includes electrofusion. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity may be used.
• Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies.
• chromatography is an example of a method that can be used in a process to purify the antibodies.
• the proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the F(ab) fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site.
• the enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the F(ab')2 fragment, which comprises both antigen-binding sites.
• the Fv fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecules.
• the Fv fragment may be derived using recombinant techniques.
• the Fv fragment includes a non-covalent VH: : VL heterodimer including an antigen-binding site that retains much of the antigen recognition and binding capabilities of the native antibody molecule.
• the antibody, antibody fragment, or derivative may comprise a heavy chain and a light chain complementarity determining region ("CDR") set, respectively interposed between a heavy chain and a light chain framework (“FR”) set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other.
• the CDR set may contain three hypervariable regions of a heavy or light chain V region.
• Suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or protein library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, yeast or the like, display library); e.g., as available from various commercial vendors such as Cambridge Antibody Technologies (Cambridgeshire, UK), MorphoSys (Martinsreid/Planegg, Del.), Bi ovation (Aberdeen, Scotland, UK)
• a peptide or protein library e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, yeast or the like, display library
• display library e.g., as available from various commercial vendors such as Cambridge Antibody Technologies (Cambridgeshire, UK), MorphoSys (Martinsreid/Plane
• Such techniques include, but are not limited to, ribosome display (Hanes et al. (1997) Proc. Natl. Acad. Sci. USA, 94:4937-4942; Hanes et al. (1998) Proc. Natl. Acad. Sci. USA, 95:14130-14135); single cell antibody producing technologies (e.g., selected lymphocyte antibody method ("SLAM”) (U.S. Patent No.
• An affinity matured antibody may be produced by any one of a number of procedures that are known in the art. For example, see Marks et al., BioTechnology, 10: 779- 783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by Barbas et al., Proc. Nat. Acad. Sci. USA, 91: 3809-3813 (1994); Schier ef a/., Gene, 169: 147-155 (1995); Yelton ei al., J. Immunol., 155: 1994-2004 (1995); Jackson et al, J.
• Antibody variants can also be prepared using delivering a polynucleotide encoding an antibody to a suitable host such as to provide transgenic animals or mammals, such as goats, cows, horses, sheep, and the like, that produce such antibodies in their milk. These methods are known in the art and are described for example in U.S. Patent Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362; and 5,304,489.
• Antibody variants also can be prepared by delivering a polynucleotide to provide transgenic plants and cultured plant cells (e.g., but not limited to tobacco, maize, and duckweed) that produce such antibodies, specified portions or variants in the plant parts or in cells cultured therefrom.
• plant cells e.g., but not limited to tobacco, maize, and duckweed
• Transgenic maize have been used to express mammalian proteins at commercial production levels, with biological activities equivalent to those produced in other recombinant systems or purified from natural sources. See, e.g., Hood et al, Adv. Exp. Med. Biol. (1999) 464: 127- 147 and references cited therein.
• Antibody variants have also been produced in large amounts from transgenic plant seeds including antibody fragments, such as single chain antibodies (scFv's), including tobacco seeds and potato tubers. See, e.g., Conrad etal. (1998) Plant Mol. Biol. 38:101-109 and reference cited therein.
• scFv's single chain antibodies
• Antibody derivatives can be produced, for example, by adding exogenous sequences to modify immunogenicity or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic. Generally, part or all of the non-human or human CDR sequences are maintained while the non-human sequences of the variable and constant regions are replaced with human or other amino acids.
• Small antibody fragments may be diabodies having two antigen-binding sites, wherein fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH VL).
• VH heavy chain variable domain
• VL light chain variable domain
• VH VL polypeptide chain
• antibody variants that have one or more amino acids inserted into a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
• the antibody may be a linear antibody.
• the procedure for making a linear antibody is known in the art and described in Zapata et al., (1995) Protein Eng. 8(10): 1057- 1062. Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
• the antibodies may be recovered and purified from recombinant cell cultures by known methods including, but not limited to, protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,
• HPLC high performance liquid chromatography
• antibodies can be labeled with a detectable moiety such as a radioactive atom, a
• Such labeled antibodies can be used for diagnostic techniques, either in vivo, or in an isolated test sample. They can be linked to a cytokine, to a ligand, to another antibody.
• Suitable agents for coupling to antibodies to achieve an antitumor effect include cytokines, such as interleukin 2 (IL-2) and Tumor Necrosis Factor (TNF); photosensitizers, for use in photodynamic therapy, including aluminum ( ⁇ ) phthalocyanine tetrasulfonate, hematoporphyrin, and phthalocyanine; radionuclides, such as iodine-131 (1311), yttrium-90 (90Y), bismuth-212 (212Bi), bismuth-213 (213Bi), technetium- 99m (99mTc), rhenium-186 (186Re), and rhenium-188 (188Re); antibiotics, such as doxorubicin, adriamycin, daunorubicin, methotrexate, daunomycin, neocarzinostatin, and carboplatin; bacterial, plant, and other toxins, such as diphtheria toxin, pseudo
• Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof.
• monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, second edition, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1988); Hammeiiing, et al., In Monoclonal Antibodies and T-Cell Hybridomas, (Elsevier, N.Y., 1981).
• the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
• the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
• Methods of generating monoclonal antibodies as well as antibodies produced by the method may comprise culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from an animal, e.g., a rat or a mouse, immunized with UCH-L1 with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.
• rats can be immunized with a UCH-L1 antigen.
• the UCH-L1 antigen is administered with an adjuvant to stimulate the immune response.
• Such adjuvants include complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes).
• RIBI muramyl dipeptides
• ISCOM immunological complexes
• Such adjuvants may protect the polypeptide from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system.
• the immunization schedule will involve two or more administrations of the polypeptide, spread out over several weeks; however, a single administration of the polypeptide may also be used.
• antibodies and/or antibody-producing cells may be obtained from the animal.
• An anti-UCH-Ll antibody- containing serum is obtained from the animal by bleeding or sacrificing the animal.
• the serum may be used as it is obtained from the animal, an immunoglobulin fraction may be obtained from the serum, or the anti-UCH-Ll antibodies may be purified from the serum.
• Serum or immunoglobulins obtained in this manner are polyclonal, thus having a
• the rat spleen is harvested and splenocytes isolated.
• the splenocytes are then fused by well-known techniques to any suitable myeloma cells, for example, cells from cell line SP20 available from the American Type Culture Collection (ATCC, Manassas, Va., US).
• ATCC American Type Culture Collection
• Hybridomas are selected and cloned by limited dilution.
• the hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding UCH-L1.
• Ascites fluid which generally contains high levels of antibodies, can be generated by immunizing rats with positive hybridoma clones.
• antibody-producing immortalized hybridomas may be prepared from the immunized animal. After immunization, the animal is sacrificed and the splenic B cells are fused to immortalized myeloma cells as is well known in the art. See, e.g., Harlow and Lane, supra. In a preferred embodiment, the myeloma cells do not secrete immunoglobulin polypeptides (a non-secretory cell line). After fusion and antibiotic selection, the hybridomas are screened using UCH-L1, or a portion thereof, or a cell expressing UCH-L1.
• the initial screening is performed using an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RIA), preferably an ELISA.
• ELISA enzyme-linked immunosorbent assay
• RIA radioimmunoassay
• PCT Publication No. WO 00/37504 An example of ELISA screening is provided in PCT Publication No. WO 00/37504.
• Anti-UCH-Ll antibody-producing hybridomas are selected, cloned, and further screened for desirable characteristics, including robust hybridoma growth, high antibody production, and desirable antibody characteristics.
• Hybridomas may be cultured and expanded in vivo in syngeneic animals, in animals that lack an immune system, e.g., nude mice, or in cell culture in vitro. Methods of selecting, cloning and expanding hybridomas are well known to those of ordinary skill in the art.
• hybridomas are rat hybridomas.
• hybridomas are produced in a non-human, non-rat species such as mice, sheep, pigs, goats, cattle, or horses.
• the hybridomas are human hybridomas, in which a human non-secretory myeloma is fused with a human cell expressing an anti-UCH-Ll antibody.
• Antibody fragments that recognize specific epitopes may be generated by known techniques.
• Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce two identical Fab fragments) or pepsin (to produce an F(ab')2 fragment).
• a F(ab')2 fragment of an IgG molecule retains the two antigen-binding sites of the larger ("parent") IgG molecule, including both light chains (containing the variable light chain and constant light chain regions), the CHI domains of the heavy chains, and a disulfide-forming hinge region of the parent IgG molecule. Accordingly, an F(ab') 2 fragment is still capable of crosslinking antigen molecules like the parent IgG molecule.
• recombinant antibodies are generated from single, isolated lymphocytes using a procedure referred to in the art as the selected lymphocyte antibody method (SLAM), as described in U.S. Patent No. 5,627,052; PCT Publication No. WO 92/02551; and Babcook etal, Proc. Natl. Acad. Sci. USA, 93: 7843- 7848 (1996).
• SAM selected lymphocyte antibody method
• single cells secreting antibodies of interest e.g., lymphocytes derived from any one of the immunized animals are screened using an antigen-specific hemolytic plaque assay, wherein the antigen UCH-L1, a subunit of UCH-L1, or a fragment thereof, is coupled to sheep red blood cells using a linker, such as biotin, and used to identify single cells that secrete antibodies with specificity for UCH-L1.
• an antigen-specific hemolytic plaque assay wherein the antigen UCH-L1, a subunit of UCH-L1, or a fragment thereof, is coupled to sheep red blood cells using a linker, such as biotin, and used to identify single cells that secrete antibodies with specificity for UCH-L1.
• variable region cDNAs are rescued from the cells by reverse transcriptase-PCR (RT-PCR) and these variable regions can then be expressed, in the context of appropriate immunoglobulin constant regions (e.g., human constant regions), in mammalian host cells, such as COS or CHO cells.
• RT-PCR reverse transcriptase-PCR
• the host cells transfected with the amplified immunoglobulin sequences, derived from in vivo selected lymphocytes can then undergo further analysis and selection in vitro, for example, by panning the transfected cells to isolate cells expressing antibodies to UCH-L1.
• the amplified immunoglobulin sequences further can be manipulated in vitro, such as by in vitro affinity maturation method. See, for example, PCT Publication No. WO 97/29131 and PCT
• antibodies are produced by immunizing a non-human animal comprising some, or all, of the human immunoglobulin locus with a UCH-L1 antigen.
• the non-human animal is a XENOMOUSE® transgenic mouse, an engineered mouse strain that comprises large fragments of the human
• the XENOMOUSE® transgenic mouse produces an adult-like human repertoire of fully human antibodies, and generates antigen-specific human monoclonal antibodies.
• XENOMOUSE® transgenic mouse contains approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and x light chain loci. See Mendez et al., Nature Genetics, 15: 146-156 (1997), Green and Jakobovits, J. Exp. Med., 188: 483-495 (1998), the disclosures of which are hereby incorporated by reference.
• WO 93/01288 (Breitling et al); PCT Publication No. WO 92/01047 (McCafferty etal); PCT Publication No. WO 92/09690 (Garrard et al); Fuchs et al, Bio/Technology, 9: 1369-1372 (1991); Hay et al, Hum.
• the recombinant antibody library may be from a subject immunized with UCH-L1, or a portion of UCH-L1.
• the recombinant antibody library may be from a naive subject, i.e., one who has not been immunized with UCH-L1, such as a human antibody library from a human subject who has not been immunized with human UCH-L1.
• Antibodies of the invention are selected by screening the recombinant antibody library with the peptide comprising human UCH-L1 to thereby select those antibodies that recognize UCH-L1.
• the invention pertains to an isolated antibody, or an antigen-binding portion thereof, that binds human UCH-L1.
• the antibody is a neutralizing antibody.
• the antibody is a recombinant antibody or a monoclonal antibody.
• antibodies can also be generated using various phage display methods known in the art.
• phage display methods functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them.
• Such phage can be utilized to display antigen-binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine).
• Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead.
• Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv, or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene ⁇ or gene VIII protein.
• phage display methods that can be used to make the antibodies include those disclosed in
• the antibody coding regions from the phage can be isolated and used to generate whole antibodies including human antibodies or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below.
• techniques to recombinantly produce Fab, Fab', and F(ab') 2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication No. WO 92/22324; Mullinax etal, BioTechniques, 12(6): 864- 869 (1992); Sawai et al, Am. J. Reprod.
• a covalent fusion is created between an mRNA and the peptide or protein that it encodes by in vitro translation of synthetic mRNAs that carry puromycin, a peptidyl acceptor antibiotic, at their 3' end.
• a specific mRNA can be enriched from a complex mixture of mRNAs (e.g., a combinatorial library) based on the properties of the encoded peptide or protein, e.g., antibody, or portion thereof, such as binding of the antibody, or portion thereof, to the dual specificity antigen.
• Nucleic acid sequences encoding antibodies, or portions thereof, recovered from screening of such libraries can be expressed by recombinant means as described above (e.g., in mammalian host cells) and, moreover, can be subjected to further affinity maturation by either additional rounds of screening of mRNA-peptide fusions in which mutations have been introduced into the originally selected sequence(s), or by other methods for affinity maturation in vitro of recombinant antibodies, as described above.
• a preferred example of this methodology is PROfusion display technology.
• the antibodies can also be generated using yeast display methods known in the art.
• yeast display methods genetic methods are used to tether antibody domains to the yeast cell wall and display them on the surface of yeast.
• yeast can be utilized to display antigen-binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine).
• yeast display methods that can be used to make the antibodies include those disclosed in U.S. Patent No. 6,699,658 (Wittrup etal.) incorporated herein by reference.
• Antibodies may be produced by any of a number of techniques known in the art. For example, expression from host cells, wherein expression vector(s) encoding the heavy and light chains is (are) transfected into a host cell by standard techniques.
• the various forms of the term "transfection" are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection, and the like.
• the antibodies of the invention in either prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells is preferable, and most preferable in mammalian host cells, because such eukaryotic cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.
• Exemplary mammalian host cells for expressing the recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216-4220 (1980), used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp, J. Mol. Biol., 159: 601-621 (1982), NS0 myeloma cells, COS cells, and SP2 cells.
• Chinese Hamster Ovary CHO cells
• dhfr-CHO cells described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216-4220 (1980
• a DHFR selectable marker e.g., as described in Kaufman and Sharp, J. Mol. Biol., 159: 601-621 (1982
• NS0 myeloma cells COS cells
• SP2 cells include
• the antibodies When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods.
• Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be understood that variations on the above procedure may be performed. For example, it may be desirable to transfect a host cell with DNA encoding functional fragments of either the light chain and/or the heavy chain of an antibody of this invention. Recombinant DNA technology may also be used to remove some, or all, of the DNA encoding either or both of the light and heavy chains that is not necessary for binding to the antigens of interest. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies of the invention.
• Afunctional antibodies may be produced in which one heavy and one light chain are an antibody of the invention (i.e., binds human UCH-L1) and the other heavy and light chain are specific for an antigen other than human UCH-L1 by crosslinking an antibody of the invention to a second antibody by standard chemical crosslinking methods.
• a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr-CHO cells by calcium phosphate-mediated transfection.
• the antibody heavy and light chain genes are each operatively linked to CMV enhancer/ AdMLP promoter regulatory elements to drive high levels of transcription of the genes.
• the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
• the selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium.
• Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells, and recover the antibody from the culture medium.
• the invention provides a method of synthesizing a recombinant antibody of the invention by culturing a host cell of the invention in a suitable culture medium until a recombinant antibody of the invention is synthesized. The method can further comprise isolating the recombinant antibody from the culture medium.
• the humanized antibody may be an antibody or a variant, derivative, analog or portion thereof which immunospecifically binds to an antigen of interest and which comprises a framework (FR) region having substantially the amino acid sequence of a human antibody and a complementary determining region (CDR) having substantially the amino acid sequence of a non-human antibody.
• the humanized antibody may be from a non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
• the term "substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequence of a non-human antibody CDR.
• a humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab')2, FabC, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence.
• a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• a humanized antibody contains both the light chain as well as at least the variable domain of a heavy chain.
• the antibody also may include the CHI, hinge, CH2, CH3, and CH4 regions of the heavy chain.
• a humanized antibody only contains a humanized light chain.
• a humanized antibody only contains a humanized heavy chain.
• a humanized antibody only contains a humanized variable domain of a light chain and/or of a heavy chain.
• the humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including without limitation IgG 1, IgG2, IgG3, and IgG4.
• the humanized antibody may comprise sequences from more than one class or isotype, and particular constant domains may be selected to optimize desired effector functions using techniques well-known in the art.
• the framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor antibody CDR or the consensus framework may be mutagenized by substitution, insertion and/or deletion of at least one amino acid residue so that the CDR or framework residue at that site does not correspond to either the donor antibody or the consensus framework. In one embodiment, such mutations, however, will not be extensive. Usually, at least 90%, at least 95%, at least 98%, or at least 99% of the humanized antibody residues will correspond to those of the parental FR and CDR sequences.
• the term "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.
• the term "consensus immunoglobulin sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related immunoglobulin sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of immunoglobulins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
• the humanized antibody may be designed to minimize unwanted immunological response toward rodent anti-human antibodies, which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.
• the humanized antibody may have one or more amino acid residues introduced into it from a source that is non-human. These non-human residues are often referred to as "import" residues, which are typically taken from a variable domain. Humanization may be performed by substituting
• hypervariable region sequences for the corresponding sequences of a human antibody.
• humanized antibodies are chimeric antibodies wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
• the humanized antibody may be a human antibody in which some hypervariable region residues, and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
• Humanization or engineering of antibodies of the present invention can be performed using any known method, such as but not limited to those described in U.S. Patent Nos.
• the humanized antibody may retain high affinity for UCH-L1 and other favorable biological properties.
• the humanized antibody may be prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available. Computer programs are available that illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
• FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristics, such as increased affinity for UCH-L1, is achieved.
• the hypervariable region residues may be directly and most substantially involved in influencing antigen binding.
• human antibodies can be generated.
• transgenic animals ⁇ e.g., mice that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production.
• the homozygous deletion of the antibody heavy-chain joining region (1 ⁇ 2) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
• Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge.
• the humanized or fully human antibodies may be prepared according to the methods described in U.S. Patent Nos. 5,770,429; 5,833,985; 5,837,243; 5,922,845;
• Anti-UCH-Ll antibodies may be generated using the techniques described above as well as using routine techniques known in the art.
• the anti-UCH- Ll antibody may be an unconjugated UCH-L1 antibody, such as UCH-L1 antibodies available from United State Biological (Catalog Number: 031320), Cell Signaling
• the anti-UCH-Ll antibody may be conjugated to a fluorophore, such as conjugated UCH-L1 antibodies available from BioVision (Catalog Number: 6960-25) or Aviva Systems Biology (Cat. Nos. OAAF01904-FITC).
• a fluorophore such as conjugated UCH-L1 antibodies available from BioVision (Catalog Number: 6960-25) or Aviva Systems Biology (Cat. Nos. OAAF01904-FITC).
• analyte of interest UCH-L1
• the methods may also be adapted in view of other methods for analyzing analytes.
• immunoassay such as sandwich immunoassay (e.g., monoclonal- monoclonal sandwich immunoassays, monoclonal-polyclonal sandwich immunoassays, including enzyme detection (enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA), competitive inhibition immunoassay (e.g., forward and reverse), enzyme multiplied immunoassay technique (EMIT), a competitive binding assay, bioluminescence resonance energy transfer (BRET), one-step antibody detection assay, homogeneous assay, heterogeneous assay, capture on the fly assay, etc.
• sandwich immunoassay e.g., monoclonal- monoclonal sandwich immunoassays, monoclonal-polyclonal sandwich immunoassays, including enzyme detection (enzyme immunoassay (EIA
• the analyte of interest, and/or peptides of fragments thereof may be analyzed using UCH-L1 antibodies in an immunoassay.
• the presence or amount of analyte e.g., UCH-L1 can be determined using antibodies and detecting specific binding to the analyte (e.g., UCH-L1).
• the antibody, or antibody fragment thereof may specifically bind to the analyte (e.g., UCH-L1).
• one or more of the antibodies can be used in combination with one or more commercially available monoclonal/polyclonal antibodies.
• Such antibodies are available from companies such as R&D Systems, Inc. (Minneapolis, MN) and Enzo Life Sciences International, Inc. (Plymouth Meeting, PA).
• analyte e.g., UCH-L1
• an immunoassay such as sandwich immunoassay (e.g.,
• monoclonal-monoclonal sandwich immunoassays monoclonal-polyclonal sandwich immunoassays, including radioisotope detection (radioimmunoassay (RIA)) and enzyme detection (enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) (e.g., Quantikine ELISA assays, R&D Systems, Minneapolis, MN)).
• radioisotope detection radioisoimmunoassay (RIA)
• enzyme detection enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA)
• ELISA enzyme-linked immunosorbent assay
• An example of a point- of-care device that can be used is i-STAT® (Abbott, Laboratories, Abbott Park, IL).
• chemiluminescent microparticle immunoassay in particular one employing the ARCHITECT® automated analyzer (Abbott Laboratories, Abbott Park, IL), as an example.
• Other methods include, for example, mass spectrometry, and immunohistochemistry (e.g., with sections from tissue biopsies), using anti-analyte (e.g., anti-UCH-Ll) antibodies (monoclonal, polyclonal, chimeric, humanized, human, etc.) or antibody fragments thereof against analyte (e.g., UCH-L1).
• anti-analyte e.g., anti-UCH-Ll
• Other methods of detection include those described in, for example, U.S. Patent Nos.
• immobilized antibodies or antibody fragments thereof may be incorporated into the immunoassay.
• the antibodies may be immobilized onto a variety of supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate (such as microtiter wells), pieces of a solid substrate material, and the like.
• An assay strip can be prepared by coating the antibody or plurality of antibodies in an array on a solid support. This strip can then be dipped into the test sample and processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot.
• a homogeneous format may be used. For example, after the test sample is obtained from a subject, a mixture is prepared. The mixture contains the test sample being assessed for analyte (e.g., UCH-L1), a first specific binding partner, and a second specific binding partner. The order in which the test sample, the first specific binding partner, and the second specific binding partner are added to form the mixture is not critical. The test sample is simultaneously contacted with the first specific binding partner and the second specific binding partner.
• analyte e.g., UCH-L1
• the test sample is simultaneously contacted with the first specific binding partner and the second specific binding partner.
• the first specific binding partner and any UCH-L1 contained in the test sample may form a first specific binding partner-analyte (e.g., UCH-L1)- antigen complex and the second specific binding partner may form a first specific binding partner-analyte of interest (e.g., UCH-Ll)-second specific binding partner complex.
• the second specific binding partner and any UCH-L1 contained in the test sample may form a second specific binding partner-analyte (e.g., UCH-Ll)-antigen complex and the first specific binding partner may form a first specific binding partner-analyte of interest (e.g., UCH-Ll)-second specific binding partner complex.
• the first specific binding partner may be an anti-analyte antibody (e.g., anti-UCH-Ll antibody that binds to an epitope having an amino acid sequence comprising at least three contiguous (3) amino acids of SEQ ID NO: 1).
• the second specific binding partner may be an anti-analyte antibody (e.g., anti- UCH-L1 antibody that binds to an epitope having an amino acid sequence comprising at least three contiguous (3) amino acids of SEQ ID NO: 1).
• the second specific binding partner is labeled with or contains a detectable label as described above.
• a heterogeneous format may be used. For example, after the test sample is obtained from a subject, a first mixture is prepared. The mixture contains the test sample being assessed for analyte (e.g., UCH-L1) and a first specific binding partner, wherein the first specific binding partner and any UCH-L1 contained in the test sample form a first specific binding partner-analyte (e.g., UCH-Ll)-antigen complex.
• the first specific binding partner may be an anti-analyte antibody (e.g., anti-UCH-Ll antibody that binds to an epitope having an amino acid sequence comprising at least three contiguous (3) amino acids of SEQ ID NO: 1).
• the order in which the test sample and the first specific binding partner are added to form the mixture is not critical._
• the first specific binding partner may be immobilized on a solid phase.
• the solid phase used in the immunoassay can be any solid phase known in the art, such as, but not limited to, a magnetic particle, a bead, a test tube, a microtiter plate, a cuvette, a membrane, a scaffolding molecule, a film, a filter paper, a disc, and a chip.
• the solid phase is a bead
• the bead may be a magnetic bead or a magnetic particle.
• Magnetic beads/particles may be ferromagnetic, ferrimagnetic, paramagnetic, superparamagnetic or ferrofluidic.
• Exemplary ferromagnetic materials include Fe, Co, Ni, Gd, Dy, Cr02, MnAs, MnBi, EuO, and NiO/Fe.
• Examples of ferrimagnetic materials include NiFe204, CoFe204, Fe 3 0 4 (or FeO'Fe 2 0 3 ).
• Beads can have a solid core portion that is magnetic and is surrounded by one or more non-magnetic layers. Alternately, the magnetic portion can be a layer around a non-magnetic core.
• the solid support on which the first specific binding member is immobilized may be stored in dry form or in a liquid.
• the magnetic beads may be subjected to a magnetic field prior to or after contacting with the sample with a magnetic bead on which the first specific binding member is immobilized.
• any unbound analyte (e.g., UCH-L1) is removed from the complex using any technique known in the art.
• the unbound analyte e.g., UCH-L1 can be removed by washing.
• the first specific binding partner is present in excess of any analyte (e.g., UCH-L1) present in the test sample, such that all analyte (e.g., UCH-L1) that is present in the test sample is bound by the first specific binding partner.
• a second specific binding partner is added to the mixture to form a first specific binding partner-analyte of interest (e.g., UCH-Ll)-second specific binding partner complex.
• the second specific binding partner may be an anti-analyte antibody (e.g., anti-UCH-Ll antibody that binds to an epitope having an amino acid sequence comprising at least three contiguous (3) amino acids of SEQ ID NO: 1).
• the second specific binding partner is labeled with or contains a detectable label as described above.
• immobilized antibodies or antibody fragments thereof may be incorporated into the immunoassay.
• the antibodies may be immobilized onto a variety of supports, such as magnetic or chromatographic matrix particles (such as a magnetic bead), latex particles or modified surface latex particles, polymer or polymer film, plastic or plastic film, planar substrate, the surface of an assay plate (such as microtiter wells), pieces of a solid substrate material, and the like.
• An assay strip can be prepared by coating the antibody or plurality of antibodies in an array on a solid support. This strip can then be dipped into the test sample and processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot.
• a sandwich immunoassay measures the amount of antigen between two layers of antibodies (i.e., at least one capture antibody) and a detection antibody (i.e., at least one detection antibody).
• the capture antibody and the detection antibody bind to different epitopes on the antigen, e.g., analyte of interest such as UCH-L1. Desirably, binding of the capture antibody to an epitope does not interfere with binding of the detection antibody to an epitope.
• Either monoclonal or polyclonal antibodies may be used as the capture and detection antibodies in the sandwich immunoassay.
• At least two antibodies are employed to separate and quantify analyte (e.g., UCH-L1) in a test sample. More specifically, the at least two antibodies bind to certain epitopes of analyte (e.g., UCH-L1) forming an immune complex which is referred to as a "sandwich".
• analyte e.g., UCH-L1
• the at least two antibodies bind to certain epitopes of analyte (e.g., UCH-L1) forming an immune complex which is referred to as a "sandwich”.
• One or more antibodies can be used to capture the analyte (e.g., UCH-L1) in the test sample (these antibodies are frequently referred to as a “capture” antibody or “capture” antibodies) and one or more antibodies is used to bind a detectable (namely, quantifiable) label to the sandwich (these antibodies are frequently referred to as the "detection” antibody or “detection” antibodies).
• the binding of an antibody to its epitope desirably is not diminished by the binding of any other antibody in the assay to its respective epitope.
• Antibodies are selected so that the one or more first antibodies brought into contact with a test sample suspected of containing analyte (e.g., UCH-L1) do not bind to all or part of an epitope recognized by the second or subsequent antibodies, thereby interfering with the ability of the one or more second detection antibodies to bind to the analyte (e.g., UCH-L1).
• a test sample suspected of containing analyte e.g., UCH-L1
• analyte e.g., UCH-L1
• the antibodies may be used as a first antibody in said immunoassay.
• the antibody immunospecifically binds to epitopes on analyte (e.g., UCH-L1).
• said immunoassay may comprise a second antibody that immunospecifically binds to epitopes that are not recognized or bound by the first antibody.
• a test sample suspected of containing analyte can be contacted with at least one first capture antibody (or antibodies) and at least one second detection antibodies either simultaneously or sequentially.
• a test sample suspected of containing analyte e.g., UCH-L1
• the at least one first capture antibody that specifically binds to a particular epitope under conditions which allow the formation of a first antibody-analyte (e.g., UCH-L1) antigen complex. If more than one capture antibody is used, a first multiple capture antibody-UCH-Ll antigen complex is formed.
• the antibodies are used in molar excess amounts of the maximum amount of analyte (e.g., UCH- Ll) expected in the test sample.
• analyte e.g., UCH- Ll
• the antibodies are used in molar excess amounts of the maximum amount of analyte (e.g., UCH- Ll) expected in the test sample.
• analyte e.g., UCH- Ll
• UCH- Ll analyte
• the at least one first capture antibody can be bound to a solid support which facilitates the separation the first antibody-analyte (e.g., UCH-L1) complex from the test sample.
• a solid support known in the art can be used, including but not limited to, solid supports made out of polymeric materials in the forms of wells, tubes, or beads (such as a microparticle).
• the antibody (or antibodies) can be bound to the solid support by adsorption, by covalent bonding using a chemical coupling agent or by other means known in the art, provided that such binding does not interfere with the ability of the antibody to bind analyte (e.g., UCH-L1).
• the solid support can be derivatized to allow reactivity with various functional groups on the antibody.
• derivatization requires the use of certain coupling agents such as, but not limited to, maleic anhydride, N- hydroxysuccinimide and l-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
• the incubation can be carried out at a pH of from about 4.5 to about 10.0, at a temperature of from about 2°C to about 45°C, and for a period from at least about one (1) minute to about eighteen (18) hours, from about 2-6 minutes, from about 7 -12 minutes, from about 5-15 minutes, or from about 3-4 minutes.
• the complex is then contacted with at least one second detection antibody (under conditions that allow for the formation of a first/multiple antibody-analyte (e.g., UCH-L1) antigen-second antibody complex).
• the test sample is contacted with the detection antibody simultaneously with the capture antibody. If the first antibody-analyte (e.g., UCH-L1) complex is contacted with more than one detection antibody, then a first/multiple capture antibody-analyte (e.g., UCH-Ll)-multiple antibody detection complex is formed.
• first antibody-analyte e.g., UCH-L1
• first antibody-analyte e.g., UCH-L1
• a period of incubation under conditions similar to those described above is required for the formation of the first/multiple antibody-analyte (e.g., UCH-Ll)-second/multiple antibody complex.
• At least one second antibody contains a detectable label.
• the detectable label can be bound to the at least one second antibody prior to, simultaneously with or after the formation of the first/multiple antibody-analyte (e.g., UCH-Ll)-second/multiple antibody complex. Any detectable label known in the art can be used.
• Chemiluminescent assays can be performed in accordance with the methods described in Adamczyk etal., Anal. Chim. Acta 579(1): 61-67 (2006). While any suitable assay format can be used, a microplate chemiluminometer (Mithras LB-940, Berthold Technologies U.S.A., LLC, Oak Ridge, TN) enables the assay of multiple samples of small volumes rapidly.
• the chemiluminometer can be equipped with multiple reagent injectors using 96-well black polystyrene microplates (Costar #3792). Each sample can be added into a separate well, followed by the simultaneous/sequential addition of other reagents as determined by the type of assay employed.
• the formation of pseudobases in neutral or basic solutions employing an acridinium aryl ester is avoided, such as by acidification.
• the chemiluminescent response is then recorded well-by-well.
• the time for recording the chemiluminescent response will depend, in part, on the delay between the addition of the reagents and the particular acridinium employed.
• the order in which the test sample and the specific binding partners) are added to form the mixture for chemiluminescent assay is not critical. If the first specific binding partner is detectably labeled with an acridinium compound, detectably labeled first specific binding partner-UCH-Ll antigen complexes form. Alternatively, if a second specific binding partner is used and the second specific binding partner is detectably labeled with an acridinium compound, detectably labeled first specific binding partner-analyte (e.g., UCH- Ll)-second specific binding partner complexes form. Any unbound specific binding partner, whether labeled or unlabeled, can be removed from the mixture using any technique known in the art, such as washing.
• Hydrogen peroxide can be generated in situ in the mixture or provided or supplied to the mixture before, simultaneously with, or after the addition of an above-described acridinium compound. Hydrogen peroxide can be generated in situ in a number of ways such as would be apparent to one skilled in the art.
• a source of hydrogen peroxide can be simply added to the mixture.
• the source of the hydrogen peroxide can be one or more buffers or other solutions that are known to contain hydrogen peroxide.
• a solution of hydrogen peroxide can simply be added.
• a detectable signal namely, a chemiluminescent signal, indicative of the presence of UCH-L1 is generated.
• the basic solution contains at least one base and has a pH greater than or equal to 10, preferably, greater than or equal to 12.
• Examples of basic solutions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, calcium hydroxide, calcium carbonate, and calcium bicarbonate.
• the amount of basic solution added to the sample depends on the concentration of the basic solution. Based on the concentration of the basic solution used, one skilled in the art can easily determine the amount of basic solution to add to the sample.
• Other labels other than chemiluminescent labels can be employed. For instance, enzymatic labels (including but not limited to alkaline phosphatase) can be employed.
• the chemiluminescent signal, or other signal, that is generated can be detected using routine techniques known to those skilled in the art. Based on the intensity of the signal generated, the amount of analyte of interest (e.g., UCH-L1) in the sample can be quantified. Specifically, the amount of analyte (e.g., UCH-L1) in the sample is proportional to the intensity of the signal generated. The amount of analyte (e.g., UCH-L1) present can be quantified by comparing the amount of light generated to a standard curve for analyte (e.g., UCH-L1) or by comparison to a reference standard. The standard curve can be generated using serial dilutions or solutions of known concentrations of analyte (e.g., UCH-L1) by mass spectroscopy, gravimetric methods, and other techniques known in the art.
• analyte of interest e.g., UCH-L1
• UCH-L1 analyt
• an aliquot of labeled analyte of interest e.g., analyte (e.g., UCH-L1) having a fluorescent label, a tag attached with a cleavable linker, etc.
• analyte of interest e.g., UCH-L1
• analyte of interest antibody e.g., UCH-L1 antibody
• an immobilized specific binding partner such as an antibody
• an immobilized specific binding partner can either be sequentially or simultaneously contacted with the test sample and a labeled analyte of interest, analyte of interest fragment or analyte of interest variant thereof.
• the analyte of interest peptide, analyte of interest fragment or analyte of interest variant can be labeled with any detectable label, including a detectable label comprised of tag attached with a cleavable linker.
• the antibody can be immobilized on to a solid support.
• the antibody can be coupled to an antibody, such as an and species antibody, that has been immobilized on a solid support, such as a microparticle or planar substrate.
• the labeled analyte of interest, the test sample and the antibody are incubated under conditions similar to those described above in connection with the sandwich assay format.
• Two different species of antibody-analyte of interest complexes may then be generated.
• one of the antibody-analyte of interest complexes generated contains a detectable label (e.g., a fluorescent label, etc.) while the other antibody-analyte of interest complex does not contain a detectable label.
• the antibody-analyte of interest complex can be, but does not have to be, separated from the remainder of the test sample prior to
• analyte of interest such as membrane-associated analyte of interest, soluble analyte of interest, fragments of soluble analyte of interest, variants of analyte of interest (membrane-associated or soluble analyte of interest) or any combinations thereof
• concentration of analyte of interest such as membrane-associated analyte of interest, soluble analyte of interest, fragments of soluble analyte of interest, variants of analyte of interest (membrane-associated or soluble analyte of interest) or any combinations thereof
• an immobilized analyte of interest e.g., UCH-L1
• a test sample e.g., UCH-L1
• at least one labeled antibody e.g., UCH-L1
• the analyte of interest can be bound to a solid support, such as the solid supports discussed above in connection with the sandwich assay format.
• the immobilized analyte of interest, test sample and at least one labeled antibody are incubated under conditions similar to those described above in connection with the sandwich assay format.
• Two different species analyte of interest-antibody complexes are then generated. Specifically, one of the analyte of interest-antibody complexes generated is immobilized and contains a detectable label (e.g., a fluorescent label, etc.) while the other analyte of interest-antibody complex is not immobilized and contains a detectable label.
• a detectable label e.g., a fluorescent label, etc.
• the non-immobilized analyte of interest-antibody complex and the remainder of the test sample are removed from the presence of the immobilized analyte of interest-antibody complex through techniques known in the art, such as washing.
• the amount of detectable label in the immobilized analyte of interest-antibody complex is then quantified following cleavage of the tag.
• the concentration of analyte of interest in the test sample can then be determined by comparing the quantity of detectable label as described above.
• a solid substrate is pre-coated with an immobilization agent.
• the capture agent, the analyte (e.g., UCH-L1) and the detection agent are added to the solid substrate together, followed by a wash step prior to detection.
• the capture agent can bind the analyte (e.g., UCH-L1) and comprises a ligand for an
• the capture agent and the detection agents may be antibodies or any other moiety capable of capture or detection as described herein or known in the art.
• the ligand may comprise a peptide tag and an immobilization agent may comprise an anti-peptide tag antibody.
• the ligand and the immobilization agent may be any pair of agents capable of binding together so as to be employed for a capture on the fly assay (e.g., specific binding pair, and others such as are known in the art). More than one analyte may be measured.
• the solid substrate may be coated with an antigen and the analyte to be analyzed is an antibody.
• a solid support such as a microparticle pre-coated with an immobilization agent (such as biotin, streptavidin, etc.) and at least a first specific binding member and a second specific binding member (which function as capture and detection reagents, respectively) are used.
• the first specific binding member comprises a ligand for the immobilization agent (for example, if the immobilization agent on the solid support is streptavidin, the ligand on the first specific binding member may be biotin) and also binds to the analyte of interest (e.g., UCH-L1).
• the second specific binding member comprises a detectable label and binds to an analyte of interest (e.g., UCH-L1).
• the solid support and the first and second specific binding members may be added to a test sample (either sequentially or simultaneously).
• the ligand on the first specific binding member binds to the immobilization agent on the solid support to form a solid support/first specific binding member complex.
• Any analyte of interest present in the sample binds to the solid support/first specific binding member complex to form a solid support/first specific binding member/analyte complex.
• the second specific binding member binds to the solid support/first specific binding member/analyte complex and the detectable label is detected.
• An optional wash step may be employed before the detection.
• more than one analyte may be measured.
• more than two specific binding members can be employed.
• multiple detectable labels can be added.
• multiple analytes of interest can be detected, or their amounts, levels or concentrations, measured, determined or assessed.
• a capture on the fly assay can be done in a variety of formats as described herein, and known in the art.
• the format can be a sandwich assay such as described above, but alternately can be a competition assay, can employ a single specific binding member, or use other variations such as are known.
• the methods of diagnosing, prognosticating, and/or assessing, as described above, can further include using other factors for the diagnosis, prognostication, and assessment.
• traumatic brain injury may be diagnosed using the Glasgow Coma Scale or the Extended Glasgow Outcome Scale (GOSE).
• GOSE Extended Glasgow Outcome Scale
• Other tests, scales or indices can also be used either alone or in combination with the Glasgow Coma Scale.
• An example is the Collinsos Los Amigos Scale.
• the Collinsos Los Amigos Scale measures the levels of awareness, cognition, behavior and interaction with the environment.
• the Collinsos Los Amigos Scale includes: Level I: No Response; Level ⁇ : Generalized Response; Level ⁇ : Localized Response; Level IV: Confused-agitated; Level V: Confused-inappropriate; Level VI: Confused-appropriate; Level VII: Automatic-appropriate; and Level VHI: Purposeful- appropriate.
• the sample is obtained after the human subject sustained an injury to the head caused by physical shaking, blunt impact by an external mechanical or other force that results in a closed or open head trauma, one or more falls, explosions or blasts or other types of blunt force trauma.
• the sample is obtained after the human subject has ingested or been exposed to a chemical, toxin or combination of a chemical and toxin.
• the sample is obtained from a human subject that suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, one or more viruses, meningitis, hydrocephalus or combinations thereof.
• the methods described herein use samples that also can be used to determine whether or not a subject has or is at risk of developing mild traumatic brain injury by determining the levels of UCH-L1 in a subject using the anti-UCH-Ll antibodies described below, or antibody fragments thereof.
• the disclosure also provides a method for determining whether a subject having, or at risk for, traumatic brain injuries, discussed herein and known in the art, is a candidate for therapy or treatment.
• the subject is at least one who: (i) has experienced an injury to the head; (ii) ingested and/or been exposed to one or more chemicals and/or toxins; (iii) suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, one or more viruses, meningitis, hydrocephalus or suffers from any combinations thereof; or (iv) any combinations of (i)-(iii); or, who has actually been diagnosed as having, or being at risk for TBI (such as, for example, subjects suffering from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, one or more viruses, meningitis, hydrocephalus or combinations thereof), and/or who demonstrates an unfavorable (i.e., clinically undesirable) concentration or amount of UCH-L1 or UCH-L1 fragment, as described herein.
• TBI any combinations of (i)-(iii)- or, who has actually been diagnosed as having, or being at risk for TBI (such as, for
• sample refers to fluid sample containing or suspected of containing UCH-L1.
• the sample may be derived from any suitable source.
• the sample may comprise a liquid, fluent particulate solid, or fluid suspension of solid particles.
• the sample may be processed prior to the analysis described herein. For example, the sample may be separated or purified from its source prior to analysis; however, in certain embodiments, an unprocessed sample containing UCH-L1 may be assayed directly.
• the source of UCH-L1 is a human bodily substance (e.g., bodily fluid, blood such as whole blood, serum, plasma, urine, saliva, sweat, sputum, semen, mucus, lacrimal fluid, lymph fluid, amniotic fluid, interstitial fluid, lung lavage, cerebrospinal fluid, feces, tissue, organ, or the like).
• Tissues may include, but are not limited to skeletal muscle tissue, liver tissue, lung tissue, kidney tissue, myocardial tissue, brain tissue, bone marrow, cervix tissue, skin, etc.
• the sample may be a liquid sample or a liquid extract of a solid sample.
• the source of the sample may be an organ or tissue, such as a biopsy sample, which may be solubilized by tissue disintegration/cell lysis.
• the sample volume may be about 0.5 nL, about 1 nL, about 3 nL, about 0.01 uL, about 0.1 uL, about 1 uL, about 5 ⁇ , about 10 ⁇ , about 100 uL, about 1 mL, about 5 mL, about 10 mL, or the like.
• the volume of the fluid sample is between about 0.01 uL and about 10 mL, between about 0.01 uL and about 1 mL, between about 0.01 uL and about 100 uL, or between about 0.1 uL and about 10 uL.
• the fluid sample may be diluted prior to use in an assay.
• the fluid may be diluted with an appropriate solvent (e.g., a buffer such as PBS buffer).
• an appropriate solvent e.g., a buffer such as PBS buffer.
• a fluid sample may be diluted about 1-fold, about 2-fold, about 3 -fold, about 4-fold, about 5-fold, about 6-fold, about 10-fold, about 100-fold, or greater, prior to use.
• the fluid sample is not diluted prior to use in an assay.
• the sample may undergo pre-analytical processing.
• Pre-analytical processing may offer additional functionality such as nonspecific protein removal and/or effective yet cheaply implementable mixing functionality.
• General methods of pre-analytical processing may include the use of electrokinetic trapping, AC electrokinetics, surface acoustic waves, isotachophoresis, dielectrophoresis, electrophoresis, or other pre- concentration techniques known in the art.
• the fluid sample may be concentrated prior to use in an assay.
• the source of UCH-L1 is a human body fluid (e.g., blood, serum)
• the fluid may be concentrated by precipitation, evaporation, filtration, centrifugation, or a combination thereof.
• a fluid sample may be concentrated about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 10-fold, about 100-fold, or greater, prior to use.
• control sample may be analyzed concurrently with the sample from the subject as described above.
• the results obtained from the subject sample can be compared to the results obtained from the control sample.
• Standard curves may be provided, with which assay results for the sample may be compared.
• Such standard curves present levels of marker as a function of assay units, i.e., fluorescent signal intensity, if a fluorescent label is used.
• standard curves can be provided for reference levels of the UCH-L1 in normal healthy tissue, as well as for "at-risk" levels of the UCH-L1 in tissue taken from donors, who may have one or more of the characteristics set forth above.
• a method for determining the presence, amount, or concentration of UCH-L1 in a test sample comprises assaying the test sample for UCH-L1 by an immunoassay, for example, employing at least one capture antibody that binds to an epitope on UCH-L1 and at least one detection antibody that binds to an epitope on UCH-L1 which is different from the epitope for the capture antibody and optionally includes a detectable label, and comprising comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of UCH-L1 in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of UCH-L1 in a calibrator.
• the calibrator is optionally, and is preferably, part of a series of calibrators in which each of the calibrators differs from the other calibrators in the series by the concentration of UCH-L1.
• kits which may be used for assaying or assessing a test sample for UCH-L1 or UCH-L1 fragment.
• the kit comprises at least one component for assaying the test sample for UCH-L1 instructions for assaying the test sample for UCH-L1.
• the kit can comprise instructions for assaying the test sample for UCH-L1 by immunoassay, e.g., chemiluminescent microparticle immunoassay.
• Instructions included in kits can be affixed to packaging material or can be included as a package insert. While the instructions are typically written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this disclosure.
• Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like.
• instructions can include the address of an internet site that provides the instructions.
• the at least one component may include at least one composition comprising one or more isolated antibodies or antibody fragments thereof that specifically bind to UCH-L1.
• the antibody may be a UCH-L1 capture antibody and/or a UCH-L1 detection antibody.
• the kit can comprise a calibrator or control, e.g., purified, and optionally lyophilized, UCH-L1, and/or at least one container (e.g., tube, microtiter plates or strips, which can be already coated with an anti-UCH-Ll monoclonal antibody) for conducting the assay, and/or a buffer, such as an assay buffer or a wash buffer, either one of which can be provided as a concentrated solution, a substrate solution for the detectable label (e.g., an enzymatic label), or a stop solution.
• the kit comprises all components, i.e., reagents, standards, buffers, diluents, etc., which are necessary to perform the assay.
• the instructions also can include instructions for generating a standard curve.
• the kit may further comprise reference standards for quantifying UCH-L1.
• the reference standards may be employed to establish standard curves for interpolation and/or extrapolation of UCH-L1 concentrations.
• the reference standards may include a high UCH- Ll concentration level, for example, about 100000 pg/mL, about 125000 pg/mL, about 150000 pg/mL, about 175000 pg/mL, about 200000 pg/mL, about 225000 pg/mL, about 250000 pg/mL, about 275000 pg/mL, or about 300000 pg/mL; a medium UCH-L1 concentration level, for example, about 25000 pg/mL, about 40000 pg/mL, about 45000 pg/mL, about 50000 pg/mL, about 55000 pg/mL, about 60000 pg/mL, about 75000 pg/mL or about 100000 pg/mL; and
• any antibodies, which are provided in the kit can incorporate a detectable label, such as a fluorophore, radioactive moiety, enzyme, biotin/avidin label, chromophore, chemiluminescent label, or the like, or the kit can include reagents for labeling the antibodies or reagents for detecting the antibodies (e.g., detection antibodies) and/or for labeling the analytes (e.g., UCH-L1) or reagents for detecting the analyte (e.g., UCH-L1).
• the antibodies, calibrators, and/or controls can be provided in separate containers or pre-dispensed into an appropriate assay format, for example, into microtiter plates,
• the kit includes quality control components (for example, sensitivity panels, calibrators, and positive controls).
• quality control components for example, sensitivity panels, calibrators, and positive controls.
• Preparation of quality control reagents is well- known in the art and is described on insert sheets for a variety of immunodiagnostic products.
• Sensitivity panel members optionally are used to establish assay performance characteristics, and further optionally are useful indicators of the integrity of the immunoassay kit reagents, and the standardization of assays,
• the kit can also optionally include other reagents required to conduct a diagnostic assay or facilitate quality control evaluations, such as buffers, salts, enzymes, enzyme co- factors, substrates, detection reagents, and the like.
• Other components such as buffers and solutions for the isolation and/or treatment of a test sample (e.g., pretreatment reagents), also can be included in the kit.
• the kit can additionally include one or more other controls.
• One or more of the components of the kit can be lyophilized, in which case the kit can further comprise reagents suitable for the reconstitution of the lyophilized components.
• kits for holding or storing a sample (e.g., a container or cartridge for a urine, whole blood, plasma, or serum sample).
• a sample e.g., a container or cartridge for a urine, whole blood, plasma, or serum sample.
• the kit optionally also can contain reaction vessels, mixing vessels, and other components that facilitate the preparation of reagents or the test sample.
• the kit can also include one or more instrument for assisting with obtaining a test sample, such as a syringe, pipette, forceps, measured spoon, or the like.
• the kit can comprise at least one acridinium-9-carboxamide, at least one acridinium-9-carboxylate aryl ester, or any combination thereof. If the detectable label is at least one acridinium compound, the kit also can comprise a source of hydrogen peroxide, such as a buffer, solution, and/or at least one basic solution. If desired, the kit can contain a solid phase, such as a magnetic particle, bead, test tube, microtiter plate, cuvette, membrane, scaffolding molecule, film, filter paper, disc, or chip.
• the kit can further comprise one or more components, alone or in further combination with instructions, for assaying the test sample for another analyte, which can be a biomarker, such as a biomarker of traumatic brain injury or disorder.
• a biomarker such as a biomarker of traumatic brain injury or disorder.
• kits or components thereof, as well as the method for assessing or determining the concentration of UCH-L1 in a test sample by an immunoassay as described herein, can be adapted for use in a variety of automated and semi -automated systems (including those wherein the solid phase comprises a microparticle), as described, e.g., U.S. Patent No.
• Abbott Laboratories (Abbott Park, IL) as Abbott Point of Care (i-STAT® or i-STAT Alinity, Abbott Laboratories) as well as those described in U.S. Patent Nos. 5,089,424 and 5,006,309, and as commercially marketed, e.g., by Abbott Laboratories (Abbott Park, IL) as ARCHITECT® or the series of Abbott Alinity devices.
• Some of the differences between an automated or semi-automated system as compared to a non-automated system include the substrate to which the first specific binding partner (e.g., analyte antibody or capture antibody) is attached (which can affect sandwich formation and analyte reactivity), and the length and timing of the capture, detection, and/or any optional wash steps.
• the first specific binding partner e.g., analyte antibody or capture antibody
• an automated or semi-automated format e.g., ARCHITECT® and any successor platform, Abbott Laboratories
• an automated or semi-automated format may have a relatively shorter incubation time (e.g., approximately 18 minutes for ARCHITECT®).
• an automated or semi-automated format e.g., ARCHITECT® and any successor platform
• a relatively shorter incubation time e.g., approximately 4 minutes for the ARCHITECT® and any successor platform.
• kits can be employed in other formats, for example, on electrochemical or other hand-held or point-of-care assay systems.
• the present disclosure is, for example, applicable to the commercial Abbott Point of Care (i-STAT®, Abbott Laboratories) electrochemical immunoassay system that performs sandwich immunoassays. Immunosensors and their methods of manufacture and operation in single-use test devices are described, for example in, U.S. Patent No.
• a microfabricated silicon chip is manufactured with a pair of gold amperometric working electrodes and a silver-silver chloride reference electrode. On one of the working electrodes, polystyrene beads (0.2 mm diameter) with immobilized capture antibody are adhered to a polymer coating of patterned polyvinyl alcohol over the electrode. This chip is assembled into an i-STAT® cartridge with a fluidics format suitable for immunoassay.
• a specific binding partner for UCH-L1 such as one or more UCH-L1 antibodies (one or more monoclonal/polyclonal antibody or a fragment thereof, a variant thereof, or a fragment of a variant thereof that can bind UCH-L1) or one or more anti-UCH-Ll DVD-Igs (or a fragment thereof, a variant thereof, or a fragment of a variant thereof that can bind UCH-L1), either of which can be detectably labeled.
• an aqueous reagent that includes p-aminophenol phosphate.
• a sample from a subject suspected of suffering from TBI is added to the holding chamber of the test cartridge, and the cartridge is inserted into the i-STAT® reader.
• a pump element within the cartridge pushes the sample into a conduit containing the chip.
• the sample is brought into contact with the sensors allowing the enzyme conjugate to dissolve into the sample.
• the sample is oscillated across the sensors to promote formation of the sandwich of approximately 2-12 minutes.
• the penultimate step of the assay the sample is pushed into a waste chamber and wash fluid, containing a substrate for the alkaline phosphatase enzyme, is used to wash excess enzyme conjugate and sample off the sensor chip.
• the alkaline phosphatase label reacts with p-aminophenol phosphate to cleave the phosphate group and permit the liberated p-aminophenol to be electrochemically oxidized at the working electrode. Based on the measured current, the reader is able to calculate the amount of UCH-L1 in the sample by means of an embedded algorithm and factory-determined calibration curve.
• the methods and kits as described herein necessarily encompass other reagents and methods for carrying out the immunoassay.
• an exemplary conjugate diluent is ARCHITECT® conjugate diluent employed in certain kits (Abbott Laboratories, Abbott Park, IL) and containing 2-(N-morpholino)ethanesulfonic acid (MES), a salt, a protein blocker, an antimicrobial agent, and a detergent.
• MES 2-(N-morpholino)ethanesulfonic acid
• An exemplary calibrator diluent is ARCHITECT® human calibrator diluent employed in certain kits (Abbott Laboratories, Abbott Park, IL), which comprises a buffer containing MES, other salt, a protein blocker, and an antimicrobial agent. Additionally, as described in U.S. Patent Application No. 61/142,048 filed December 31, 2008, improved signal generation may be obtained, e.g., in an i-STAT® cartridge format, using a nucleic acid sequence linked to the signal antibody as a signal amplifier. Adaptation of a cartridge for multiplex use, such as used for i-Stat, has been described in the patent literature, such as for example, U.S. Patent No. 6,438,498, the contents of which are herein incorporated by reference.
• kits as described herein may also involve single molecule counting.
• a method for analyte analysis may involve assessing an analyte present in a sample.
• the assessing may be used for determining presence of and/or concentration of an analyte in a sample.
• the method may also be used for determining presence of and/or concentration of a plurality of different analytes present in a sample.
• the device can be a microfluidics device, digital microfluidics device (DMF), a surface acoustic wave based microfluidic device (SAW), an integrated DMF and analyte detection device, an integrated SAW and analyte detection device, or robotics based assay processing
• the assays and kits also optionally can be employed to assess UCH-L1 in other diseases, disorders, and conditions as appropriate.
• the method of assay also can be used to identify a compound that ameliorates diseases, such as traumatic brain injury. For example, a cell that expresses UCH-L1 can be contacted with a candidate compound. The level of expression of UCH-L1 in the cell contacted with the compound can be compared to that in a control cell using the method of assay described herein.
• the present invention has multiple aspects, illustrated by the following non- limiting examples.
• the present invention has multiple aspects, illustrated by the following non- limiting examples.
• Monoclonal antibody pairs such as Antibody A as a capture monoclonal antibody and Antibody B and C as a detection monoclonal antibody, were used.
• Antibody A is an exemplary anti-UCH-Ll antibody that was internally developed at Abbott Laboratories (Abbott Park, IL).
• Antibody B and C recognize different epitopes of UCH-L 1 and enhance the detection of antigen in the sample that were developed by Banyan Biomarkers (Alachua, Florida).
• Other antibodies that were internally developed at Abbott Laboratories (Abbott Park, IL) also show or are expected to show similar enhancement of signal when used together as capture antibodies or detection antibodies, in various combinations.
• the UCH-L 1 assay design was evaluated against key performance attributes.
• the cartridge configuration was Antibody Configuration: Antibody A (Capture Antibody)/ Antibody B+C (Detection Antibody); Reagent conditions: 0.8% solids, 125 ⁇ g /mL Fab Alkaline Phosphatase cluster conjugate; and Sample Inlet Print: UCH-L1 standard.
• the assay time was 10-15 min (with 7- 12 min sample capture time).
• TRACK-TBI Pilot study based on clinical data from three clinical sites, helped refine TBI Common Data Elements and created a prototype of the TBI Information Commons for the TRACK-TBI study.
• CER comparative effectiveness research
• the controls were adult orthopedic trauma patients who met the following criteria: 1. An Abbreviated Injury Score of ⁇ 4 (not life threatening) for their extremity and/or pelvis injury and/or rib fracture; 2. Met the same inclusion and exclusion criteria as the TBI subjects except that the criterion of having undergone a CT or MRI in the ED for suspected head injury did not apply. TBI was ruled out for the current injury by interviewing potential controls about loss of consciousness (LOC), disturbance of consciousness, and posttraumatic amnesia (PTA)/RA; 3. Each site was provided a plan for the number of controls to target according to age and gender distributions derived from the TBI Cohort; and 4.
• LOC loss of consciousness
• PTA posttraumatic amnesia
• Controls were enrolled into the CA-MRI cohort for follow-up and drop to comprehensive assessment (CA) at 2-weeks if unable to complete the MRI visit.
• Subject Eligibility Adult patients were enrolled of all ages presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria, in which the patient had sustained a traumatically induced physiological disruption of brain function, as manifested by > one of the following: any period of loss of consciousness (LOC); any loss of memory for events (e.g., amnesia) immediately before or after the accident; any alteration of mental state at the time of the accident (feeling dazed, disoriented, and/or confused); and/or focal neurologic deficits that may or may not be permanent. Traumatically induced included the head being struck, the head striking an object, or the brain undergoing an acceleration/deceleration movement (e.g., whiplash) without direct external trauma to the head.
• LOC loss of consciousness
• any loss of memory for events
• the Brief Assessment (BA) Cohort included 1200 total subjects, with 400 subjects each for ED, ADM, and ICU Groups. The following data was gathered for the BA Cohort: demographic and full clinical course data; blood draw for serum, plasma, DNA and RNA on Day 1 ( ⁇ 24 hours of injury); repeat blood draw for serum within 3-6 hours of the Day 1 baseline collection (optional for sites to include this component); clinical brain CT scan from Day 1 acquired as part of hospital course; and outcome data collected via structured telephone interview at 2 weeks, 3, 6, and 12 months using NIH TBI-CDEs v.2.0 Core outcome measures as published on the NINDS CDE website.
• the Compressive Assessment (CA) Cohort included 1200 total subjects, with 300 subjects + 100 controls each for ED, ADM, and ICU Groups.
• the Comprehensive Assessment + MRI (CA+MRI) Cohort included 600 total subjects, with 200 each for ED, ADM, and ICU Groups. The following data was gathered for the CA+MRI Cohort: demographic and full clinical course data; high density daily clinical data for ADM and ICU Groups; blood draw for serum, plasma, RNA, and DNA on Day 1 ( ⁇ 24 hours of injury); repeat blood draw for serum within 3-6 hours of the Day 1 baseline collection (optional for sites to include this component); blood draw for serum, plasma, and RNA on Day 3 (48-72 hours) and 5 (96-120 hours) for ADM and ICU; collection of cerebrospinal fluid on days 1 through 5 (optional for sites to include this component); all clinical head CT scans acquired as part of hospital course; blood draw for serum, plasma and RNA at 2 weeks and 6 months; 3T research MRI acquired at 2 weeks and 6 months; and outcome data collected via structured in-person interview at 2 weeks, 6, and 12 months and at 3 month via structured telephone interview using NIH TBI-CDEs
• UCH-L1 was measured in a subset of 59 TRACK TBI patients in the i-STAT assay format (Table 4).
• each patient had an extensive medical evaluation including head CT, neuropsychiatry testing, Glasgow Coma Score (GCS), and many patients also had a follow up MRI within 2 weeks of injury.
• GCS Glasgow Coma Score
• FIG. 1 shows that UCH-L1 levels correlated with injury throughout the first 24 hours after injury (range approximately 2- 23 hours).
• Table 5 shows the possible outcomes of TBI patients using a UCH-L1 reference level confirmed by CT scan.
• Sensitivity was determined by the test: TP/T TBI and specificity was determined by the test: TN/TNOTTBL PPV was determined by TP/TposrrivE. NPV was determined by
• TN/TNEGATWE Accuracy was determined by (TP + TN)/TALL SUBJECTS- [0382]
• Table 6 shows the results of using UCH-L1 cut-off levels of 100 pg/mL and 300 pg/mL compared to imaging results.
• a subject that has sustained or may have sustained a head injury can be evaluated for the presence or absence of a tramautic brain injury.
• the methods of the present disci sour e can determine that a subject with UCH-L1 levels of at least 100 pg/mL will have a greater than 86% probability of having sustained a traumatic brain injury based on imaging result.
• the methods of the present disclosure can determine that a subject with UCH- Ll levels of at least 300 pg/mL will have a greater than 96% probability of having sustained a tramautic brain injury based on imaging result.
• FIGS. 2 and 3 show receiver operating characteristic (ROC) analysis of UCH-L1 and CT scan results for all of the subjects by Time Point (FIG. 2) and by change in UCH-L1 levels at Time Point 2 compared to Time Point 1 (FIG. 3).
• FIG. 4 shows the receiver operating characteristic (ROC) analysis of UCH-L1 levels and CT scan results for all of the subjects by the absolute amount (“absolute delta”) (i.e., change between the UCH-L1 levels in the first time point ("Time Point 1") to the UCH-L1 levels in the second time point (“Time Point 2”)).
• Table 7 shows the analysis of TRACK data in a sample size of 191 patients, specifically, the analysis of the change between Time Point 2 and Time Point 1 in UCH-L1 levels.
• the Time Point 1 sample was taken within 24 hours from injury and Time Point 2 sample was taken about 3-6 hours after the Time Point 1 sample was taken.
• FIG. 5 and 6 See also FIGS. 5 and 6.
• FIG. 5 shows a box and whisker plot indicating the UCH-L1 levels determined in all of the patients of the study at Time Point 1 and Time Point 2.
• FIG. 6 shows the assay kinetics median Z-score of testing results by time point. These data were simply analyses comparing the time points, and are not based on CT, MRI or GCS +/-.
• the TRACK data from the 191 samples was further analyzed based on when the Time Point 1 sample was taken, e.g., 0 to about 6 hours after injury ("0-6 hour group”), about 6 to about 12 hours after injury ("6-12 hour group”) and correlated with head CT scan results and/or GCS scores.
• the UCH-L1 levels in the Time Point 1 and Time Point 2 samples were compared to the positive or negative head CT scan results and/or GCS scores indicating mild or moderate/severe TBI. As this analysis was based on the time of when the Time Point 1 sample was taken, the number of subjects per group was small. See Table 8.
• FIGS. 7A and 7B show the UCH-L1 results in the subjects from the 0-6 hour group that had positive or negative head CT scans.
• FIGS. 8A and 8B show the UCH-L1 results in the subjects from the 6-12 hour group that had positive or negative head CT scans.
• FIGS. 7A and 8A show the distribution of the UCH-L1 levels at Time Point 1 and Time Point 2 in the subjects that had a positive or negative CT scan.
• the UCH-L1 levels in the CT positive subjects were higher than the CT negative subjects at both Time Point 1 and Time Point 2 for both the 0-6 hour group and the 6-12 hour group.
• FIGS. 7B and 8B show the ROC curves correlating the UCH-L1 levels at Time Point 1 and Time Point 2 with CT scan result.
• the sensitivity and specificity of reference levels for 0-6 hour and 6-12 hour groups based on the ROC curves are shown in Table 9.
• FIG 9A shows the change ("delta") in UCH-L1 levels of the Time Point 2 sample from the Time Point 1 sample in subjects from the 0-6 hour group that had positive or negative head CT scans
• FIG. 10A shows the absolute amount (“absolute delta”) in UCH-L1 levels of this group
• FIG. 9B shows the change ("delta") in UCH-L1 levels in the Time Point 2 sample from the Time Point 1 sample in subjects from the 6-12 hour group that had positive or negative head CT scans
• FIG. 10B shows the absolute amount (“absolute delta”) in UCH-L1 levels of this group.
• Subjects having a positive head CT scan had a greater decrease or change in UCH-L1 levels from Time Point 1 to Time Point 2 compared to subjects having a negative head CT scan.
• the subjects from the 0-6 hour group had a larger change in UCH-L1 levels compared to subjects from the 6-12 hour group.
• the data was analyzed to examine samples in which the Time Point 1 sample was taken between 0-10 hours after injury ("0-10 hour group”) and compared to the respective Time Point 2 samples, as well as samples in which the Time Point 1 sample was taken more than 10 hours after injury (">10 hour group”) and compared to the respective Time Point 2 samples.
• FIG 16 shows a ROC curve of the fold-change in the UCH-L1 levels (UCH-L1 levels at Time Point 1 / UCH-L1 levels at Time Point 2) correlated with a positive or negative head CT scan.
• This fold reference level does well at predicting a positive CT in a subject, wherein a fold-change less than 1.5 predicted a positive CT scan result in the subject
• the fold-change between the levels in Time Point 1 and Time Point 2 was determined in subjects of the 0-12 hour group.
• a ROC curve of the fold-change in the UCH-L1 levels (UCH-L1 levels at Time Point 1 / UCH-L1 levels at Time Point 2) was correlated with a positive or negative head CT scan (data not shown).
• the fold reference level of 1.81 (i.e., Time Point 1 result / Time Point 2 result) had a sensitivity of 93% and specificity of 36% if the Time Point 1 sample is taken within the first 12 hours after injury.
• This fold reference level does well at predicting a positive CT in a subject, wherein a fold-change less than 1.81 predicted a positive CT scan result in the subject and thus classifies the subject as needing a CT scan.
• a ROC curve of the fold-change in the UCH-L1 levels (UCH-L1 levels at Time Point 2 / UCH-L1 levels at Time Point 1) was correlated with a positive or negative head CT scan (data not shown).
• the fold reference level of 0.55 i.e., Time Point 2 result / Time Point 1 result
• This fold reference level does well at predicting a positive CT in a subject, wherein a fold-change more than 0.55 predicted a positive CT scan result in the subject and thus classifies the subject as needing a CT scan, while a fold-change less than 0.55 classifies the subject as negative for needing a CT scan.
• ROC analysis was also performed to show that if the UCH-L1 level at time point 1 is greater than 550 pg/mL or if the fold-change between time point 2 and time point 1 is greater than 0.55, then the subject is classified as positive for needing a CT scan; if the UCH-L1 level at time point 1 is less than 550 pg/mL or if the fold-change between time point 2 and time point 1 is less than 0.55, then the subject is classified as negative for needing a CT scan.
• These reference levels had a sensitivity of 100% and specificity of 32%.
• FIGS. 11 A and 1 IB show the UCH-Ll results in the subjects from the 0-6 hour group that were identified as having mild or moderate to severe (“moderate/severe") TBI based on their GCS score.
• FIGS. 12A and 12B show the UCH-Ll results in the subjects from the 6-12 hour group that were identified as having mild or moderate to severe
• FIGS. 11 A and 12A show the distribution of the UCH-Ll levels at Time Point 1 and Time Point 2 in the subjects determined to have mild or moderate/severe.
• the UCH-Ll levels in the moderate/severe subjects were significantly higher than the mild subjects at both Time Point 1 and Time Point 2 for both the 0-6 hour group and the 6-12 hour group.
• the UCH-Ll levels in the 0-6 hour group and 6-12 hour group had a striking decrease from Time Point 1 to Time Point 2.
• FIGS. 1 IB and 12B show the ROC curves correlating the UCH-Ll levels at Time Point 1 and Time Point 2 with GCS scores. The sensitivity and specificity of reference levels for 0-6 hour and 6-12 hour groups based ROC curves are shown in Table 11.
• FIG. 13 A shows the change ("delta") in UCH-L1 levels of the Time Point 2 sample from the Time Point 1 sample in subjects of the 0-6 hour group.
• FIG. 13B shows the change ("delta") in UCH-L1 levels in the Time Point 2 sample from the Time Point 1 sample in subjects of the 6-12 hour group.
• FIG. 14A shows the absolute amount (or change between Time Point 1 and Time Point 2; "absolute delta”) in UCH-L1 levels of 0-6 hour group and FIG. 14B shows a ROC curve correlating the UCH-L1 levels at Time Point 1 and Time Point 2 with GCS scores (mild vs. moderate/severe).
• FIG. 15A shows the absolute amount (or change between Time Point 1 and Time Point 2; ("absolute delta") in UCH-L1 levels of 6-12 hour group and
• FIG. 15B shows a ROC curve correlating the UCH-L1 levels at Time Point 1 and Time Point 2 with GCS scores (mild vs. moderate/severe).
• Subjects determined to have moderate/severe TBI based on the GCS score had a larger decrease or change in UCH-Ll levels from Time Point 1 to Time Point 2 compared to subjects determined to have mild TBI based on the GCS score.
• FIGS. 19 and 20 show the ROC curves correlating the absolute amount ("absolute delta") in UCH-L1 levels with the CT scan result for the 0-11 hour group and >11 hour group, respectively.
• FIGS. 19 and 20 show the ROC curves correlating the absolute amount ("absolute delta") in UCH-L1 levels with the CT scan result for the 0-11 hour group and >11 hour group, respectively.
• 21 and 22 show the ROC curves correlating the absolute amount ("absolute delta") in UCH-L1 levels with the CT scan result for the 0-10 hour group and 0-12 hour group, respectively.
• the sensitivity and specificity of absolute amounts (or the change between Time Point 1 and Time Point 2) in UCH-L1 levels for the 0-10 hour, 0-11, and 0-12 groups based on the ROC curves are shown in Table 13.
• ROC analysis was also performed to show that if the UCH-L1 level at time point 1 is greater than or equal to 550 pg/mL or if the fold-change between time point 2 and time point 1 is greater than 0.73, then the subject is classified as having moderate to severe TBI; if the UCH-L1 level at time point 1 is less than 550 pg/mL or if the fold-change between time point 2 and time point 1 is less than 0.73, then the subject is classified as having mild TBI.
• These reference levels had a sensitivity of 100% and specificity of 42.5%.
• ROC analysis was also performed to show that if the UCH-L1 level at time point 1 is greater than or equal to 450 pg/mL or if the fold-change between time point 2 and time point 1 is greater than 0.73, then the subject is classified as having moderate to severe TBI; if the UCH-L1 level at time point 1 is less than 450 pg/mL or if the fold-change between time point 2 and time point 1 is less than 0.73, then the subject is classified as having mild TBI.
• These reference levels had a sensitivity of 100% and specificity of 40%.
• ROC analysis was also performed to show that if the UCH-L1 level at time point 1 is greater than or equal to 350 pg/mL or if the fold-change between time point 2 and time point 1 is greater than 0.73, then the subject is classified as having moderate to severe TBI; if the UCH-L1 level at time point 1 is less than 550 pg/mL or if the fold-change between time point 2 and time point 1 is less than 0.73, then the subject is classified as having mild TBI.
• These reference levels had a sensitivity of 100% and specificity of 32.5%.
• the present disclosure provides specific UCH-L1 reference values and corresponding assay methods that can be used to evaluate a subject for a tramautic brain injury, in addition or as an alternative to, standard clinical assessments.
• a method of aiding in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head comprising: a) performing an assay on a sample taken from the subject within 24 hours after a suspected injury to the head to measure or detect a level of ubiquitin car boxy-terminal hydrolase LI (UCH-L1) in the sample; and b) determining whether the subject has sustained mild or moderate to severe traumatic brain injury (TBI) , wherein the subject is determined as having moderate to severe traumatic brain injury when (i) the level of UCH-L1 in the sample is higher than a reference level of UCH-L1 and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1; (ii) there is a statistically significant increase or decrease from the level of UCH-L1 in a sample taken at a first time point to the level of UCH-L1 in a sample taken at a second
• Clause 4 The method of clause 3, wherein the subject is suspected as having moderate to severe traumatic brain injury based on the Glasgow Coma Scale score.
• Clause 7 The method of clause 3, wherein the subject is suspected as having mild traumatic brain injury based on the Glasgow Coma Scale score.
• Clause 8 The method of clause 7, wherein the reference level is correlated with subjects having mild traumatic brain injury.
• Clause 10 The method of any one of clauses 1 to 9, wherein the reference level is determined by an assay having a sensitivity of between at least about 85% to 100% and a specificity of between at least about 30% to 100%.
• Clause 11 The method of any one of clauses 1 to 10, wherein the reference level is determined by an assay having a sensitivity of at least about 99% and a specificity of at least about 75%.
• Clause 12 The method of any one of clauses 1 to 11, wherein the reference level is between at least about 50 pg/mL to about 12000 pg/mL.
• Clause 13 The method of any one of clauses 1 to 12, wherein the reference level is between at least about 65 pg/mL to about 9019 pg/mL.
• Clause 14 The method of any one of clauses 1 to 13, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 33%.
• Clause 15 The method of clause 14, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is about 311 pg/mL.
• Clause 16 The method of any one of clauses 1 to 13, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of about 100%.
• Clause 17 The method of clause 16, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is about 9019 pg/mL.
• Clause 18 The method of any one of clauses 1 to 13, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about
• Clause 19 The method of clause 18, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 98 pg/mL.
• Clause 20 The method of any one of clauses 1 to 13, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 63%.
• Clause 21 The method of clause 20, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 209 pg/mL.
• Clause 22 The method of any one of clauses 1 to 13, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 96%.
• Clause 23 The method of clause 22, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about S69 pg/mL.
• Clause 24 The method of clause 4, wherein the absolute amount is correlated with subjects having moderate and severe traumatic brain injury.
• Clause 27 The method of clause 26, wherein the absolute amount is correlated with Glasgow Coma Scale score of 13-15.
• Clause 28 The method of any one of clauses 1 to 4, 7, or 24 to 27, wherein the absolute amount is determined by an assay having a sensitivity of between at least about 70% to 100% and a specificity of between at least about 30% to 100%.
• Clause 29 The method of clause 28, wherein the sample is taken within 0 to 6 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of about 100%.
• Clause 30 The method of clause 29, wherein the sample is taken within 0 to 6 hours after the suspected injury and the absolute amount is about 2S28 pg/mL.
• Clause 31 The method of clause 30, wherein the sample is taken within 6 to 12 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of at least about 70% and a specificity of at least about 92%.
• Clause 32 The method of clause 31, wherein the sample is taken within 6 to 12 hours after the suspected injury and the absolute amount is about 129 pg/mL.
• Clause 33 The method of clause 28, wherein the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 36%.
• Clause 34 The method of clause 33, wherein the sample is taken within 6 to 12 hours after the suspected injury and the absolute amount is about 25 pg/mL.
• Clause 35 The method of clause 28, wherein the sample is taken within 0 to 1 1 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 32%.
• Clause 36 The method of clause 35, wherein the sample is taken within 0 to 11 hours after the suspected injury and the absolute amount is about 25 pg/mL.
• Clause 37 The method of clause 28, wherein the sample is taken within 0 to 12 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of at least about 75% and a specificity of at least about 76%.
• Clause 38 The method of clause 37, wherein the sample is taken within 0 to 12 hours after the suspected injury and the absolute amount is about 129 pg/mL.
• a method of aiding in determining the extent of traumatic brain injury in a human subject who has sustained or may have sustained a suspected injury to the head comprising: a) performing an assay on at least two samples obtained from the subject, the first sample taken from the subject within 24 hours of the suspected injury and the second sample taken from the subject from about 3 to about 6 hours after the first sample is taken; b) detecting in the at least two samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; c) determining the level of UCH-L1 in each of the first sample and second sample and determining if the level of UCH-L1 decreases or increases from the first sample to the second sample; and d) determining the extent of the traumatic brain injury in the subject based on whether the level of UCH-L1 decrease
• UCH-L1 ubiquit
• Clause 40 The method of clause 39, wherein the first sample is taken within 0 to about 6 hours after the suspected injury.
• Clause 41 The method of clauses 39 or 40, wherein the subject is determined to have moderate to severe traumatic brain injury when the level of UCH-L1 increases or decreases between at least about 20 pg/mL to at least about 6100 pg/mL from the first sample to the second sample.
• Clause 42 The method of clause 41, wherein the first sample is taken within 0 to about 6 hours after the suspected injury and the level of UCH-L1 increases or decreases by at least about 2528 pg/mL
• Clause 43 The method of clause 41 , wherein the first sample is taken within 6 to about 12 hours after the suspected injury and the level of UCH-L1 increases or decreases by at least about 129 pg/mL
• Clause 44 The method of clause 41 , wherein the first sample is taken within 0 to about 10 or about 11 hours after the suspected injury and the level of UCH-L1 increases or decreases by at least about 25 pg/mL.
• Clause 45 The method of clause 41, wherein the first sample is taken within 0 to about 12 hours after the suspected injury and the level of UCH-L1 increases or decreases at least about 129 pg/mL.
• Clause 46 The method of any one of clauses 1 to 45, further comprising treating a human subject assessed as having moderate to severe traumatic brain injury with a traumatic brain injury treatment.
• Clause 47 The method of any one of clauses 1 to 45, further comprising monitoring a human subject assessed as having mild traumatic brain injury.
• a method of aiding in the determination of whether to perform a head computerized tomography (CT) scan on a human subject that has sustained or may have sustained a suspected injury to the head comprising: a) performing an assay on at least two samples obtained from the subject, the first sample taken from the subject within 24 hours of the suspected injury and the second sample taken from the subject from about 3 to about 6 hours after the first sample is taken; b) detecting in the at least two samples an early biomarker of traumatic brain injury, said early biomarker consisting of ubiquitin carboxy-terminal hydrolase LI (UCH-L1), wherein the onset of the presence of UCH-L1 appears within about 0 to about 6 hours after the suspected injury; c) determining the level of UCH-L1 in each of the first sample and second sample and determining if the level of UCH-L1 decreases or increases from the first sample to the second sample; and d) determining whether to perform a CT scan on the subject based on whether the
• Clause 50 The method of clause 49, wherein: the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 2-fold from the first time point to the second time point; the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase or decrease is less than about 1.81 -fold from the first time point to the second time point; the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 0.50-fold from the second time point to the first time point; the first time point is about 0 to about 12 hours after the suspected injury and the statistically significant increase is more than about 0.55-fold from the second time point to the first time point; or the first time point is about 0 to about 12 hours after the suspected injury, the reference level of UCH-L1 is about 550 pg/mL, and the statistically significant increase is more than about 0.55-fold from the second time point to the first time point
• Clause 51 The method of any one of clauses 48 to 50, wherein the subject has received a CT scan before or after the assay is performed.
• Clause 52 The method of clause 51 , wherein the subject is suspected as having a traumatic brain injury based on the CT scan.
• Clause 53 The method of any one of clauses 49, 51, or 52, wherein the reference level is correlated with positive head computed tomography.
• Clause 54 The method of any one of clauses 49 or 51 to 53, wherein the reference level is determined by an assay having a sensitivity of between at least about 80% to 100% and a specificity of between at least about 30% to 100%.
• Clause 55 The method of any one of clauses 49 or 51 to 54, wherein the reference level is between at least about 50 pg/mL to about 1000 pg/mL.
• Clause 56 The method of any one of clauses 49 or 51 to 55, wherein the reference level is between at least about 86 pg/mL to about 700 pg/mL.
• Clause 57 The method of any one of clauses 49 or 51 to 56, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 37.5%.
• Clause 58 The method of clause 57, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is about 370 pg/mL.
• Clause 59 The method of any one of clauses 49 or 51 to 56, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 75%.
• Clause 60 The method of clause 59, wherein the sample is taken within 0 to 6 hours after the suspected injury and the reference level is about 509 pg/mL.
• Clause 61 The method of any one of clauses 49 or 51 to 56, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of at least about 96% and a specificity of at least about 30%.
• Clause 62 The method of clause 61, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 96 pg/mL.
• Clause 63 The method of any one of clauses 49 or 51 to 56, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of at least about 86% and a specificity of at least about 35%.
• Clause 64 The method of clause 63, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 86 pg/mL.
• Clause 65 The method of any one of clauses 49 or 51 to 56, wherein the sample is taken between about 0 hours to 12 hours after the suspected injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 32%.
• Clause 66 The method of clause 65, wherein the sample is taken between about 6 hours to 12 hours after the suspected injury and the reference level is about 550 pg/mL.
• Clause 67 The method of any one of clauses 49, 51, or 52, wherein the absolute amount is correlated with positive head computed tomography.
• Clause 68 The method of clause 67, wherein the absolute amount is determined by an assay having a sensitivity of between at least about 80% to 100% and a specificity of between at least about 30% to 100%.
• Clause 69 The method of clause 68, wherein the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of at least about 85% and a specificity of at least about 41%.
• Clause 70 The method of clause 69, wherein the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 25 pg/mL.
• Clause 71 The method of clause 68, wherein the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 35%.
• Clause 72 The method of clause 71 , wherein the sample is taken within 0 to 10 hours after the suspected injury and the absolute amount is about 23 pg/mL.
• Clause 73 The method of any one of clauses 1 to 72, wherein the second sample is taken from the human subject between about 5 hours to about 16 hours or about 3 hours to about 6 hours after injury to the head.
• Clause 74 The method of any one of clauses 1 to 73, wherein the second sample is taken from the human subject at about 3 hours, at about 4 hours, at about 5 hours, at about 6 hours, at about 7 hours, at about 8 hours, at about 9 hours, at about 10 hours, at about 11 hours, or at about 12 hours after injury to the head.
• Clause 75 The method of any one of clauses 1 to 74 further comprising performing an assay on the samples to measure or detect a level of one or more other biomarkers that are not UCH-L1.
• Clause 76 The method of clause 75, wherein the assay comprises: I. measuring or detecting a level of one or more other biomarkers in the first sample and the second sample, ⁇ . determining a decrease or increase in the level of the one or more other biomarkers from the first sample to the second sample, and HI. assessing the human subject as having mild traumatic brain injury if there is a statistically significant decrease or increase in the level of the one or more other biomarkers from the first sample to the level of the one or more other biomarkers in the second sample
• Clause 77 The method of clause 75 or 76, wherein the one or more other biomarkers is selected from the group consisting of SIOOP, neuron-specific enolase (NSE), glial fibrillary acidic protein (UCH-L1), Apo lipoprotein 1, Tau, C-reactive protein (CRP), free brain-derived neurotrophic factor (BDNF), p-Tau, total BDNF, troponin I (Tnl), and a combination thereof.
• the one or more other biomarkers is SlOOft BDNF, or CRP.
• Clause 79 The method of any one of clauses 1 to 78, further comprising treating a human subject assessed as having mild traumatic brain injury with a mild traumatic brain injury treatment.
• Clause 80 The method of any one of clauses 1 to 79, further comprising monitoring a human subject assessed as having mild traumatic brain injury.
• Clause 81 The method of any one of clauses 1 to 80, wherein measuring the level of UCH-L1 is done by an immunoassay.
• Clause 82 The method of any one of clauses 1 to 81, wherein measuring the level of UCH-L1 comprises: A. contacting the sample, either simultaneously or sequentially, in any order with: (1) a capture antibody, which binds to an epitope on UCH-Ll or UCH-L1 fragment to form a capture antibody-UCH-Ll antigen complex, and (2) a detection antibody which includes a detectable label and binds to an epitope on UCH-Ll that is not bound by the capture antibody, to form a UCH-Ll antigen-detection antibody complex, such that a capture antibody-UCH-Ll antigen-detection antibody complex is formed, and B. measuring the amount or concentration of UCH-Ll in the sample based on the signal generated by the detectable label in the capture antibody-UCH-Ll antigen-detection antibody complex.
• Clause 83 The method of any one of clauses 1 to 82, wherein the sample is selected from the group consisting of a whole blood sample, a serum sample, a cerebrospinal fluid sample and a plasma sample.
• Clause 84 The method of any one of clauses 1 to 83, wherein the sample is obtained after the human subject sustained an injury to the head caused by physical shaking, blunt impact by an external mechanical or other force that results in a closed or open head trauma, one or more falls, explosions or blasts or other types of blunt force trauma.
• Clause 85 The method of any one of clauses 1 to 83, wherein the sample is obtained after the human subject has ingested or been exposed to a chemical, toxin or combination of a chemical and toxin.
• Clause 86 The method of clause 85, wherein the chemical or toxin is fire, mold, asbestos, a pesticide, an insecticide, an organic solvent, a paint, a glue, a gas, an organic metal, a drug of abuse or one or more combinations thereof.
• Clause 87 The method of any one of clauses 1 to 83, wherein the sample is obtained from a human subject that suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, a virus, meningitis, hydrocephalus or combinations thereof.
• Clause 88 The method of any one of clauses 1 to 83, wherein said method can be carried out on any human subject without regard to factors selected from the group consisting of the human subject's clinical condition, the human subject's laboratory values, the human subject's classification as suffering from mild, moderate to severe traumatic brain injury, the human subject's exhibition of low or high levels of UCH-L1, and the timing of any event wherein said human subject may have sustained an injury to the head.
• TBI mild or moderate to severe traumatic brain injury
• the level of UCH-L1 in the sample is higher than a reference level of UCH- Ll and the subject is determined as having mild traumatic brain injury when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1;
• the level of UCH-L1 in the sample is higher than a reference level of UCH- Ll or when there is a significant increase or decrease of an amount X from the level of UCH-L1 in a sample taken at a first time point to the level of UCH-L1 in a sample taken at a second time point and the subject is determined as having mild traumatic brain injury when the level of UCH- Ll in the sample is lower than a reference level of UCH-L1 or when there is no significant increase or decrease greater than amount X from the level of UCH-L1 in a sample taken at a first time point to the level of UCH-L1 in a sample taken at a second time point.
• a method of evaluating a human subject for a head injury comprising:
• TBI traumatic brain injury
• the subject has sustained a moderate to severe TBI when the level of UCH- Ll in the sample is higher than a reference level of UCH-L1, and wherein the subject has sustained a mild TBI when the level of UCH-L1 in the sample is lower than a reference level of UCH-L1 ; (ii) the subject has sustained a moderate to severe TBI when there is a
• the subject has sustained a moderate to severe TBI when the level of UCH- Ll decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the subject has sustained a mild TBI when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample;
• the subject has sustained a moderate to severe TBI when the level of UCH- Ll decreases or increases by at least a first absolute amount from the first sample to the second sample, and wherein the subject has sustained a mild TBI when the level of UCH-L1 decreases or increases by at least a second absolute amount from the first sample to the second sample.
• the first time point is about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease is selected from the group consisting of:
• Clause 92 The method of any of clauses 89 to 91 , wherein the subject has received a Glasgow Coma Scale score before or after the assay is performed.
• Clause 93 The method of clause 92, wherein the subject is suspected as having moderate to severe TBI based on the Glasgow Coma Scale score.
• Clause 94 The method of any of clauses 89 to 93, wherein the reference level is correlated with subjects having moderate to severe TBI.
• Clause 96 The method of clause 92, wherein the subject is suspected as having mild TBI based on the Glasgow Coma Scale score.
• Clause 97 The method of any of clauses 89 to 92, wherein the reference level is correlated with subjects having mild TBI.
• Clause 98 The method of clause 97, wherein the reference level is correlated with a Glasgow Coma Scale score of 13-15.
• Clause 99 The method of any of clauses 89 to 98, wherein the reference level is (a) determined by an assay having a sensitivity of between at least about 85% to about 100% and a specificity of between at least about 30% to about 100%; (b) determined by an assay having a sensitivity of at least about 99% and a specificity of at least about 75%; (c) between at least about 50 pg/mL to about 12000 pg/mL; or (d) between at least about 65 pg/mL to about 9019 pg/mL.
• Clause 100 The method of any of clauses 89 to 99, wherein the sample is (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 33%; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of about 100%; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 30%; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 63%; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 90% and a specificity of at least
• Clause 101 The method of any of clauses 89 to 100, wherein the sample is (a) taken within 0 to about 6 hours after the suspected head injury and the reference level is about 311 pg/mL; (b) taken within 0 to 6 hours after the suspected head injury and the reference level is about 9019 pg/mL; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 98 pg/mL; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 209 pg/mL; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 569 pg/mL.
• Clause 102 The method of clause 89 or 90, wherein the absolute amount is correlated with subjects having moderate to severe TBI.
• Clause 103 The method of clause 102, wherein the absolute amount is correlated with a Glasgow Coma Scale score of 3-12.
• Clause 104 The method of clause 89 or 90, wherein the absolute amount is correlated with subjects having mild TBI.
• Clause 105 The method of clause 104, wherein the absolute amount is correlated with a Glasgow Coma Scale score of 13-15.
• Clause 106 The method of any of clauses 89, 90, and 102 to 105, wherein the absolute amount is determined by an assay having a sensitivity of between at least about 70% to about 100% and a specificity of between at least about 30% to about 100%.
• Clause 107 The method of clause 106, wherein the sample is (a) taken within about 0 to about 6 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of about 100%; (b) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 70% and a specificity of at least about 92%; (c) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 36%; (d) taken within about 0 to about 11 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of about 100% and a specificity of at least about 32%; or (e) taken within about 0 to about 12 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 75% and a specificity of at least about
• Clause 108 The method of clause 106 or 107, wherein the sample is: (a) taken within about 0 to about 6 hours after the suspected head injury and the absolute amount is about 2528 pg/mL; (b) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is about 129 pg/mL; (c) taken within about 6 to about 12 hours after the suspected head injury and the absolute amount is about 25 pg/mL; (d) taken within 0 to 11 hours after the suspected head injury and the absolute amount is about 25 pg/mL; or (e) taken within about 0 to about 12 hours after the suspected head injury and the absolute amount is about 129 pg/mL.
• a method of aiding in determining the extent of traumatic brain injury in a human subject who has sustained or may have sustained a head injury comprising:
• UCH- Ll ubiquitin carboxy-terminal hydrolase LI
• determining the extent of the traumatic brain injury in the subject based on whether the level of UCH-L1 decreases, increases, or remains the same from the first sample to the second sample, wherein determining the extent of the traumatic brain injury comprises determining whether the subject has sustained a mild or a moderate to severe traumatic brain injury.
• a method of evaluating the extent of traumatic brain injury (TBI) in a human subject comprising:
• UCH- Ll ubiquitin carboxy-terminal hydrolase LI
• Clause 111 The method of clause 109 or 110, wherein the first sample is taken within about 0 to about 6 hours after the suspected head injury.
• Clause 112. The method of any of clauses 109 to 111, wherein the subject is determined to have moderate to severe TBI when the level of UCH-L1 increases or decreases between at least about 20 pg/mL to at least about 6100 pg/mL from the first sample to the second sample.
• Clause 113 The method of clause 109 or 110, wherein the first sample is (a) taken within about 0 to about 6 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 2S28 pg/mL; (b) taken within about 6 to about 12 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 129 pg/mL; (c) taken within about 0 to about 10 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 25 pg/mL; (d) taken within about 0 to about 11 hours after the suspected head injury and the level of UCH-L1 increases or decreases by at least about 25 pg/mL; or (e) taken within about 0 to about 12 hours after the suspected head injury and the level of UCH-L1 increases or decreases at least about 129 pg/mL.
• Clause 114 The method of any of clauses 89 to 1 13, further comprising (a) treating a human subject assessed as having mild or moderate to severe TBI with a treatment for TBI; and optionally, (b) monitoring the human subject after receiving said treatment.
• Clause 115 The method of any of clauses 89 to 113, further comprising monitoring a human subject assessed as having mild or moderate to severe TBI.
• samples such as biological samples
• the CT scan is performed when the level of UCH-L1 in the first sample is higher than a reference level of UCH-L1, and wherein the CT scan is not performed when the level of UCH-L1 in the first sample is lower than a reference level of UCH-L1;
• the CT scan is performed when there is a statistically significant increase or decrease in the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample, and wherein the CT scan is not performed when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample;
• the CT scan is performed when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the CT scan is not performed when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample.
• a method of evaluating whether to perform a head computerized tomography (CT) scan on a human subject comprising:
• the CT scan is performed when the level of UCH-L1 in the first sample is higher than a reference level of UCH-L1, and wherein the CT scan is not performed when the level of UCH-L1 in the first sample is lower than a reference level of UCH-L1;
• the CT scan is performed when there is a statistically significant increase or decrease in the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample, and wherein the CT scan is not performed when there is no statistically significant increase or decrease from the level of UCH-L1 in the first sample to the level of UCH-L1 in the second sample;
• the CT scan is performed when the level of UCH-L1 decreases or increases by at least an absolute amount from the first sample to the second sample, and wherein the CT scan is not performed when there is no decrease or increase by at least an absolute amount in the level of UCH-L1 from the first sample to the second sample.
• Clause 118 The method of clause 116 or 117, wherein: the first time point is about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease is less than about 2-fold from the first time point to the second time point; the first time point is about 0 to about 12 hours after the suspected head injury and the statistically significant increase or decrease is less than about 1.81 -fold from the first time point to the second time point; the first time point is about 0 to about 12 hours after the suspected head injury and the statistically significant increase is more than about 0.50-fold from the second time point to the first time point; the first time point is about 0 to about 12 hours after the suspected head injury and the statistically significant increase is more than about O.SS-fold from the second time point to the first time point; or the first time point is about 0 to about 12 hours after the suspected head injury, the reference level of UCH-L1 is about 550 pg/mL, and the statistically significant increase is more than about 0.55-fold from the second time point to the first
• Clause 119 The method of any of clauses 116 to 118, wherein the subject has received a CT scan before or after the assay is performed.
• Clause 120 The method of clause 119, wherein the subject is suspected as having a traumatic brain injury based on the CT scan.
• Clause 121 The method of any of clauses 116 to 120, wherein the reference level is correlated with positive head CT scan.
• Clause 122 The method of any of clauses 116 to 121 , wherein the reference level is (a) determined by an assay having a sensitivity of between at least about 80% to about 100% and a specificity of between at least about 30% to about 100%; (b) between at least about 50 pg/mL to about 1000 pg/mL; or (c) between at least about 86 pg/mL to about 700 pg/mL.
• Clause 123 The method of any of clauses 116 to 122, wherein the sample is (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 37.5%; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of about 100% and a specificity of at least about 75%; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 96% and a specificity of at least about 30%; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of at least about 86% and a specificity of at least about 35%; or (e) taken between about 0 hours to about 12 hours after the suspected head injury and the reference level is determined by an assay having a sensitivity of sensitivity of
• Clause 124 The method of any of clauses 116 to 123, wherein the sample is (a) taken within about 0 to about 6 hours after the suspected head injury and the reference level is about 370 pg/mL; (b) taken within about 0 to about 6 hours after the suspected head injury and the reference level is about 509 pg/mL; (c) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 96 pg/mL; (d) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 86 pg/mL; or (e) taken between about 6 hours to about 12 hours after the suspected head injury and the reference level is about 550 pg/mL.
• Clause 125 The method of clause 116 or 117, wherein the absolute amount is correlated with positive head CT scan.
• Clause 127 The method of clause 126, wherein the sample is: (a) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 85% and a specificity of at least about 41%; or (b) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is determined by an assay having a sensitivity of at least about 90% and a specificity of at least about 35%.
• Clause 128 The method of clause 126, wherein the sample is: (a) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is about 25 pg/mL; or (b) taken within about 0 to about 10 hours after the suspected head injury and the absolute amount is about 23 pg/mL.
• Clause 129 The method of any of clauses 89 to 128, wherein the second sample is taken from the subject between about 5 hours to about 16 hours or about 3 hours to about 6 hours after the suspected head injury.
• Clause 130 The method of any of clauses 89 to 128, wherein the second sample is taken from the subject at about 3 hours, at about 4 hours, at about 5 hours, at about 6 hours, at about 7 hours, at about 8 hours, at about 9 hours, at about 10 hours, at about 11 hours, or at about 12 hours after the suspected head injury.
• Clause 131 The method of any of clauses 89 to 130, further comprising performing an assay on the samples to measure or detect a level of one or more other biomarkers that are not UCH-L1.
• Clause 134 The method of clause 133, wherein the one or more other biomarkers is SIOOP, BDNF, or CRP.
• Clause 135. The method of any of clauses 89 to 134, wherein the method further comprises (a) treating a human subject assessed as having mild or moderate to severe TBI with a treatment for TBI; and optionally, (b) monitoring the human subject after receiving said treatment.
• Clause 136 The method of any of clauses 89 to 135, further comprising monitoring a human subject assessed as having mild or moderate to severe TBI.
• Clause 137 The method of any of clauses 89 to 136, wherein measuring the level of UCH-L1 comprises performing an immunoassay.
• a capture antibody which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a capture antibody-UCH-Ll antigen complex
• a detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the capture antibody, to form a UCH-L1 antigen- detection antibody complex
• Clause 139 The method of any of clauses 89 to 138, wherein the sample is selected from the group consisting of a whole blood sample, a serum sample, a cerebrospinal fluid sample and a plasma sample.
• Clause 140 The method of any of clauses 89 to 139, wherein the sample is obtained after the subject sustained a head injury caused by physical shaking, blunt impact by an external mechanical or other force that results in a closed or open head trauma, one or more falls, explosions or blasts or other types of blunt force trauma.
• Clause 141 The method of any of clauses 89 to 139, wherein the sample is obtained after the subject has ingested or been exposed to a chemical, toxin or combination of a chemical and toxin.
• Clause 142 The method of clause 141, wherein the chemical or toxin is fire, mold, asbestos, a pesticide, an insecticide, an organic solvent, a paint, a glue, a gas, an organic metal, a drug of abuse or one or more combinations thereof.
• Clause 143 The method of any of clauses 89 to 139, wherein the sample is obtained from a subject that suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, a virus, meningitis, hydrocephalus or combinations thereof.
• Clause 144 The method of any of clauses 89 to 139, wherein the method can be carried out on any human subject without regard to factors selected from the group consisting of the human subject's clinical condition, the human subject's laboratory values, the human subject's classification as suffering from mild or moderate to severe TBI, the human subject's exhibition of low or high levels of UCH-L1 , and the timing of any event wherein the human subject may have sustained head injury.
• Clause 145 The method of any of clauses 89 to 144, wherein the sample is a biological sample.
• Clause 146 The method of any of clauses 89 to 145, wherein the sample is a whole blood sample.
• Clause 147 The method of any of clauses 89 to 145, wherein the sample is a serum sample.
• Clause 148 The method of any of clauses 89 to 145, wherein the sample is a plasma sample.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• General Physics & Mathematics (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Neurosurgery (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Neurology (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68545025

Family Applications (1)

Country Status (2)

Families Citing this family (2)

Family Cites Families (7)

• 2018
  • 2018-03-23 EP EP18716856.2A patent/EP3602069A1/de active Pending
  • 2018-03-23 CN CN201880020489.5A patent/CN110494752A/zh active Pending

Also Published As

Similar Documents

Legal Events